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ABSTRACT 
Rotavirus (RV) is one of the major causes of acute viral gastroenteritis in children. 
Symptoms include fever, vomiting and watery diarrhea which may lead to fatal 
dehydration. Before the development of RV vaccines and their introduction into 
National Immunization Programs, RV gastroenteritis caused more than 400,000 
deaths each year globally.  RV vaccines are currently used in more than 90 countries, 
and the number of deaths has decreased to a third, but RV still remains as one of 
the main causes of mortality in children under five years of age. The majority of the 
fatalities occur in low-to-middle income countries, whereas in developed countries, 
RV is the cause of a substantial medical and financial burden. After the introduction 
of vaccines, an increase of diversity and changes in circulating RV strains have been 
reported globally. 
RotaTeq consists of five human-bovine reassortant RVs (G1P[5], G2P[5], 
G3P[5], G4P[5] and G6P[8]) on bovine G6P[5] backbone. The shedding of RotaTeq 
vaccine viruses was originally reported to occur at a low level but more recent studies 
have shown higher rates of shedding. In early studies, the duration of shedding 
ranged from a week, even up to hundreds of days in immunocompromised children. 
Nevertheless, the characteristics of RotaTeq vaccine strain shedding have not been 
studied thoroughly. Similarly, the formation and potential higher virulence of 
vaccine-derived double-reassortant G1P[8] (vdG1P[8]) is mainly unknown. 
This thesis focused on studying the characteristics of RotaTeq vaccine virus 
shedding in children without symptoms of acute gastroenteritis. First, stool samples 
collected from children hospitalized due to a respiratory tract infection between 2009 
and 2011 were studied. The study showed that prolonged asymptomatic shedding 
was more common than previously expected. The occurrence of shedding was highly 
associated with vaccine genotype G1 as it was detected in 93 % of the cases. Half of 
the children shed for more than 14 days, and the longest duration of shedding was 
84 days after the third dose of the RotaTeq vaccine.  
Secondly, in a prospective study, 301 children received the RotaTeq vaccine at 
their respective child welfare clinic according to the Finnish schedule at the ages of 
two, three and five months. RotaTeq vaccine strains were detected in the stools of 
93 % of the children 5-10 days after the first dose of the vaccine. Of those children, 
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20 % continued to shed until the third dose of the vaccine, whereas only two children 
were detected with the vaccine strain in stools three months after the third dose. The 
study confirmed G1 to be highly prevalent in shedding: it was found in 82 % of the 
samples taken after the first dose, it was the only genotype found in long-term 
shedding continuing up to eight months of age. Children who became long-term 
shedders were found with more severe symptoms after the first dose of the vaccine, 
whereas similar association was not found when comparing the possible vdG1P[8] 
combination to other genotypes. Altogether these results suggest that the five-strain-
containing RotaTeq vaccine functions in a similar manner as the single human 
G1P[8] strain vaccine, Rotarix. 
RV was added as part of the microbe strain collection in Finland in 2013, and all 
laboratory confirmed RV cases from the entire country covering all age groups were 
collected for genotyping. This material was used to study the long-term effects of 
the RotaTeq vaccine on circulating RV genotypes in a high vaccine coverage setting 
for five consecutive RV seasons from September 2013 to August 2018. The total 
number of RV cases remained stable and at a low level throughout the follow-up, 
indicating that the RotaTeq vaccine has remained highly efficacious. In children, 
diversification and redistribution of circulating genotypes, similar to other RotaTeq-
using countries, was detected, as G1P[8], G2P[4] and G4P[8] were replaced by 
G12P[8], G9P[4] and G9P[8]. Two distinct age clusters were also identified, as in 
addition to children, RV was detected in the elderly more frequently than expected. 
The genotypes of this age group differed from those of the children, as G2P[4] was 
predominant during most of the follow-up period. The changes in the circulating 
genotypes were detected in the elderly a season later, suggesting transmission of the 
disease from children to older age groups. Overall, this period is long enough to 
suggest that wild-type RVs cannot be eliminated from circulation even with a high-
coverage vaccination using a highly efficacious live oral RV vaccine. 
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TIIVISTELMÄ 
Rotavirukset ovat merkittävimpiä ripulitaudin (gastroenteriitin) aiheuttajia lapsilla. 
Pahimmillaan tauti voi johtaa vakavaan kuivumaan ja kuolemaan, ja ennen nykyisten 
rokotteiden käyttöönottoa rotavirusten aiheuttama gastroenteriitti johti vuosittain yli 
400 000 lapsen kuoleman maailmanlaajuisesti. Merkittävin osa kuolemaan johtavista 
tautitapauksista esiintyy kehitysmaissa. Vaikka rotavirusrokotteita on otettu käyttöön 
yli 90 maassa ja rotavirukseen liittyvien kuolemien määrä on laskenut 
kolmannekseen, rotavirukset ovat silti edelleen yleisin kuolinsyy alle 5-vuotiailla 
lapsilla. Rotavirusrokotteiden käyttöönoton jälkeen on havaittu, että kiertävät 
rotaviruskannat ovat muuntuneet ja aiemmin harvinaiset rotaviruskannat ovat 
yleistyneet. 
Suun kautta otettava rotavirusrokote RotaTeq, koostuu viidestä ihmisen ja 
vasikan rotaviruksista muodostetuista yhdistelmistä (G1P[5], G2P[5], G3P[5], 
G4P[5] ja G6P[8]). Ennen rokotteiden käyttöönottoa tehdyissä tutkimuksissa 
kyseisten rokotevirusten erityksen ulosteisiin havaittiin olevan vähäistä, mutta 
myöhemmissä tutkimuksissa erityksen on huomattu olevan aiemmin luultua 
yleisempää. Rokotusta seuraavan rokotevirusten erityksen kesto on tutkimuksesta 
riippuen vaihdellut viikosta kuukauteen, mutta pitkittynyttä, jopa useiden satojen 
päivien kestoista eritystä on raportoitu immuunipuutteisilla lapsilla. Rokotevirusten 
erittymisen kliininen merkitys on kuitenkin jäänyt epäselväksi. Eritykseen on 
yhdistetty niin kutsuttu rokoteperäinen kaksoisyhdistelmä G1P[8] virus, jossa 
rokotteen kaksi kantaa G1P[5] sekä G6P[8]  ovat risteytyneet keskenään. Kyseisen 
viruksen on esitetty omaavan muita kantoja suuremman taudinaiheuttamiskyvyn. 
Väitöskirjan tavoitteena oli tutkia RotaTeq-rokotteen sisältämien viruskantojen 
eritystä lapsilla. Ensimmäisessä tutkimuksessa rokotevirusten pitkäkestoisen 
erityksen havaittiin olevan aiemmin esitettyä yleisempää ja esiintyvän jopa lapsilla, 
jotka olivat joutuneet sairaalahoitoon hengitystieinfektion vuoksi ilman maha-
suolikanavan oireita. Aineistossa rokotevirusten eritys yhdistyi selkeästi yhteen 
rokoteviruksista, sillä genotyyppi G1 oli löydöksenä 93 % tapauksista (N=30). Puolet 
lapsista eritti rokotevirusta ulosteisiin yli 14 päivää edellisestä rokotuksesta, 
pisimmillään eritys jatkui jopa 84 päivää rokotuksesta.  
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Rokotevirusten erityksen tarkempaa tutkimista varten toteutettiin erillinen 
tutkimus, johon osallistui yhteensä 301 lasta, jotka saivat RotaTeq-rokotteen 
kansallisen rokotusohjelman mukaisesti (2, 3 ja 5kk iässä). Rokotevirusten eritystä 
ulosteisiin havaittiin jopa 93%:lla lapsista 5-10 päivää ensimmäisen rokoteannoksen 
jälkeen. Erityksen yleisyys väheni ajan kuluessa ja enää noin viidennes lapsista jatkoi 
eritystä juuri ennen kolmatta rokoteannosta otetuissa näytteissä. Pitkittynyttä 
rokoteviruksen eritystä kolmen kuukauden kuluttua viimeisestä rokoteannoksesta eli 
noin kahdeksan kuukauden ikään saakka, havaittiin kahdella lapsella. Tutkimus 
varmisti aiemman tutkimuksen löydöksen G1 genotyypin merkittävyydestä 
rokotevirusten erityksessä, sillä kyseinen genotyyppi havaittiin 82 %:ssa ensimmäisen 
rokoteannoksen jälkeen kerätyistä näytteistä, ja ainoana genotyyppinä pitkittyneessä 
rokoteviruksen erityksessä. Rokoteviruksen eritystä käsittelevät tutkimukset 
viittaavat siihen, että käytännössä viittä yhdistelmärotavirusta sisältävä RotaTeq-
rokote käyttäytyy elimistössä yhden rotaviruskannan G1P[8] sisältävän rokotteen 
(Rotarix) tavoin. 
Vuonna 2013 rotavirus lisättiin osaksi tartuntatautiasetuksessa ilmoitettavia 
mikrobilöydöksiä. Tähän liittyen kaikki maan kliiniset laboratoriot ovat olleet 
velvoitettuja toimittamaan positiiviseksi toteamansa rotavirusnäytteet 
jatkotutkimuksiin genotyypitystä varten. Kyseinen materiaali mahdollisti 
tutkimuksen RotaTeq rokotteen pitkäaikaisvaikutuksista Suomessa kiertäviin 
rotavirus genotyyppeihin sekä rotavirustautitaakkaan. Tutkimusjakso alkoi 
syyskuussa 2013 ja jatkui elokuun 2018 loppuun. Rotaviruksen aiheuttaman 
tautitaakan havaittiin pysyneen pienenä, merkkinä rokotteen tehon säilymisestä vielä 
lähes kymmenen vuotta käyttöönoton jälkeen. Kiertävissä rotaviruskannoissa 
havaittiin selkeää monipuolistumista sekä aiemmin yleisten rotaviruskantojen 
korvautumisen uusilla Suomessa aiemmin harvinaisilla rotaviruskannoilla, erityisesti 
lasten tautitapauksissa. G1P[8], G2P[4] sekä G4P[8] korvaantuivat G12P[8], G9P[4] 
ja G9P[8] kannoilla. Vastaava ilmiö on havaittu myös muissa RotaTeq-rokotetta 
käyttävissä maissa. Tämän lisäksi, tautitapaukset osoittautuivat keskittyvän selkeästi 
kahteen ikäryhmään ja tautitapauksia havaittiinkin odotettua enemmän lasten lisäksi 
yli 70-vuotiailla ikäihmisillä. Toisinkuin lapsilla, kyseisessä ikäryhmässä tautitapaukset 
olivat useasti G2P[4] rotaviruskannan aiheuttamia. Ikäihmisten rotaviruskannat 
muuttuivat yhden kauden jäljessä lapsiin nähden, joten tämän perusteella voidaankin 
ajatella lasten toimivan lähteenä ikäihmisten rotavirustautitapauksille. Tutkimuksen 
yhteenvetona voidaan todeta, että korkeasta rokotekattavuudesta huolimatta, 
nykyisillä eläviä viruksia sisältävillä rotavirusrokotteilla rotavirustaudin hävittäminen 
ei ole mahdollista. 
ix 
CONTENTS 
1 Introduction .................................................................................................................... 15 
2 Review of literature ........................................................................................................ 16 
2.1 Biology of rotavirus ............................................................................................ 16 
2.1.1 Structure of the virion and rotavirus genomics ............................. 16 
2.1.2 Classification and nomenclature...................................................... 18 
2.1.3 Replication......................................................................................... 18 
2.1.4 Antigenic epitopes and antibodies .................................................. 20 
2.2 Rotavirus disease ................................................................................................ 20 
2.2.1 Clinical picture and pathophysiology .............................................. 21 
2.2.2 Laboratory detection of rotaviruses ................................................ 23 
2.2.3 Immune response ............................................................................. 24 
2.2.3.1 Innate immune response ................................................ 24 
2.2.3.2 Acquired immunity ......................................................... 25 
2.2.4 Long-term protection and correlates of protection ....................... 28 
2.3 Epidemiology of rotavirus ................................................................................. 31 
2.3.1 Burden of disease ............................................................................. 31 
2.3.2 Circulating rotavirus strains ............................................................. 32 
2.3.3 Rotavirus in adults ............................................................................ 34 
2.4 Rotavirus vaccines .............................................................................................. 35 
2.4.1 Development of rotavirus vaccines ................................................ 35 
2.4.1.1 Animal rotavirus vaccines .............................................. 38 
2.4.1.2 Animal-human reassortant vaccines .............................. 39 
2.4.1.3 Human rotavirus vaccines .............................................. 40 
2.4.2 Current rotavirus vaccines ............................................................... 40 
2.4.2.1 Human rotavirus vaccine, Rotarix ................................. 40 
2.4.2.2 Human-bovine reassortant vaccine, RotaTeq .............. 41 
2.4.2.3 Other rotavirus vaccines and vaccines under 
development .................................................................... 42 
2.4.3 Vaccination of adults ........................................................................ 43 
2.4.4 Effects of universal rotavirus vaccinations..................................... 44 
2.4.4.1 Real-life vaccine effects and effectiveness of current 
rotavirus vaccines ............................................................ 44 
2.4.4.2 Indirect vaccine effects ................................................... 45 
2.4.4.3 Effects on circulating strains.......................................... 46 
2.4.4.4 Potential genetic pressure due to rotavirus vaccines ... 47 
2.4.5 Vaccine safety ................................................................................... 48 
2.4.6 RotaTeq vaccine-derived double-reassortant strain ...................... 50 
2.4.7 Shedding of rotavirus vaccine strains ............................................. 51 
x 
2.4.7.1 RotaTeq ............................................................................51 
2.4.7.2 Rotarix ..............................................................................52 
3 Aims of the study ............................................................................................................54 
4 Material and methods .....................................................................................................55 
4.1 Material collection ...............................................................................................55 
4.1.1 Study I ................................................................................................55 
4.1.2 Study II ...............................................................................................55 
4.1.3 Studies III-IV .....................................................................................57 
4.2 Laboratory methods ............................................................................................58 
4.2.1 Sample preparation ............................................................................58 
4.2.2 RNA extraction (I-IV) ......................................................................58 
4.2.3 RT-PCR (I-IV) ...................................................................................59 
4.2.3.1 VP7 detection and G-typing by RT-PCR ......................59 
4.2.3.2 VP4 detection by RT-PCR ..............................................60 
4.2.3.3 VP6 detection by RT-PCR ..............................................61 
4.2.4 Sequencing and sequence analysis (I-IV).........................................62 
4.2.5 ELISA.................................................................................................64 
4.2.6 Cell culture in MA104 cells (I-II) .....................................................65 
4.3 Statistical methods (II, III, IV) ...........................................................................66 
5 Results ..............................................................................................................................67 
5.1 Shedding of RotaTeq vaccine strain rotaviruses...............................................67 
5.1.1 Prevalence of shedding (I,II) ............................................................67 
5.1.2 Duration of vaccine virus excretion (I, II) ......................................67 
5.1.3 Genotypes and combinations (I, II) ................................................70 
5.1.4 Shedding of vaccine-derived double-reassortant G1P[8] 
(I, II, unpublished) ............................................................................72 
5.1.5 Genetics of long-term shedding (unpublished) ..............................73 
5.1.6 Symptoms associated with vaccine strain shedding (II) .................75 
5.2 Rotavirus epidemiology in Finland 4 to 9 years after vaccine 
introduction (III, IV) ..........................................................................................77 
5.2.1 Circulating rotavirus genotypes in children (III, IV) ......................78 
5.2.1.1 Rotavirus vaccine effects on rotavirus disease and 
circulating genotypes (IV) ...............................................79 
5.2.1.2 RotaTeq vaccine-derived strains (III, IV) ......................81 
5.2.1.3 Rotavirus in vaccinated and unvaccinated children (IV)
 ...........................................................................................81 
5.2.2 Rotaviruses detected in adults and the elderly (III, IV) .................83 
6 Discussion........................................................................................................................84 
6.1 Shedding of RotaTeq vaccine rotaviruses .........................................................84 
6.2 Epidemiology of rotavirus in Finland 4 to 9 years after vaccine 
introduction .........................................................................................................88 
xi 
7 Conclusion and future prospects .................................................................................. 92 
Acknowledgements .................................................................................................................... 95 
References................................................................................................................................... 97 
Original communications ........................................................................................................ 123 
 
xii 
ABBREVIATIONS 
AGE Acute gastroenteritis 
ASC Antibody secreting cell 
DLP Double-layered particle 
dsRNA Double-stranded RNA 
ELISA Enzyme-linked immunosorbent assay 
Ig Immunoglobulin 
INF Interferon 
IS Intussusception 
mAb Monoclonal antibody 
NIP National Immunization Program 
NSP Non-structural protein 
REST Rotavirus Efficacy and Safety Trial 
RT-PCR Reverse transcription-polymerase chain reaction 
RTI Respiratory tract infection 
RV Rotavirus 
RVGE Rotavirus gastroenteritis 
THL National Institute for Health and Welfare 
VE Vaccine efficacy 
VP Viral protein 
vdG1P[8] Vaccine-derived double-reassortant 
 
xiii 
LIST OF ORIGINAL PUBLICATIONS 
This thesis is based on the following publications, which are referred to in the text 
by their Roman numerals. 
 
I Markkula J, Hemming M, Vesikari T. Detection of vaccine-derived 
rotavirus strains in nonimmunocompromised children up to 3-6 
months after RotaTeq vaccination. Pediatric Infectious Diseases 
Journal. 2015 Mar; 34(3):296-8. 
II Markkula J, Hemming-Harlo M, Vesikari T. Shedding of oral 
pentavalent bovine-human reassortant rotavirus vaccine indicates 
high uptake rate of vaccine and prominence of G-type G1. Vaccine. 
Accepted 4 Dec 2019.  
III Markkula J, Hemming-Harlo M, Salminen M, Savolainen-Kopra C, 
Pirhonen J, al-Hello H, Vesikari T. Rotavirus epidemiology 5-6 years 
after universal rotavirus vaccination: persistent rotavirus activity in 
older children and elderly. Infectious Diseases (Lond). 2017 
May;49(5):388-395. 
IV Markkula J, Hemming-Harlo M, Savolainen-Kopra C, al-Hello H, 
Vesikari T. Continuing rotavirus circulation in children and adults 
despite high coverage rotavirus vaccination in Finland. Journal of 
Infection. Article In Press. Accepted 26 Sep 2019. 
 
 
  
xiv 
 
  
 15 
1 INTRODUCTION 
Rotavirus (RV), a viral particle with the appearance of a wheel (Latin: rota = wheel), 
was detected for the first time in 1973 in the electron microscopy of duodenal 
biopsies and stool samples obtained from small children with acute gastroenteritis 
(AGE) symptoms. The novel virus was found and reported almost concomitantly 
by Bishop et al.(1) in Australia and by Flewett et al.(2) in the UK. However, the virus 
was discovered already ten years earlier in animals suffering from diarrhea(3,4). 
After its discovery in humans, the significance of the virus was understood as it 
showed to be the major causative agent of seasonal epidemics of diarrhea in small 
children, causing a high number of hospitalizations and deaths annually. It was 
estimated that on the verge of the implementation of the current RV vaccines at the 
beginning of 2000, RV gastroenteritis (RVGE) caused 450,000 deaths in children 
under five years of age globally, with the death toll being greater in developing 
countries(5). However, mortality was even greater prior to the development of oral 
rehydration therapy and its spread to developing countries. The significant burden 
of the disease inspired studies on the pathogen, and the development of RV vaccines 
began already in the 1980s with a Jennerian approach using animal and attenuated 
human RV strains as the first vaccine templates. The development took nearly 20 
years until Rotashield, the first RV vaccine, was licensed and taken into use in the 
US in 1998. Unfortunately, the vaccine was soon suspended and eventually 
withdrawn due to increased risk for intussusception (IS)(6). Half a decade later, after 
extensive safety and efficacy trials, the current RV vaccines, RotaTeq and Rotarix, 
were licensed. These vaccines are presently used globally, and the number of deaths 
due to RV has decreased drastically(7). Finland adopted the RotaTeq vaccine in 
September 2009, and since then, outpatient visits and hospitalizations due to RV 
have decreased by 90 %(8,9). 
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2 REVIEW OF LITERATURE 
2.1 Biology of rotavirus 
2.1.1 Structure of the virion and rotavirus genomics 
RVs are non-enveloped double-stranded ribonuclease acid (dsRNA) viruses with an 
icosahedral protein capsid. The capsid consists of an outer, intermediate and inner 
layer (Fig. 1). The size of an infectious triple-layered particle is around 100 nm. The 
RV genome consists of 11 segments of dsRNA contained within the inner core layer. 
Six of the genome segments code for six structural viral proteins (VP1-4, VP6-7) and 
the remaining five segments for six non-structural proteins (NSP1-6). Gene segment 
11 encodes for both NSP5 and NSP6. 
The structure of RV has been studied using cryo-electron microscopy and x-ray 
crystallography. The inner core layer consists of 120 molecules of the scaffolding 
protein, VP2 (2690 bp, 102 kDa), into which 12 replication enzyme complexes are 
attached(10). The complexes are formed of a viral RNA-dependent RNA 
polymerase, VP1 (3302 bp, 125 kDa), and a capping enzyme, VP3 (2591 bp, 88 
kDa)(11,12). On top of the VP2 core is the intermediate layer formed by 780 VP6 
(1356 bp, 45 kDa) protein units in the form of trimers that interact with both the 
inner and outer layer(13). Highly conserved VP6 is the most abundant protein in the 
RV virion, and it stabilizes the triple-layered particle structure by binding the VP2 
and VP7 layers together(10,14). The protein also has antigenic and immunogenic 
properties(15–17). The calcium-binding glycoprotein VP7 (1062 bp, 37 kDa) 
particles are arranged into 260 trimers on top of the intermediate VP6 layer(18). 
Protease-sensitive attachment protein VP4 (2362 bp, 87 kDa) trimers form 60 spike 
structures that are attached to the VP6 layer at their base and held in place by the 
surrounding VP7 trimers(19,20). VP7 and VP4 form the outer layer of the virion 
and both also induce neutralizing antibodies(18,19). During cell entry, intestinal 
trypsin-like proteases cleave the VP4 protein by proteolysis into two polypeptides, 
VP5* (stalk and basis) and VP8* (head of the spike) which remain associated in the 
virion(20).  
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The RV protein capsid has three different types of channel, of which type I 
channels are formed by VP6 and VP2 units; they function as exit routes from the 
virion for the transcribed messenger RNA (mRNA)(21). Type II channels are 
formed of VP6, and they are located around the type 1 channels. The 60 VP4 spike 
proteins are on the edge of these channels(22–24). Type III channels are also located 
in the intermediate VP6 layer in the form of hexamers. All three channels function 
as binding sites for human VP6 antibodies(24). 
Non-structural proteins are located inside the virion, and they each have a specific 
role in RV replication and pathogenesis. NSP1 (1581 bp, 58 kDa) affects the innate 
immune system by down-regulating the interferon (INF) system, and it delays cell 
death by degrading pro-apoptotic proteins at the beginning of RV replication(25,26). 
NSP2 (1059 bp, 35 kDa) has the ability to bind to single-stranded RNA non-
specifically(27), to destabilize nucleic acid helix structure(28), and has also several 
enzymatic activities(29,30). The NSP2 and NSP5 complex forms the viroplasm in 
the infected cells in which RV replication occurs(31). NSP5 (667 bp, 21kDa) is a 
serine- and threonine-rich dimer-forming protein that binds to both single- and 
double-stranded RNA, but possible other specific functions of NSP5 remain 
unclear(32,33). NSP6 (278 bp, 12 kDa) is encoded by the same segment 11 as NSP5, 
and it is known to interact with NSP5; like NSP5, the precise role of NSP6 is still 
unknown(34). NSP3 (1074 bp, 36 kDa) facilitates mRNA translation and suppresses 
host protein synthesis(35,36). NSP4 (751 bp, 20 kDa) is the only non-structural 
protein without an RNA-binding function. The protein is multi-functional as it 
modulates the intracellular accumulation and cellular distribution of viral proteins in 
the viroplasm, and therefore it is essential in controlling RV transcription and 
replication(37,38). NSP4 has also been shown to act as a viral enterotoxin(39). 
 
Figure 1.  A) Schematic illustration of the structure of rotavirus. B) Multiple rotavirus particles 
detected by transmission electron microscope. Electron microscope picture: Dr Graham 
Beards under the Creative Commons Attribution 3.0 Unported License(40). 
 18 
2.1.2 Classification and nomenclature 
RVs belong to the genus Rotavirus of the Reoviridae family. RVs have been traditionally 
classified into groups (I or II) by serological methods based on the antigenic 
properties of VP6, the inner layer protein. More recently, classification has been 
made according to the amino acid sequence of the VP6. On the basis of our current 
knowledge, there are eight different serogroups (A to H) which infect different 
species. Serogroups A to C and H are known to infect humans. Group A RVs cause 
more than 90 % of all RV infections in humans.(41) Genetic reassortment is possible 
only between RVs of the same group(42). 
RVs are further divided into genotypes, or G- and P-types, according to the 
nucleotide sequences of the outer layer proteins VP7 and VP4, respectively. G stands 
for “glycosylated” and P for “protease-sensitive”, according to the main function of 
the protein. To date, at least 27 different G-types and 35 P-types have been 
identified.(43,44) Genotypes of the other nine RV group A genes have also been 
identified, and the schematics for representing the whole genome constellation of 
RV, VP7-VP4-VP6-VP1-VP2-VP3-NSP1-NSP2-NSP3-NSP4-NSP5/6, has been 
defined using the following abbreviations Gx-P[x]-Ix-Rx-Cx-Mx-Ax-Nx-Tx-Ex-Hx, 
where x is an Arabic number; indicating the genotype(44). Genotypes can be further 
divided into subgenotypic lineages on the basis of phylogenetics. Antigenic 
properties may differ greatly between the lineages of the same genotype (45).  
2.1.3 Replication 
 
RV infects mature enterocytes in the middle and the tip of the villi, and also the 
enteroendocrine cells in the small intestine(46,47). The RV replication cycle can be 
divided into five steps: attachment to the host cell, cell entry, transcription and 
translation, virus particle assembly and maturation, and release. 
RV attachment to the host cell is a complex process that is still partly unknown. 
The process begins when intestinal protease-like trypsin cleaves VP4 into VP8* and 
VP5* particles. This causes VP5* to undergo conformational change which causes 
the protein to become more rigid and expose hydrophobic loops, both of which are 
important for cell entry(48,49). Binding is initiated by VP8*, which has been shown 
to interact with sialic acid on cellular glycans and histo-blood group antigens(50–52). 
After initial attachment by VP8*, several co-receptors – such as integrins and heat 
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shock protein 70 – also take part in the process and interact with VP5* and VP7 to 
mediate viral entry(50,53). 
RV cell entry is strain-dependent as most strains enter using clathrin-mediated 
endocytosis, but other pathways have also been reported(49,54). As the RV-
containing endosome enters the cell, the calcium level decreases, and the calcium-
active VP7 layer is solubilized together with VP8* and VP5*. This increases the 
permeability of the endosomal membrane, and the transcriptionally active double-
layered particles (DLP) are released into the cytoplasm.(55–58) 
Release of DLPs activates the transcription of RV plus-strand RNA, which is 
facilitated by 12 transcription complexes (VP1+VP3) attached below the inner VP2 
layer. Each complex transcribes only one dedicated genome segment. Transcribed 
RNAs are capped and extruded from the DLP into the cytoplasm through type I 
channels.(21,59) Antibodies against VP6 attach over these channels and inhibit 
intracellular translation(24). Plus-strand RNA serves as a template for the translation 
of viral proteins but also as a template for genomic dsRNA production(60). RV 
utilizes the host cell’s protein synthesis machinery, and viral mRNAs compete with 
cellular mRNA for translation. NSP3 bound to viral mRNA enhances viral RNA 
translation while similarly interfering with cellular protein synthesis(36,61). 
Newly translated viral proteins and plus-strand RNA accumulate into viroplasms, 
cytoplasmic inclusions formed by NSP2, NSP5 and intracellular lipid 
droplets(31,62–64). VP1 and VP3 form 11 polymerase complexes that bind to 
specific plus-strand RNA segments that each encode different proteins(65). 
Synthesis of dsRNA is activated when the complex attaches to the self-assembled 
VP2 layer. After completion of the VP2 layer, the middle VP6 layer self-assembles 
to form DLPs.(66,67) 
Nascent DLPs are then budded through the endoplasmic reticulum for 
maturation. During the formation of the outer layer, DLPs are transiently enveloped. 
First, VP4 trimers are attached over the VP6 layer in interaction with NSP4, and 
finally VP7 trimers are layered on top, securing the VP4 trimers in place and 
completing the infectious triple-layered particle structure(66,68,69). Mature virions 
are then released from the cells by direct lysis or by the Golgi-independent transport 
system(70,71). 
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2.1.4 Antigenic epitopes and antibodies 
 
The structure of RV contains several antigenic structures. To date, at least VP7, VP4, 
VP6 and NSP4 have been shown to induce a monoclonal antibody (mAb) response. 
The outward-facing side of the outer layer protein VP7 contains two antigenic 
epitope regions, 7-1 and 7-2, of which the first is divided into subregions 7-1a and 
7-1b. Both, 7-1 and 7-2 have been shown to be bound with numerous different 
mAbs mainly in a serotype-specific manner.(18) Antibodies against VP7 have been 
shown to neutralize the virus by stabilizing the VP7 structure and blocking the 
uncoating of the VP7 capsid(18,72).  
The trypsin-cleaved progeny of the intermediate-layer protein-sensitive VP4 
protein, VP8* and VP5*, both contain several antigenic sites: VP8* four (8-1, 8-2, 8-
3 and 8-4) and VP5* five (5-1, 5-2, 5-3, 5-4 and 5-5)(48,73,74). Anti-VP4 mAbs have 
been thought to neutralize and affect in a serotype-specific manner mainly against 
VP8*, hence inhibiting viral binding. However, Nair et al.(75) showed that anti-VP5* 
mAbs were also neutralizing, but the mechanism is yet unknown(76–78). The 
authors showed that VP5* mAbs generated broad heterotypic protection in humans 
that is not serotype-related(75).  
Similar to the other two capsid proteins, the most abundant inner layer protein, 
VP6, has antigenic and immunogenic properties and two distinguished epitope 
regions(24,79). Anti-VP6 mAbs bind to the transcriptional pores on the surface of 
the VP6 layer, inhibiting transcription, which leads to intracellular neutralization, that 
is not shown in traditional in vitro neutralization studies(80,81).  
Of the non-structural proteins, some reports have been published on the 
protection elicited by NSP4, the viral enterotoxin. In two mural studies, NSP4 
antiserum showed protection from RV diarrhea when immunized before infection, 
and in the other study, it also halted the disease process when administered after the 
onset of diarrhea.(39,82) However, immunoglobulin (Ig) G levels against NSP4 have 
shown to be modest in humans questioning the role of NSP4(16,83). 
2.2 Rotavirus disease 
RVs are highly contagious due to three factors: Firstly, the infective dose of RV is 
low and only a few viral particles are needed for clinical infection(84). Secondly, the 
virus is transmitted through the fecal-oral route, and it is able to survive on different 
surfaces and media even for months. In addition, aerosol as a possible transmission 
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route has been speculated for more than 30 years without solid evidence.(85) Thirdly, 
a large number (up to 1010 particles per gram) of viruses are shed into stools already 
before the onset of symptoms, and shedding may continue for weeks after 
infection(86–88). 
2.2.1 Clinical picture and pathophysiology 
The clinical picture of RV infection in children is broad, ranging from asymptomatic 
infection to severe, life-threatening AGE. The infection usually begins with vomiting 
and fever that are accompanied 24 to 48 hours later with watery diarrhea that ranges 
from mild to severe. The combination of diarrhea, vomiting and fever may lead to 
severe dehydration, hyperchloremic acidosis and in the worst case to death.(89,90) 
RV incubation time ranges from one to two days and the illness itself is usually lasts 
5-7 days(89,91). 
 
Diarrhea 
To date, the exact mechanism of RV-associated diarrhea is not fully understood, and 
it is likely that there are more than one mechanism causing. One suggested 
mechanism is secretory diarrhea caused by the viral enterotoxin NSP4 and enteric 
nervous system activation. The association of NSP4 with diarrhea was first detected 
in mice(39). Later studies have revealed that the binding of NSP4 to intestinal cells 
activates signaling system, which promotes calcium-dependent chloride 
channels(92,93). This leads to secretion of chloride ions into the gut lumen and to 
an increased osmotic gradient transporting water, resulting in secretory diarrhea. 
NSP4 also increases intracellular calcium levels, which increases serotonin release 
from the enteroendocrine cells; this in turn increases intestinal motility by activating 
the enteric nerves innervating the small intestine(94,95).  
Another mechanism may be malabsorption in the small intestine due to 
enterocyte damage and death. Only a few biopsies from children with RVGE have 
been studied, but they have shown an irregularity of the mucosal cell lining with 
shortening and blunting of the villi together with an increase of inflammatory cells 
in the lamina propria(1,96,97). It is known that NSP4 has an effect on cell apoptosis 
but also causes changes in the tight junctions of the intestinal cell lining leading to 
increased permeability(98,99). This theory has been criticized, however, as oral 
rehydration therapy has shown great response in RVGE(53). 
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Vomiting 
 
Release of serotonin due to NSP4 has been shown to activate afferent vagal nerves, 
a two-way pathway between the gut and the brain, causing stimulus in the vomiting 
center and producing vomiting and a sense of emesis during RV infection(47). Liquid 
flow through the gut has also been shown to be delayed during acute RV infection, 
also causing vomiting and nausea. Gastric emptying is also regulated by the vagal 
nerve circuitry, and therefore it is likely that the NSP4-serotonin pathway may cause 
decreased motility, but the relation to RV is still to be determined.(53,100) 
 
Fever 
 
Elevated levels of different cytokines functioning as endogenous pyrogens – 
including interleukin-6 and tumor necrosis factor-α – have been reported in the 
serum of feverish children with RVGE(101).  
 
Extraintestinal spread 
 
Even though the gut is the main organ system for RV replication, recent studies have 
shown that the spread of RV antigens into the serum (antigenemia) is common (in 
up to 90 % of children showing gastroenteritis symptoms) also in immunocompetent 
children, and it is associated with a more severe clinical picture(102,103). In some 
cases, antigenemia is also related to viremia, the presence of whole infective RV 
particles in the circulation(102). However, the clinical significance of viremia has 
remained unknown. In addition, there have been case reports of RNAemia; RV RNA 
has been detected in several different tissues, such as cerebrospinal fluid of children 
with meningitis(104), and in the liver and biliary tract tissue of children with biliary 
atresia(105). 
Vesikari Score system 
Several numeric scales have been developed to assess the severity of AGE and as a 
scientific tool to study vaccine impact. The most commonly used is the 20-point 
Vesikari score system(106). The grading of symptoms is shown in Table 1. The 
severity is scaled according to total points as follows: <11 points – mild, 11-15 points 
– moderate, ≥16 severe. 
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Table 1.  The 20-point Vesikari scoring system. 
Symptom or sign 
Points 
1 2 3 
Duration of diarrhea (d) 1-4 5 ≥6 
Max no. diarrheal stools/24h 1-3 4-5 ≥6 
Duration of vomiting (d) 1 2 ≥3 
Max no. vomiting episodes/24h 1 2-4 ≥5 
Fever 37.1-38.4 38.5-38.9 ≥39.0 
Dehydration - 1-5 % ≥6 % 
Treatment Polyclinical rehydration Hospitalization - 
2.2.2 Laboratory detection of rotaviruses 
As previously described, RV was first visualized using electron microscopy, which 
was highly specific for detecting morphologically unique RV but had a low 
throughput of samples and was expensive as a diagnostic tool(1,2,107). Electron 
microscopy remained as the gold standard for RV detection for a long time, despite 
having a relatively low sensitivity of around 80 %. Over time, many other methods 
have been used for RV detection, such as immune-electron microscopy, latex 
agglutination and immunofluorescence. In diagnostic use, different enzyme 
immunoassay derivatives, such as enzyme-linked immunosorbent assay (ELISA), 
based on the use of RV antibodies to detect the RV antigen, have superseded the 
previous methods due to a combination of high sensitivity, low-cost and speed.(108–
110) 
ELISA has remained as the robust diagnostic method par excellence. The 
development of the reverse transcription-polymerase chain reaction (RT-PCR) has 
replaced serotyping by genotyping, and the method has several advantages in 
comparison to ELISA. It is more sensitive, and in addition to the positive-negative 
result, all gene segments may be sequenced and possible changes in the sequences 
traced(111). However, RT-PCR as a procedure is time consuming and the therefore 
RV antigen-detecting ELISA continues to be the main assay in diagnostics. Recently, 
due to the latest developments in the real-time RT-PCR technique, PCR has also 
increased its potential for detecting RV and other viral causatives of AGE in one 
rapid multiplex assay(112). In research use, next generation sequencing methods 
have been established for efficient sequencing of the whole RV genome(113). 
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2.2.3 Immune response 
Human immune response to RV infection is multifactorial and still in many parts 
unknown. It consists of innate and acquired components of which the first initiates 
the response while recognizing the virus and thereafter signals an acquired response 
to initiate. Main features of host immune response against RV are summerized in 
Table 2. 
2.2.3.1 Innate immune response 
 
The innate immune system is complex but agile in eliciting the initial defensive 
measures when encountering microorganisms or foreign substances. It consists of 
several different components, including recognizing molecules, the complement 
system, antigen-presenting cells, macrophages, monocytes and granulocytes. 
Epithelial cells are also part of the innate immune system, as they form a physical 
barrier against pathogens and excrete chemokines and cytokines, signaling to and 
recruiting other cells.(114) The response varies depending on the infected cell type 
and the infecting RV strain, and therefore the following is only a short description 
of the innate immune response to RV.  
Table 2.  Main characteristics of innate and acquired immunity against rotavirus infection. 
 Innate immunity Acquired immunity 
Rotavirus recognition Intracellular receptors binding on RV Antigens presented by antigen presenting 
cells (macrophages, dendritic cells) 
Method of action ▪ Interferon mediated pathways leading to 
“antiviral state”  
▪ Activation of acquired immunity 
B cell response 
▪ Production of mAb (IgA, IgG and IgM) 
▪ Long-term protection 
T cell response 
▪ B cell activation (CD4+) 
▪ Direct cell lysis (CD8+) 
Related cells Epithelial cells, dendritic cells Dendritic cells, B and T cells 
Rotavirus escape 
methods 
Inhibitory effects by NSP1 Mutations of antigenic sites decreasing 
affinity of mAbs 
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After cell entry, RV is recognized by and bound to several receptors – such as 
melanoma differentiation-associated gene-5, retinoic acid-inducible gene-I, and toll-
like receptors – eliciting host transcription factors, including INF regulatory factor 3 
and nuclear transcription factor-κB(115,116). These factors furthermore activate the 
expression of type I INFs and INF-stimulated genes, leading to abundant excretion 
of different INFs and INF-stimulated genes, mainly INF-α and INF-β, to 
neighboring cells(33,115). INF-α and INF-β then activate the Janus kinase-signal 
transducer and activator of transcription protein signaling pathway, leading to 
upregulation of numerous INF-stimulated genes and other immune effector cells, 
and to an “antiviral state”. However, to date the specific mechanisms of only a few 
INF-stimulated genes have been discovered but the role of INFs as a signal mediator 
in RV infection was established early on.(33,117,118)  
Dendritic cells are probably the most important in eliciting the immune response 
against RV, as they combine both innate and acquired immune systems(119). It has 
been reported that plasmacytoid dendritic cells are highly resistant against RV 
replication, unlike other cells; they secrete INF-α and INF-β in high amounts after 
recognizing the viral particle(120). In addition, plasmacytoid dendritic cells have 
been shown to elicit T cell independent B cell activation in RV infected mice also 
mediated by type I INFs and to play a role in the induction of mucosal IgA 
response(119,121). 
The  interferon antagonist protein NSP1 has an important role in inhibiting the 
innate immune response against RV(26). In the light of the current knowledge, the 
effects of NSP1 are targeted mainly against the production of IFN-β. It mediates 
proteasomal degradation of the host transcription factors – such as INF regulatory 
factors 3 and 7 – needed in the transcription of IFN-β and in the indirect inhibition 
of nuclear transcription factor-κB, all leading to a decrease in the production of INF-
β(122,123). NSP1 also affects on the later stages of the “antiviral state” by inhibiting 
phosphorylation of the signal transducer and activator of transcription-1(124). 
2.2.3.2 Acquired immunity 
Acquired or adaptive immunity is the second line of defense, and it is needed in case 
the innate immune system cannot eliminate the pathogen. The acquired immune 
system is based on recognition of a specific antigen, a part of an infectious organism, 
which elicits an immune response. It acts together with the innate immunity, as 
antigen-presenting cells such as macrophages and dendritic cells are needed for 
pathogen recognition and to elicit a reaction in the cells of the adaptive immune 
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system. The system consists of B and T cells, of which the first act against pathogens 
outside human cells and the latter against the pathogens that have infected or have 
been taken into host cells.(114) 
 
B cell response 
B cells mediate humoral immunity by synthesizing and excreting antigen-specific 
antibodies. They are classified into immature, mature, memory and plasma cells, each 
having specific function. When a naïve mature B cell captures an antigen and in a 
lymph node presents it to a CD4+ T cell – also known as the helper T cell –, the B 
cell begins to rapidly proliferate and interacts with follicular dendritic cells presenting 
the same antigen. B cells with the highest affinity against the presented antigen are 
selected while the rest are removed by apoptosis. After interacting with the helper T 
cell, these proliferated high affinity B cells change the type of Ig produced from IgM 
to either IgA, IgE or IgG. These cells then specialize into plasma or memory cells 
by an unknown mechanism. The function of plasma cells is to synthesize and excrete 
antigen-specific Igs into the bloodstream. Some of these cells, called long-lived 
plasma cells, migrate into the bone marrow and secrete IgG and IgA in large 
amounts, eliciting a long-lasting protection against the pathogen. Long-lived memory 
B cells, expressing IgA, IgE or IgG, also enable a rapid response against a subsequent 
encounter with the antigen by turning into Ig secreting plasma cells.(114) 
Of the Ig isotypes, IgM, IgG and IgA are the most common and have been shown 
to be important in the immune response against RV. IgM is the first antibody to be 
produced in RV infection. It lacks viral neutralization qualities, but it forms an 
antigen-specific B cell receptor together with IgD on the surface of the B cells, which 
is needed for isotype switch. IgGs are usually located in the circulation or lymphoid 
tissue, and are long-lived, with an approximate half-life of 23 days. Their main 
functions include opsonizing the attached antibody for phagocytosis, antigen 
presentation for natural killer cells, and activation of complement. IgA can be 
divided into serum and secretory IgA. Secretory IgA is synthesized and secreted by 
plasma cells located in Peyer’s patches in the lamina propria, a layer of connective 
tissue beneath the mucosal epithelium. The synthesized IgA is then transported to 
an extracellular fluid compartment such as the gastrointestinal or respiratory 
tract.(114) 
During a first-time encounter, plasmacytoid dendritic cells recognize RV, causing 
a type I IFN response; this leads to the initiation of a T cell independent B cell 
response and to a notable expansion in the number of B cells(119,121,125). This in 
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turn results in early mucosal synthesis and the secretion of RV VP6 specific low-
affinity IgM, accompanied days later by RV-specific IgA, which is later on supported 
by T cell dependent B cell activation and abundant IgA synthesis(125–128). 
According to studies in mice, RV antibody response is regionally distributed, as IgA 
is abundantly synthesized in intestinal tissue and only fractions can be measured in 
the circulation during the acute phase. Systemic antibody response is more likely to 
be mediated by circulating RV-specific IgM and IgG.(129–132) However, the role 
of antibodies in the clearance of infection is not clear, as Franco et al.(133) showed 
that B cell deficient mice cleared the infection similar to controls. 
 
Maternal antibodies 
Anti-RV IgG is transferred transplacentally from the mother to the fetus while IgA 
is transferred to the newborn via the colostrum and breastmilk(134). The serum IgG 
levels of infants are similar to those of mothers, providing the newborn protection 
during the first months of life, after which the IgG level begins to decline until a 
further increase due to natural RV infection or vaccination.(135,136). Orally 
obtained IgA remains in the gut, providing temporal local protection as long as 
lactation continues(135). Both IgA and IgG levels in breastmilk are higher in low- 
than in high-income settings and could cause lower vaccine uptake and thereby be 
one explanation for the poorer vaccine real-life effectiveness seen in low income 
setting(137,138).  
 
T cell response 
T cells are divided into two main subgroups, CD4+ and CD8+, according to their 
surface co-receptor molecules. Naïve T cells are activated by an interaction with an 
antigen-presenting cell, such as a macrophage or dendritic cell, leading to 
proliferation, differentiation or survival. As earlier mentioned, CD4+ T cells are 
needed in B cell activation, but they also secrete several cytokines affecting numerous 
cells of both innate and acquired immunity. In the case of RV infection, subtype TH1 
CD4+ T cells produce IFN-γ and interleukin-2, which increases the activation of 
macrophages, CD8+ T cells and natural killer cells. CD8+ T cells are activated 
principally in the same manner as CD4+ cells, but in some cases, for an unknown 
reason, CD4+ cells are needed in the process. Their main function is to kill infected 
cells via two pathways, of which the major route increases the target cell’s 
permeability by adding pores to the cell membrane; the other pathway causes 
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apoptosis by signaling pathway activation. After elimination of the T cell response, 
a small proportion of CD4+ and CD8+ T cells transform into memory cells, which 
enable a quicker and more efficient response in comparison to the initial response 
when the same pathogen is met again.(114) 
The majority of studies on cell-mediated immune response against RV have been 
conducted in mice, and therefore the results cannot be directly extrapolated to 
humans. In murine models, CD4+ T cells have been shown to be crucial for eliciting 
B cell-mediated antibody response against RV and especially for long-term 
protection against subsequent infections(139,140). CD8+ T cells have been 
associated with RV clearance, but they also take part in short-term 
protection(140,141). It has been shown that CD8+ T cells are not absolutely 
necessary for clearance of RV, but their absence causes a delay in 
clearance(133,140,142,143). A lack of CD4+ T cells or both,CD4+ and CD8+ T 
cells, on the other hand, led to prolonged infection at a low level, showing T cell 
independent B cell activity controlling but not resolving the infection(142). 
2.2.4 Long-term protection and correlates of protection 
 
Cellular mechanisms of long-term RV immunity 
Both B and T cells probably have an effect on long-term immunity. According to a 
murine study, a total lack of B cells leads to recurring RV infections, suggesting that 
antibodies are vital for the formation of long-term immunity, while the role of T 
cells is not as clear(133). Other murine studies have shown indications of the 
involvement of effector – but not memory – CD8+ T cells on short-term 
protection(141,144). CD4+ T cells are also involved in development of protection 
after parenteral inoculation with non-live VP6 particles(145). 
As acute-phase antibody secreting plasma cells (ASCs) are rather short-lived, 
long-term protection is based on memory B cells. Yuan et al.(132) studied the 
locational distribution of plasma and memory cells in gnotobiotic pigs after oral 
inoculation with virulent and attenuated human RV strain and challenged the pigs 
with virulent strain. Inoculation with the virulent strain mimicking response to a 
natural RV infection; it elicited a high response in IgA ASCs and a moderate 
response in IgG ASCs and IgG memory B cells of intestinal lamina propria. Whereas 
vaccination with the attenuated RV strain – similar to current RV vaccination in 
humans – showed no ASC response, instead there was a high IgG memory cell 
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response in the spleen. After the challenge with the virulent RV strain, the responses 
between the groups were different. Pigs with the initially virulent infection showed 
only a moderate IgA ASC response, while pigs inoculated with the attenuated RV 
elicited an IgA and IgG ASC response in the lymphoid tissue of lamina propria. 
Memory B cells responses also differed, as pigs originally inoculated with the virulent 
strain showed a broad IgG-related response in the intestinal lymphatic tissue, spleen 
and peripheral blood, whereas in the attenuated group, the response was moderate, 
IgM- and IgG-related and only seen in the peripheral blood.(132) 
Studies on memory T cell function in long-term protection are still underway. 
Offit et al.(146) measured increased lymphoproliferative activity in children up to 
eight months after RV infection. However, the increase began not until after the 
acute phase of primary infection. By contrast, Mäkelä et al.(147) did not find a similar 
persistence as the responses declined soon after RV infection, including also 
secondary infection. The authors used healthy adults as controls and found higher 
activity in asymptomatic adults than in infected children. A similar finding was made 
by Jaimes et al.(148), and both of the authors speculated that as RV-specific memory 
T cells express a gut-associated homing receptor, the number of the cells circulating 
in the peripheral blood is low but eventually increases to a significant level after an 
increasing number of reinfections(147,149). 
Clinical correlates of protection 
One of the first clinical reports on protection against natural RV infection was by 
Chiba et al.(150), who studied three consecutive RV epidemic seasons in an 
orphanage in Japan. The children had increasing serum antibody levels after 
consecutive infections, and in some cases, the second or third infection became 
asymptomatic suggesting that recurring infections could provide protection against 
following infections(150). Velázquez et al.(151) followed RV infections in a cohort 
of Mexican children for the first two years of life. In that study, the primary RV 
infection was the most severe while the following infections appeared with milder 
symptoms and eventually became subclinical. In fact, after two infections, protection 
against moderate to severe disease was calculated to be 100 %(151). 
While in the clinical studies, protection by natural RV infection seems evident 
and inevitable with recurrent infections eventually leading to protection against 
further symptomatic infections, from the immunological perspective the case is not 
as unambiguous. The role of different Igs and antigenic structures has varied greatly 
between studies. In adults and children, some studies have shown that clinical 
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protection correlated with serum IgG(152,153), others have shown that serum 
IgA(154) was the determinant of protection, while in some studies(155,156) both of 
the presented Igs elicited protection. In early adult challenge studies, Kapikian et 
al.(157) and Green et al.(158) showed that clinical protection correlated with high 
serum neutralizing mAb titers against VP7 or VP4. Later studies in children have 
found a similar correlation(150,155). However, no such correlation was found in two 
studies by Ward et al.(152,159).  
During the course of time and numerous clinical vaccine studies, the serum IgA 
level against VP6 has been shown to be a good – but not optimal – clinical correlate 
of protection, especially against severe RV disease, as measured in the licensure 
studies of the two current vaccines, RotaTeq and Rotarix(154–156,160,161). The 
protein is highly antigenic, as shown by Svensson et al.(15) and Johansen et al.(162), 
who studied serum samples obtained from children with radioimmunoprecipitation 
assays. In these studies, VP6 elicited a noticeably stronger serum antibody (IgG and 
IgA) response in comparison to other RV components, including VP7 and 
VP4(15,162). Murine studies have shown protection after systemic exposure to anti-
VP6 mAbs and intranasal immunization with VP6, supporting the role of VP6 IgA 
as a mediator and correlate of protection(81,145,163). Despite being a good measure 
of clinical protection against wild-type RV infection, IgA is not needed for protection 
in murine model, unlike IgG(164).  
Protection after natural RV infection has been shown to be highly homotypic, 
but the infection also elicits antibodies against other strains(150,165). Yuan et 
al.(166) suggested that protection against natural RV infection is mainly strain-
specific (homotypic) and correlates especially with IgG against VP7 and VP4 but 
heterotypic protection was also detected(166). In a Mexican follow-up study by 
Velazquez et al.(151), only 2 out of 22 paired infections were caused by the same 
genotype, suggesting strain-specific protection. On the other hand, Chiba et al.(150) 
measured high antibody titers against the causative strain but increases in titers 
against other strains as well. Ultimately, the most conclusive evidence on behalf of 
heterotypic protection is the high efficacy and real-life effectiveness of the single 
human RV strain G1P[8] vaccine(161,167–169).  
 
Vaccine elicited immunity 
 
Patel et al.(170) analyzed clinical vaccine studies conducted on both of the currently 
used vaccines, Rotarix and RotaTeq, and found an inverse relation between 
measured serum IgA levels and childhood mortality in children aged under five years 
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of age – a higher post-vaccination titer resulted in lower mortality. Serum IgA levels 
also seemed to predict vaccine efficacy well for both vaccines. Another analysis made 
solely on Rotarix pre-licensure data found evidence of a relation between serum IgA 
seroconversion and efficacy(171). In fact, Patel et al.(170) made a similar observation 
regarding Rotarix, but in that material, seroconversion did not correlate with vaccine 
efficacy in children who received RotaTeq vaccine. Even though the role of serum 
IgA has shown some evidence as a marker for protection, the findings contain 
inconsistencies, signifying that natural as well as vaccine-induced protection against 
RV is multifactorial. It is as well likely that the immunity provided by natural RV 
infection and vaccination differ. 
2.3 Epidemiology of rotavirus 
2.3.1 Burden of disease 
In 2016, it was estimated that RVGE causes approximately 230,000 deaths in all age 
groups globally, of which 130,000 occur in children under five years of age(7). Before 
the licensure and introduction of RV vaccinations, the annual death toll was more 
than 450,000 only in children younger than five years(5). Geographically, mortality 
is greatly unbalanced, as most deaths are seen in developing countries with limited 
healthcare resources, a lack of clean water and childhood malnutrition. While death 
due to RV is rare in industrialized countries, RV is still a common cause for 
hospitalization, thus inducing an economic burden(9,172–174). 
 
Rotavirus seasonality 
No certain pattern has been identified to explain differences in the seasonality of RV 
disease between different countries. For a long time, it was thought that climate 
would explain why clear high activity seasons are present in temperate zones while 
the disease is seen throughout the year in the tropics(175,176). However, more 
recent analyses have shown that although the weather might have an effect on RV 
circulation, the climate does not explain changes in RV activity, which rather is a 
sum of several factors. In fact, income level has been shown to be a better predictor 
of annual fluctuations compared to climate zones(177). Furthermore, recent 
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computer models have shown that changes in birth-rate may have an effect on RV 
epidemics, as epidemics occur earlier during the years with a high birth-rate(178). 
2.3.2 Circulating rotavirus strains 
Surveillance of circulating RV strains began already in the 1970s. The primary goal 
of the surveillance was to gain better knowledge of the pathogen, then to collect 
strain-specific data for vaccine development and finally to study the effects of RV 
vaccines on the circulating strains. During this more than 40-year period of follow-
up, despite natural fluctuations in the circulating strains, four main genotypes 
remained common: G1P[8], G2P[4], G3P[8] and G4P[8]. Globally, these genotypes 
have caused approximately 90 % of all RV cases, G1 being the most common 
serotype(179,180) 
A large review by Santos et al.(180) covering the pre-vaccination era from the 
1970s to 2003 reported geographical differences in the genotype distribution, as 
G1P[8] was most common in Australia, Europe and North America, while in Africa, 
Asia and South America other genotypes, such as G3, G4 and G8 were more 
common during that 30-year period. In addition, the number of different uncommon 
combinations of VP7 and VP4 was far higher in these areas, forming nearly a third 
of the cases (Fig. 2). Of the VP4 types, P[6] was practically seen only in Africa, where 
it was the second most common P-type after P[8], while in other regions, P[8] and 
P[4] were seen in more than 90 % of the cases.(180) 
Before the introduction of RV vaccines, it was speculated that the strains 
contained in the vaccine would be suppressed and new strains would emerge as a 
cause of mutations and reassortment caused by the vaccines. However, already at 
the end of the 1990s, before the licensure of RV vaccines, the G9P[6] strain emerged 
globally at a common level and through reassortment with a P[8] strain, the formed 
strain G9P[8] became the fifth main RV strain(181–186). A few years later, in the 
mid to late of 2000s, another novel genotype, G12P[8], was detected in several 
countries and the prevalence soon rose to the common level, becoming the sixth 
main RV strain to date(187–190). Phylogenetic analyses have shown that the strain 
originated from porcine G12 that has reassorted with the human G1P[8] 
strain(191,192). It was reported early on that these novel strains were more capable 
of causing severe clinical disease, but in total the results are controversial, as there 
are reports showing similar or milder severity in comparison to the “original” strains 
such as G1(188,193–197). 
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Figure 2.  Geographical distribution of the most common rotavirus G-types before rotavirus vaccine 
introductions(180). World map by user: Vardion, modified under the Creative Commons 
Attribution 3.0 Unported License(40). 
In addition to geographical differences, circulating strains have a natural tendency to 
fluctuate year-to-year and even during a single season. In a large study analyzing RV 
genotypes and the occurrence during and outside the high season in Europe, it was 
noted that G1P[8] was dominant during the high seasons, but this predominance 
declined during the off seasons and other genotypes became more frequent(198). 
Analysis of epidemiological genotype data has suggested that the period of 
predominance of one strain ranges from 3 to 11 years, and in the case of G1, the 
cycle is on average longer, from 5 to 11 years(199). In fact, Pitzer et al.(199) 
speculated that a possible explanation for the cyclic nature of the predominant strain 
might lie in homo- and heterotypic immunity. The fluctuation of RV genotypes is 
the sum of several factors on the individual and population level. The accumulation 
of children with a strong homotypic immune response against the predominant 
strain may predispose to infection by heterotypic strain, which eventually may lead 
to ousting of the predominant strain.(199) 
 
Finland 
The earliest data describing RV epidemiology in Finland dates back to the 1980s, 
when over four seasons of follow-up (1986-1990), G1 was the most common 
genotype. However, natural fluctuation of RV genotypes was apparent, as G4 was 
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by far more common during the 1988-89 season.(200) A similar predominance of 
G1 continued also in the 1990s and up to two seasons (2006-2008) before the 
vaccine introduction in 2009(201,202). No major changes in the circulating 
genotypes were seen during the first two seasons (2009-2011) after the introduction 
of the RotaTeq vaccine at the beginning of September 2009. Although G4 was 
indeed more common during the first season, G1 retained its predominance during 
the latter season.(203) Another two season (2012-14) follow-up was conducted by 
Hemming-Harlo et al.(8) showing a low RV presence overall. The low total number 
(40 cases) of wild-type RV cases detected during those seasons signaled the high 
effectiveness of the vaccine. Genotype distribution did not offer any surprises as 
G4P[8] (11 cases) was more common in total compared to G1P[8] (10 cases). 
G12P[8], a novel genotype, was observed for the first time in Finland during the 
2012-13 season.(8) 
2.3.3 Rotavirus in adults 
RV was noted also as a common pathogen for adults in the 1970s, but due to the 
outbreak occurrence and the milder or even asymptomatic clinical picture, RV has 
been viewed as a disease of children(204–206). Therefore the occurrence of RV in 
adults has remained partly less known, but it has been estimated that in the elderly 
population aged 70 and above, RV causes approximately 58,000 deaths annually(7). 
In addition, pathogen testing is not standard of care in adults with periodic diarrhea 
in most countries. The notion of previous RV infections being protective against the 
development of severe symptoms in recurring infections in children probably 
expands also into adults and the elderly(156). 
The incubation period of RV in adults ranges from two to six days; this is longer 
than in children, whereas the duration of illness itself is usually shorter, one to four 
days, in adults. The clinical picture varies greatly(157). The main symptoms are the 
same as in children, but dehydration is more seldom in adults. The development of 
a more severe clinical picture or prolonged diarrhea is usually related to 
immunocompromising or other co-morbidities such as malignancy or diabetes(207–
209). In the US, approximately 30 % of the cases are associated with lowered 
immune response(210). 
RV disease in adults is mostly endemic and cases are seen throughout the year, 
whereas in children there is a clear high season during the winter months(176). The 
prevalence of disease in adults ranges from the estimated 3 to 18 % in the US, to 
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14  % in Japan and even up to 63 % seen in Mexico during the winter 
months(176,211,212). However, most of the studies evaluating RV prevalence in 
adults were conducted before licensure of RV vaccines, and therefore the numbers 
are probably overestimates of current situation, as a 50 % decrease in the RV cases 
of adults was seen after the initiation of pediatric RV vaccinations in the US(210). A 
similar decrease in all cause AGE was reported as well in all adult age groups in the 
UK, but to a lesser extent(174,213). Even though the decline of the burden of RV 
disease in adults after the vaccine introduction suggests transmission from children 
to adults, there are studies were such an association has not been found(207,214). 
The most common genotypes are G1P[8], G2P[4], G3P[8], G4P[8] and G9P[8], 
similar to those found in children(209,215–218). Several reports of outbreaks in 
nursing and retirement homes have shown that RV can also potentially cause a local 
epidemic in a closed community of adults and the elderly even without potential 
disease transmission from children. These outbreaks have mainly been caused by 
G2P[4], but there are reports of G4P[8], G8P[8] and G12P[8] being the causative 
genotype.(206,219–225) RV has also been shown to be a noticeable viral pathogen 
in travelers’ diarrhea causing approximately 10 % of all cases, especially in Africa and 
Latin America(226,227). Travel may also enhance transmission and the spread of 
novel genotypes around the globe(209). 
2.4 Rotavirus vaccines 
2.4.1 Development of rotavirus vaccines 
The significant RV-related morbidity and mortality created a drive to develop a 
vaccine against the virus. On the basis of studies involving adult volunteers, it was 
assumed that fecal IgA levels would be the best correlate for host response and 
therefore an oral live vaccine would be the best option.(228) It was also noted in a 
small subset of children that sequential RV infections were caused by different RV 
serotypes signaling immunological memory against certain strains(229). However, as 
the knowledge about the virus and immunity was slender, the approach used in 
vaccine development was Jennerian, taking advantage of cross-reactivity between 
similar group antigens of human and animal RVs also known as serogroups. Animal 
RVs were preferentially selected as they belonged to a similar serogroup (VP6) 
(RIT4237, RRV) as circulating human RVs G1 and G2 and/or because they had 
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been shown to cause asymptomatic or mild infection in humans (WC3) and because 
they grew well in cell cultures. Human RV strains could not be used until it was 
learned that their growth in cell culture could be enhanced by trypsin. Following 
paragraphs discuss the most important vaccine candidates, currently used and some 
of the future RV vaccines still underdevelopment.  
Summary of the vaccines discussed during the following paragraphs is presented 
in Table 3. 
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Table 3.  Summary of past, current and future rotavirus vaccines and vaccine candidates. 
Past vaccine candidates RV strain Characteristics 
 Animal    
 RIT4237 Bovine G6P[1] Modest VE, well-tolerated 
 
WC3 Bovine G6P[5] Low VE, well-tolerated. Further development to RotaTeq 
 
RRV Rhesus monkey G3P[5] High VE (homotypic only), post vaccination fever reactions 
 Animal-human reassortant   
 
RRV-TV, Rotashield Human G1, G2, G4 VP7 on rhesus G3P[5] backbone  
High VE, well-tolerated. Withdrawn due to 
increased risk for intussusception 
 Human-bovine(UK) 
reassortant 
Human G1, G2, G4 VP7 on 
bovine UK strain High VE, well-tolerated 
 Human    
 M37 G1P[6] Poor VE, well-tolerated 
 
89-12 G1P[8] High VE, well- tolerated. Further development to Rotarix 
Current main vaccines   
 
Rotarix Same G1P[8] as 89-12 High VE (high income countries), well-tolerated. Globally most used RV vaccine. 
 
RotaTeq Human G1, G2, G3, G4 and P[8] on bovine G6P[5] backbone 
High VE (high income countries), well-
tolerated. Used in Finland since 2009.  
Other currently used vaccines   
 RotaSiil Human-bovine reassortant G1-G4 and G9 
VE similar to seen by the main vaccines 
in a low income setting. Both licensed and 
used in India. 
 
 Rotavac Human G9P[11] 
 Rotavin-M1 Human G1P[8] Developed and used in Vietnam 
 Lamb RV Lamb G10P[12] Developed and used in China. 
Under development 
 RV3-BB Naturally attenuated G3P[6] Decent VE, currently in clinical studies 
 Parenteral P2-VP8-P[8] VP8* P[8] fused to tetanux toxin Clinical studies on humans 
 Rota- and norovirus 
combination vaccine  Recombinant VP6 In mural studies 
VE = vaccine efficacy 
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2.4.1.1 Animal rotavirus vaccines 
RIT4237 
RIT4237, the first oral RV vaccine candidate that reached clinical trials in children, 
was based on a cell culture-attenuated (154 passages) bovine RV G6P[1] strain that 
was originally isolated from calves in Nebraska(230,231). The G6P[1] strain shared 
the same VP6 (subgroup 1) with the other most common human RVs, and it also 
showed cross-reactivity against other subgroups (2 and 3)(230). RIT4237 showed 
promising results in the first efficacy trials conducted in Finland in 1983, showing 50 
% and 88 % protection against any and severe RV disease, respectively, with only 
one dose(230). However, in studies done in developing countries, the efficacy was 
seemingly lower: In Peru 40 % and 75 %, respectively, and in Gambia with only 33 
% efficacy against RV disease of any severity(232,233). The vaccine was withdrawn 
from further development due to the modest efficacy in developing countries. 
 
WC3 
The vaccine based on cell culture-attenuated bovine RV WC3 strain G6P[5]. In the 
early studies, WC3 showed better serological results with lower inoculum than 
RIT4237, producing less adverse effects, and therefore it was considered as a 
potential vaccine candidate.(234) However, the vaccine showed low efficacy against 
human RVs in clinical studies and further development was halted(235,236). 
 
RRV 
 
Rhesus RV, RRV, vaccine strain (G3P[5]) originated from stools of a rhesus 
monkey(237). The strain was attenuated and adapted to vaccine use by cell culture. 
The strain was selected because it was not reported to infect humans and induced 
neutralizing antibodies against serotype 3(238). In clinical studies, RRV was shown 
to be highly efficacious (80 %) against homologous RV strains, whereas efficacy 
against heterologous strains was only 48 %(239–241). The vaccine was more 
antigenic compared to  RIT4327, but it showed higher reactogenicity, causing fever 
reactions 3-4 days post vaccination(239,242,243). The lack of heterotypic protection 
and the increased reactogenicity led to the end of development of a pure RRV 
vaccine. 
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2.4.1.2 Animal-human reassortant vaccines 
 
RRV-TV, Rotashield 
 
The observation of natural reassortment of genes between two RV strains infecting 
the same cell culture inspired the creation of a reassortant vaccine, which combined 
lower reactogenicity of animal RV and the broad serotype protection of human 
RV(244). This resulted in RRV-TV, the rhesus-human reassortant tetravalent 
vaccine, which was later licensed as RotaShield (Wyeth). The vaccine contained 
human G1, G2 and G4 VP7 proteins on a rhesus G3P[5] RV backbone.(245,246) 
The used vaccine dose was lower than in previous RRV studies, which resulted in 
fewer fever reactions following vaccination(247). In the largest clinical studies 
conducted in the US and Finland, the vaccine showed to be highly efficacious, 
especially against severe RV disease (80-91 %) while the efficacy against all-severity 
RVGE varied from 49 to 66 %(248,249). However, in the Latin American countries 
of Venezuela, Peru and Brazil, the efficacy was lower, and ranged from 26 to 48 % 
against any RV disease and from 30 to 88 % against severe RVGE(250–252). The 
vaccine was administered in three doses at the ages of two, four and six months.  
RRV-TV was licensed in the US in 1998, and was in use up to 1999, when it was 
withdrawn due to an association with an increased risk for IS after vaccination(6). 
Nonetheless, in terms of real-life efficacy, RRV-TV was highly efficacious, as seen 
in a retrospective case-control study conducted by Staat et al.(253), where the real-
life efficacy of the full RRV-TV regimen against hospitalization was 100 % and even 
a single dose provided 89 % efficacy against RV-associated hospitalization. More 
recently, the vaccine has been studied in Ghana, where it was given in neonatal 
setting in a two-dose schedule to minimize risk of IS(254). 
 
Human-bovine (UK) reassortant vaccine 
 
Concomitantly with the development of RRV-TV a similar tetravalent RV vaccine 
based on a bovine UK strain was studied. The vaccine showed similar efficacy as 
RRV-TV and was well tolerated(255). However, as RRV-TV was withdrawn due to 
intussusception, the development of the human-bovine RV vaccine was also 
discontinued by Wyeth. 
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2.4.1.3 Human rotavirus vaccines 
M37 
The M37 (G1P[6]) strain was obtained from the stools of a neonate with an 
asymptomatic RV infection in Caracas, Venezuela in 1982(256). The strain was 
attenuated by propagation in African green monkey cells for 21 passages. The 
vaccine was well-tolerated but only moderately immunogenic, and it showed poor 
heterologous seroresponses.(257,258) In an efficacy trial conducted in Finland, the 
M37 vaccine showed no clinical protection against RV disease(259). 
89-12 
The human RV vaccine candidate based on the strain 89-12 (G1P[8]) was isolated 
from the stools of a child with RVGE in Cincinnati, USA, during the 1988-1989 RV 
season(236). The strain induced a broad cross-reactive neutralizing antibody 
response and the infection caused by the strain seemed to protect against subsequent 
RV infection(260,261). The strain was attenuated by a total of 33 passages in two 
African green monkey kidney cell lines. The vaccine was chosen to be given in two 
doses. Safety and immunogenicity studies showed that the vaccine was well tolerated 
and immunogenic.(262) The initial efficacy trial, conducted in the US, showed  high 
(89 %) efficacy against RVGE of any severity and 78 % efficacy against severe RV 
disease(263). In a two-year follow-up, the efficacy remained high at 76 % against any 
severity RVGE and 84 % against severe disease(264). The strain was further 
developed, and the final vaccine became known as Rotarix. 
2.4.2 Current rotavirus vaccines 
2.4.2.1 Human rotavirus vaccine, Rotarix 
The most used RV vaccine globally, Rotarix (GSK, Rixensart, Belgium), originates 
from the 89-12 strain. The strain was cloned by plaque purification and further 
propagated for another 10 passages in Vero cells to develop the RIX4414 strain used 
in the vaccine. In the pilot safety and immunogenicity study, RIX4414 showed to be 
highly immunogenic, similar to 89-12, and was tolerated even better than the 
predecessor strain.(265) In an efficacy study conducted in Finland, RIX4414 showed 
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72 % efficacy against RV disease of any severity and 85 % efficacy against severe 
RVGE after the administration of two doses(266). Other studies from Singapore 
and Latin America showed the vaccine to be well tolerated, that the vaccine efficacy 
was high (up to 86 % against severe RVGE), and that the vaccine was also highly 
efficacious (up to 83 %) against non-G1 strains (267–269). A large European efficacy 
study confirmed the high efficacy against severe (up to 90 %) and any severity (up 
to 87 %) RV disease(270). 
A large phase 3 safety and efficacy trial was conducted in 11 Latin American 
countries and Finland, and contained 63,000 infants who received two doses of the 
Rotarix vaccine. The vaccine showed 85 % efficacy against severe RVGE and an 
efficacy of at least 87 % against genotypes G1P[8], G3P[8], G4P[8] and G9P[8]. 
However, against the completely heterologous strain G2P[4], the efficacy was only 
41 %. Overall, the vaccine was assessed as well tolerated and safe. IS was detected 
in six children who had received the vaccine and in 16 placebo recipients, indicating 
a low risk of IS.(161) 
2.4.2.2 Human-bovine reassortant vaccine, RotaTeq 
The human-bovine reassortant vaccine, RotaTeq (Merck, Kenilworth, NJ, US), was 
developed in similar manner as RRV-TV, reassorting four human VP7 genes (G1, 
G2, G3 and G4) and human VP4 gene P[8] into a bovine WC3 G6P[5] strain 
backbone. Human RVs were isolated from the RV positive stools samples of infants 
in the Children’s Hospital Philadelphia.(271) The WC3-based vaccine, as discussed 
earlier, was found to show poor protection against human RVs, but it was highly 
immunogenic and well tolerated, and therefore it was assessed as a good template 
for further vaccine development when reassorted with more immunopotent surface 
proteins from human RVs. The monovalent proof of concept vaccine contained 
only G1 VP7, but it showed high efficacy, from 64 to 100 %(272,273). Other 
reassortants containing three other VP7s and VP4 were added to the vaccine to 
broaden the spectrum of protection to cover all major wild-type RV strains(271). 
Bivalent (G1+G2) and quadrivalent (G1-G3 and P[8], and G1-G4]) compositions 
were tested showing similar or even higher efficacy(274–276).  
RotaTeq went through a large efficacy and safety trial named the Rotavirus 
Efficacy and Safety Trial (REST). The placebo-controlled randomized trial included 
over 70,000 participants and was conducted in 11 countries including the US and 
Finland. The vaccine showed 74 % efficacy against RVGE of any severity and 98 % 
efficacy against severe disease.(160) In the original study, the efficacy was shown 
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against genotypes G1-G4 contained in the vaccine, but the Finnish Extension Study 
showed that the RotaTeq vaccine was likewise highly (92 %) efficacious against 
G9P[8], a partly heterotypic strain not contained in the vaccine(277). The REST 
study showed major reductions in RV-related healthcare visits, as in the follow-up 
up to two years after vaccination, a 96 % reduction in hospitalizations and a 94 % 
reduction in emergency department visits was noted. In the REST material, the 
number of IS cases was lower in the vaccine recipients compared to the recipients 
of the placebo which was an important finding after the withdrawal of RotaShield 
due to IS.(160) 
RotaTeq was added to the Finnish National Immunization Program (NIP) in the 
beginning of September 2009. The vaccine is given as a three-dose regimen at the 
ages of two, three and five months with minor national variance. First-dose 
vaccination coverage has been over 90 % since the introduction(9). 
2.4.2.3 Other rotavirus vaccines and vaccines under development 
Several other RV vaccines have been developed and taken into use, mainly in Asia. 
Two of these vaccines, RotaSiil (human-bovine reassortants G1-G4 and G9) and 
Rotavac (G9P[11]) are currently used in India and have also been prequalified by the 
World Health Organization(278–280). The efficacy of both of these vaccines has 
been 35 % against any severity RVGE and 55 to 67 % against severe 
RVGE(281,282). This is somewhat similar to the efficacy shown by Rotarix and 
RotaTeq in developing countries(283,284). Other vaccines know to be in use are the 
single attenuated human RV G1P[8] vaccine Rotavin-M1 in Vietnam and the lamb 
RV (G10P[12]) vaccine in China. The published efficacy data for the latter two 
vaccines is lean(285,286).  
Of the RV vaccines still under development, RV3-BB is based on the naturally 
attenuated human RV strain G3P[6]. The strain has been shown to cause 
asymptomatic infection in newborns and similarly to provide protection against 
severe RV infection.(287) A more recent efficacy study showed a 75 % efficacy using 
an infant administration schedule (8, 14 and 18 weeks) and 51 % efficacy in the 
neonatal schedule (0-5 d, 8 and 14 weeks)(288). 
 
Third generation rotavirus vaccines 
 
Despite the second-generation live oral RV vaccines being shown to be highly 
efficacious in developed countries, in developing areas the effectiveness of the 
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vaccines has remained low to moderate despite high vaccine coverage(289). As basic 
studies have tried to explain the difference seen in effectiveness, vaccine 
development of third-generation RV vaccines has focused on non-live RV particles 
usually administered parenterally or intracutaneously. With no RV replication in the 
gut, these vaccines would have the potential advantage of a lower risk of IS. It would 
also be possible to combine these subunit vaccines together with other childhood 
vaccines, which could improve vaccine coverage. 
Approaches in the field are numerous, but the parenteral P2-VP8-P[8] subunit 
vaccine was the first third-generation RV vaccine to advance to clinical 
trials(290,291). The vaccine is based on the tetanus toxin P2 epitope fused truncated 
VP8* protein, which contains most of the neutralizing epitopes of the whole VP4 
protein(292). The vaccine has been shown to be immunogenic and well tolerated in 
children(291). No efficacy data has yet been published. Further studies are currently 
ongoing on a trivalent (P[4], P[6] and P[8]) composition(291). In addition, a 
combination subunit vaccine against RV and norovirus is currently under 
development. Recombinant VP6 protein, which has been produced in the 
baculovirus system in insect cells, functions as the RV subunit inducing neutralizing 
antibodies and also as an adjuvant for the norovirus component of the vaccine(293). 
2.4.3 Vaccination of adults 
Even though adults have usually been the first subjects in RV vaccine clinical trials, 
the vaccine safety, immunogenicity and efficacy in this population has not been well 
determined. In 2014, Lawrence et al.(294) conducted a clinical trial assessing the 
safety and immunogenicity of the RotaTeq vaccine in 66 elderly people (aged 65-80 
years). Two thirds received the three-dose RotaTeq vaccine regimen and one third 
formed the placebo group. The vaccine was determined to be safe and well tolerated 
in this age group with no reports of severe adverse events. The study reported for 
the first time RV serology of the elderly showing relatively high rotavirus antibody 
levels reflecting to previous infections. Despite of the antibody levels, increase of 
serum neutralizing antibody titers against RV was detected, and roughly a third of 
the recipients had a 3-fold rise after three vaccine doses. The results indicated that 
despite previous RV exposure and waning immunity, the RV vaccine may have 
potential in this age cohort.(294) However, no further studies have been conducted. 
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2.4.4 Effects of universal rotavirus vaccinations 
Already in 2009, the World Health Organization recommended the inclusion of the 
RV vaccination into vaccination program of every country. To date, RV vaccines 
have been introduced in 98 countries and the number is increasing. The proportion 
of countries using RV vaccine varies geographically. The highest proportion of 
countries using RV vaccines are in Africa, where the burden of disease and mortality 
is highest as well, whereas in developed regions such as Europe, the proportion is 
lower.(295) 
2.4.4.1 Real-life vaccine effects and effectiveness of current rotavirus vaccines 
Since the introduction of the RV vaccines, the number of annual RV related deaths 
in children under five years of age has decreased from 450,000 to 130,000(5,7). 
According to a recent study by Troeger et al.(296), during the last 26 years, from 
1990 to 2016, RV-associated mortality has decreased by 48 % in children under five 
years of age. It has been estimated that globally RV vaccines cover only 28 % of 
children aged under five, but they still averted 28,000 RV related deaths in 2016(296).  
In Finland, high-coverage RV inoculations have resulted in an over 90 % 
reduction in RV-related hospitalizations and outpatient visits(9,297). Mass 
vaccination has also decreased all-cause AGE hospitalizations by 69 %.(9) In the US, 
another country mainly using RotaTeq, RV-related hospitalizations of children under 
the age of five years have decreased by 84 %(298,299). Similar reports have been 
published also from other high vaccine coverage countries, such as Belgium and 
England who both use Rotarix with a 85 % and 77 % reduction, respectively, in RV 
hospitalizations in comparison to the pre-vaccine period(213,300). 
Both the Rotarix and RotaTeq have shown high real-life vaccine efficacy (VE) in 
post-licensure clinical studies; however, a clear RV mortality-related gradient is 
present when comparing VE between different regions(301). In high income 
countries with low RV mortality, such as Belgium (Rotarix), Finland (RotaTeq) and 
the US (both, mainly RotaTeq), post-licensure studies have reported real-life vaccine 
effectiveness against hospitalization ranging from 86 to 94 % for 
RotaTeq(297,298,302,303) and from 83 to 90 % for Rotarix(168,302). In pre-
licensure studies, the VE of Rotarix against G2P[4] was significantly lower (41 %) 
than against other genotypes. However, in more recent clinical studies conducted in 
Belgium and Brazil, VE against G2P[4] ranged from 77 to 85 %(161,168,169).  
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In countries with moderate to high RV mortality, the effectiveness of current RV 
vaccines has been shown to be considerably lower. A consensus VE calculated by 
Jonesteller et al.(301) was 49 % for RotaTeq and from 58 to 66 % for Rotarix. While 
the RV vaccine related reduction in hospitalizations and emergency department visits 
of children aged under five years has been shown to be on average 71 % in low-
mortality settings, in moderate and high mortality regions the reduction was lower, 
approximately 60 %. In children in their first year of life, the difference in median 
reduction between low (80 %) and high (46 %) mortality settings was even higher. 
Interestingly, there was no difference in reduction between low (80 %) and moderate 
(78 %) mortality areas.(289) 
 The difference between high and low income countries cannot be explained by 
circulating genotypes, as even though the number of strains is more diverse and they 
contain also the P[6] strains uncommon in high income settings and absent from the 
vaccines, the VE is similarly low also against the common strains such as G1(304). 
To date, multiple affecting factors have been proposed, including malnutrition 
(especially vitamin A and zinc deficiency), a higher proportion of antiviral 
glycoproteins contained in breast milk, co-infection of other enteropathogens, 
difference in the gut microbiome and histo-blood group antigens(305–309). 
2.4.4.2 Indirect vaccine effects 
RV vaccination-induced indirect effects have been reported from several countries 
soon after the implementation of the vaccines. In the US, studies utilizing several 
different registries have shown supporting data on the reduction of the disease 
burden also in the unvaccinated population of children and adults. Baker et al.(303) 
used a time series analysis on insurance diagnosis data to estimate the direct and 
indirect effects of RV vaccination in the US; they found that the indirect VE against 
RV hospitalization in adults and children above 10 years of age ranged from 35 to 
56 %. Lopman et al.(310) estimated that vaccinations averted 10,000 RVGE 
hospitalizations in the unvaccinated 5-24-year-old age group in 2008. Similarly in 
Belgium, the number of RV cases in children aged 10 years and older reduced by a 
half after vaccine introduction(300). In Austria, mass vaccination program decreased 
nosocomial and community-acquired RV infections in neonates and unvaccinated 
children under 42 days old(311). However, in low-income settings, studies have not 
shown the indirect benefits of RV vaccination on a similar scale. In Malawi, Bennett 
et al.(312) reported a reduced risk against RV infection for a year after vaccine 
introduction, but the effect was lost when the study period was extended or in cases 
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of severe disease. In Rwanda, the number of hospitalizations decreased by a third in 
the older children after implementation of the RV vaccine(313). By contrast, in 
studies conducted in Zambia and South Africa, no indirect protection was 
detected(314,315).  
2.4.4.3 Effects on circulating strains 
Assessing vaccine effects on circulating RV strains is not straightforward, as it is 
difficult to distinguish them from natural strain fluctuation, which is multifactorial 
and mainly unknown. Both individual- and population-level homotypic and 
heterotypic immunity against RV is perhaps the most important factor causing 
changes in the circulating genotypes by increasing immune pressure, which may 
eventually lead to replacement of the predominant strain(151,287). Other factors 
affecting strain circulation are increased mobility and the migration of people, 
genetic mutations and host factors as previously discussed.  
Several studies from different regions have reported changes in the circulating 
genotypes after the implementation of a RV vaccine. Soon after the introduction of 
the Rotarix vaccine in Brazil in 2006, G2P[4] became the predominant 
strain(316,317). It was speculated that the predominance was due to the previously 
reported lower efficacy of Rotarix against partly heterotypic G2P[4]; however, a 
broader examination showed that the prevalence of the strain was already increasing 
in Brazil and the surrounding countries during and before implementation, 
supporting natural fluctuation(161,318–320). Predominance of G2P[4] in Brazil 
continued for a total of five years and was then replaced by alternating G3 and G12 
strains(321). Phylogenetic studies did not find signs of selective pressure, but instead 
the G2P[4] strains found at the beginning and end of the predominance were 
genetically distinct, supporting the natural fluctuation theory(322,323).  
G2P[4] has also become predominant in other countries using Rotarix as well. In 
Belgium, the strain became predominant a few years after the introduction of the 
vaccine, and it has remained predominant since, even though the prevalence has 
decreased in neighboring countries without high-coverage RV vaccination 
programs(189,324). The strain has similarly become predominant after the 
introduction of the vaccine also in the Australian territories using Rotarix, but it 
shares dominance with a novel, similarly partially heterotypic equine-like G3P[8] 
strain(325,326). Matthijnssens et al.(327) reported that in Belgium, G2P[4] was more 
prevalent in vaccinated children hospitalized due to RVGE, indicating a possible 
selective pressure from the vaccine. Using Belgian pre- and post-vaccination data 
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and mathematical modelling, Pitzer et al.(328) concluded that the Rotarix vaccine 
had indeed partially influenced to the prolonged predominance of G2P[4], as the 
data suggested that both natural and vaccine-induced immunity were weaker against 
heterotypic strains compared to homotypic strain. 
In the Australian territories using RotaTeq, G12P[8] has become dominant (326). 
A similar change has been reported in the US, where G1P[8] was first substituted by 
G3P[8] and then by G12P[8], which has predominated ever since(329). In fact, a 
similar transition was detected in Australia(325). A recent study by Ogden et al.(330) 
described several differences in the antigenic epitopes between G12P[8] strains 
detected in the US and RotaTeq vaccine strains which may explain the increased 
prevalence in vaccinated children(330).  
Another interesting vaccine-related effect is the biennial incidence pattern seen 
in the US soon after the introduction of the RotaTeq vaccine(298,303). A similar 
phenomenon has not been reported in other countries with a high RV vaccine 
coverage, such as Belgium and Finland(8,300). However, in a recent study, Shah et 
al.(331) reported that as the number of RV cases in the US has decreased, the 
magnitude of biennial seasonality has also decreased. The authors speculated that 
the increase in the previously fairly low (up to 73 %) vaccine coverage may have been 
the cause and could eventually lead to the elimination of the biennial 
pattern(331,332). 
2.4.4.4 Potential genetic pressure due to rotavirus vaccines 
At the beginning of the large-scale introduction of RV vaccines, it was speculated 
that vaccines would cause increased genetic pressure on the circulating strains, 
eventually leading to escape mutants and lower vaccine efficacy(333). The outward-
facing amino acid sites of VP7 and VP4 proteins have been shown to be vulnerable 
to genetic pressure which has led to mutations affecting antibody binding and 
increasing potential for escape neutralization(334). In addition, there are several 
reports of genetic variance detected in the genotypes during the post-vaccination 
period. In Belgium, an analysis of VP7 and VP4 proteins of the epidemiological 
samples by Zeller et al.(335) revealed that, already at the beginning of mass 
vaccination, the genotype lineages contained by the two vaccines differed from the 
circulating strains, and a substantial amount of these changes are located at the 
antigenic sites. In a more recent and more comprehensive whole genome analysis of 
the G1P[8] strains from the pre- and post-vaccine period, Zeller et al.(336) reported 
that lineages similar to the Rotarix G1P[8] strain were reduced, possibly due to 
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vaccine implementation, but no other evidence of selection pressure was apparent. 
Similar to the case in Belgium, da Silva et al.(337) have reported no sign of genetic 
pressure in G1P[8] over a 27-year follow-up period in Brazil. 
In the Australian territory of Victore, which uses RotaTeq, a post-introductional 
increase of G1 (lineage 2) RVs was detected when compared to samples collected 
before the vaccine’s introduction(338). An analysis of G1P[8] VP7 and VP8* 
covering the 20-year period did not find any changes in the VP7 sequences, but by 
contrast VP8* had several substitutions also in the epitope regions. Also, the P[8] 
lineage changed from 1 to 3 after the introduction of RotaTeq. However, these 
changes did not express genetic pressure by the vaccine; they were more or less part 
of natural fluctuation and reassortance.(339) Hemming et al.(339) speculated that 
these minor changes seen in G1P[8] could be related to a less pronounced 
neutralizing antibody response caused by RotaTeq in comparison to the human 
G1P[8] strain of Rotarix. An exchange of a whole gene was reported by Bucardo et 
al.(340) in Nicaragua, where two vaccinated children were reported having a 
breakthrough infection caused by human wild-type G1P[8] RV, of which the NSP2 
gene originated from the RotaTeq vaccine strain.  
2.4.5 Vaccine safety 
Intussusception 
IS refers to telescope-like overlapping of one part of the intestine into another, 
causing obstruction, venous congestion and edema, resulting in ischemia that 
without treatment may lead to intestinal necrosis, and even perforation and 
peritonitis(Fig. 3). Natural incidence of IS begins to increase after the first month of 
life and is at highest at the age of 4-6 months, which coincides with the timing of RV 
vaccines(341). 
As previously discussed, the first licensed RV vaccine, RRV-TV, was withdrawn 
after nine months of use due to an increased risk for IS. In a case-control study by 
Murphy et al.(6), vaccine recipients had an approximately 22-fold higher risk for 
developing IS 3-14 days after the first dose of the vaccine in comparison to 
unvaccinated infants. The increase in risk for IS was also three times higher 3-14 
days after receiving the second dose of the RRV-TV vaccine. It was estimated that 
continuation of the vaccination would have caused one excess case of IS per 5,000-
10,000 vaccinated children.(6) The cause of IS due to the RRV-TV vaccine has 
remained unknown, but the age of the recipients has been shown to be an important 
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factor, as 80 % of the IS cases reported by Murphy et al.(6) were seen in 50 % 
recipients aged at least three months at the time of the first dose, overlapping with 
the natural increase of the incidence of IS(342–344). 
 
Figure 3.  Schematic of intussusception where sections of small bowel have overlapped causing 
obstruction and venous congestion. Schematic by Olek Remesz, adapted under the 
Creative Commons Attribution 3.0 Unported License(40). 
Pre-licensure studies of the RotaTeq and Rotarix RV vaccines contained IS as the 
primary safety objective, showing no or a minimal increase in the risk for IS between 
vaccine and placebo recipients(160,161). However, several post-licensure studies 
have detected a small increase in the risk for IS after receiving either of the RV 
vaccines. In Finland, the reported increase was one excess case per 96,000 children 
for the first 21 days after the first dose of the RotaTeq vaccine but no further increase 
after the later doses(345). Similar small increases of the incidence of IS have also 
been reported in Australia and the US with both of the vaccines, and in England 
with Rotarix(346–350). Even though the current studies have shown that the present 
RV vaccines are in fact associated with a small increase in the risk for IS, the global 
consensus is that the benefits – the averted deaths and hospitalizations – outweigh 
the risk of IS greatly(351,352). 
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Adventitious viruses 
In 2010, both of the current RV vaccines, Rotarix and RotaTeq, were found to be 
contaminated with the DNA of adventitious viruses. Rotarix was found with porcine 
circovirus 1 (PCV1) DNA, possibly carried over in porcine pancreas-derived trypsin 
that was used in passaging Vero cell cultures. RotaTeq was found with a small 
quantity of simian retrovirus 1 (SRV1) originating from Vero cells.(353) Other 
studies also reported a small number of fragments of PCV 1 and PCV 2 DNA in the 
RotaTeq vaccine(354,355), and the origin was confirmed to be the trypsin used(356). 
The high number of infectious PCV1 in the vaccine led to the development of PCV-
free Rotarix, which is currently ongoing clinical studies. Hence, neither the Rotarix 
nor RotaTeq vaccine, currently in use, are explicitly PCV-free. 
2.4.6 RotaTeq vaccine-derived double-reassortant strain 
Recombination of the viruses contained in the RotaTeq vaccine was reported for the 
first time already in a safety and efficacy study of the quadrivalent form of the 
forthcoming vaccine. During the study, four children were detected shedding 
recombinant RV, which consisted of human surface proteins G1 and P[8] on a 
bovine WC3 backbone.(275) Re-reassortance was not further studied in pre-
licensure studies, probably as it was kept as a sign of successful vaccine replication 
in the gut, while two of the vaccine strains (G1P[5] and G6P[8]) infected the same 
enterocyte and the outer VP7 genes were exchanged. 
Since then, the increased virulence of the vdG1P[8] strain has been reported. In 
2009, Payne et al.(357) reported symptomatic transmission of a vdG1P[8] from a 
vaccinated younger sibling to an unvaccinated older sibling who visited an 
emergency department and received intravenous rehydration due to RVGE. A stool 
sample of the child was ELISA positive for RV, and further RT-PCR and genotyping 
showed RotaTeq G1 VP7 and RotaTeq P[8] VP4 on a WC3 bovine RV backbone, 
similar to that reported by Clark et al.(275) five years earlier. The younger sibling, 
who had received the RotaTeq vaccine 10 days before the onset of symptoms, was 
considered the only possible route for transmission. Hemming et al.(358) noted three 
cases of infants who developed AGE symptoms up to a week after receiving the first 
(two cases) or the second (one case) dose of the RotaTeq vaccine. After RT-PCR 
and sequencing vdG1P[8] was detected in the stools of all the children. In another 
case report by Hemming et al.(359), vdG1P[8] was detected in the stools of a seven-
year-old child who was hospitalized for intravenous dehydration due to RVGE. In 
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this case, the transmission pattern remained unknown as the older siblings were 
unvaccinated and the younger vaccinated sibling was already two-years old. Six 
symptomatic vdG1P[8] cases were also detected in Australia among more than 500 
samples collected as part of an Australian three-year RV surveillance (2007-2010). 
Of these samples, four were collected from children showing gastroenteritis 
symptoms after receiving the RotaTeq vaccine and two were collected in an 
emergency department setting due to severe AGE(360).  
2.4.7 Shedding of rotavirus vaccine strains 
As both of the vaccines contain live RVs replicating in the enterocytes of the small 
intestine, the progeny viruses are shed in stools. Detection of vaccine strains has 
been used as one marker for vaccine uptake since early RV vaccine studies. Both 
vaccine strains are occasionally found in stool samples collected from both 
symptomatic and asymptomatic individuals in RV or AGE 
surveillance(8,329,361,362). Prolonged shedding obviously indicates prolonged 
intestinal infection, but the significance of such a chronic infection is unknown. 
2.4.7.1 RotaTeq 
RotaTeq strain shedding was studied in the pre-licensure studies and as reported low, 
as only 32 out of 360 (9 %) recipients were shedding four to six days after the first 
dose of the vaccine. The numbers were even lower after the following doses, as no 
shedding was detected after the second dose, and only one out of 385 (0.3 %) 
children after the third vaccine dose was detected with the vaccine virus in the stool 
sample.(363) Shedding was also assessed in several studies conducted on RotaTeq 
precursors, with none of them showing higher rates compared to the final 
product(364). In the developmental and pre-licensure studies on RotaTeq, shedding 
was studied using cell culture plaque assay, an insensitive method in comparison to 
RT-PCR. In a later partial re-analysis by Matson et al.(365) using RT-PCR for bovine 
VP6, shedding was detected in half (65 out of 130) of the recipients after the first 
dose.  
Significantly higher rates of shedding have been identified in more recent post-
licensure studies, specifically designed to study the excretion of the RotaTeq vaccine 
viruses in the stools after inoculation. In these studies the rate of shedding after the 
first vaccine dose has varied from 21 % (ELISA) up to 94 % (real-time RT-PCR) 
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depending on the method of detection(366–368). Genotypes related to shedding 
have been studied a little. In the previously mentioned safety and efficacy study for 
the quadrivalent form of the vaccine by Clark et al.(275), 7 out of 161 (4.3 %) 
children were detected shedding, and of those, five were detected with G6P[8] and 
two with vdG1P[8] in the stools. A recent but more methodologically focused study 
by Higashimoto et al.(369) found G1 the most commonly shed genotype, followed 
by G6. However, the study population consisted of only 12 children and it did not 
include P-typing. 
In pre-clinical studies, the presence of the RotaTeq vaccine viruses in stools was 
studied typically once during three to seven days after inoculation without further 
surveillance on the total duration. However, the vaccine strains replicate in a similar 
manner but possibly not at a similar rate as wild-type RVs, and therefore the presence 
may be even longer than reported. In a large RV surveillance study conducted in 
Australia by Ye et al.(368), prolonged (>14 days) shedding was reported up to 14 
weeks after receiving the third dose of the RotaTeq vaccine with the median duration 
of 3, 1.5 and 1 week after the first, second and third dose of the vaccine, respectively. 
In another systematic study by Hsieh et al.(367), the prolonged presence of vaccine 
viruses was detected only after the first dose, continuing up to 28 days post-
inoculation, and in only 11 % of the recipients. 
In immunocompromised children, vaccine-derived RV strains may be present 
even longer and cause difficult symptoms. Patel et al.(370) reported three cases of 
vaccinated children with severe combined immunodeficiency. Of these children, all 
had received at least one dose of the RotaTeq vaccine, after which they developed 
persistent diarrhea leading to failure to thrive and eventually to a diagnosis of severe 
combined immune deficiency. At its longest, the RotaTeq vaccine strain was present 
at the age of 13 months, 11 months after the administration of the latest vaccine, 
dose and it was cleared only after stem-cell transplantation.(370) Other supporting 
reports have been published since(371,372). Severe combined immunodeficiency-
related prolonged replication in the gut has also been shown to lead to mutations in 
the antigenic epitopes of VP7 and VP4, but the effects of these changes have not 
been established(373). 
2.4.7.2 Rotarix 
Shedding of Rotarix was not assessed in the main licensure study(161). However, in 
pre-licensure studies, the human RV strain, RIX4414, showed a greater tendency to 
replicate and be shed into stools in comparison to bovine-human reassortant strains 
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of RotaTeq(364). The shedding rates detected by ELISA seven days after the latest 
dose varied depending on the given inoculum, ranging from 21 to 80 % after the 
first dose of the vaccine and from 11 to 24 % after the second(265,267,269,374,375). 
In a more recent study using real-time RT-PCR for detection, Hsieh et al.(367) have 
reported a shedding rate of 94 % after the first dose of Rotarix and 53 % after the 
second.   
Prolonged shedding of the Rotarix strain was reported in the pre-licensure 
studies. In a large Latin American study, a single recipient was detected with the 
vaccine strain in stools at the time of the second inoculum, 60 days after the first 
dose(375). However, Phua et al.(267) noted that approximately one child out of eight 
continued to shed at least 15 days after receiving the second dose of RIX4414, but 
the exact duration was not determined. In a post-licensure study with 28 days of 
sampling after both doses, 20 % and 8 % of the recipients, respectively, were 
shedding for longer than 14 days. In a retrospective RV surveillance study conducted 
in Scotland, the longest period from inoculation to detection was 43 days(376). As 
with RotaTeq, prolonged diarrhea has been reported in immunocompromised 
(SCID) Rotarix recipients(372,377). 
Transmission of the Rotarix virus from a vaccinated to an unvaccinated child was 
reported in a study by Phua et al.(267), where three placebo recipients were detected 
with the vaccine strain in stools, of which two out of three also seroconverted. In 
another study by Dennehy et al.(374), two placebo recipients with vaccine group 
siblings were also detected with the vaccine strain and were seroconverted. In a 
randomized placebo-controlled study, asymptomatic transmission of the vaccine 
virus was detected in fifth of sibling pairs(378). The authors did not find genetic 
changes in comparison to vaccine recipients whereas amino acid mutations have 
been reported in a case of symptomatic sibling transmission possibly increasing 
virulence(378,379).  
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3 AIMS OF THE STUDY 
The aims of the present study were the following: 
 
1. To study the prevalence and duration of the shedding of human-bovine 
reassortant rotavirus vaccine (RotaTeq) strains in vaccine recipients and to 
assess symptoms related to shedding 
 
2. To study rotavirus genotypes associated with vaccine virus shedding and, 
specifically, the role of the vaccine-derived double-reassortant G1P[8] 
rotavirus 
 
3. To examine the genetics of shed G1 vaccine viruses during prolonged 
multiplication 
 
4. To determine current rotavirus disease burden in all age groups in Finland 
after four to nine years of mass-vaccination 
5. To investigate changes in circulating wild-type rotavirus genotypes after 
universal rotavirus vaccination in Finland 
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4 MATERIAL AND METHODS 
4.1 Material collection 
4.1.1 Study I 
The study material was part of a larger prospective study(203,380), investigating the 
etiology of AGE and respiratory tract infection (RTI) in children, conducted at 
Tampere University Hospital from September 1, 2009 to August 31, 2011. The study 
protocol was approved by the Ethics Committee of Pirkanmaa Hospital District. All 
children under 16 years of age seen in the emergency room or admitted to a pediatric 
ward with AGE symptoms and admitted children with RTI symptoms were eligible 
for the original study. Written informed consent was obtained from a parent or legal 
guardian before enrollment to the study. 
For Study I, children with only RTI symptoms were included in the analysis. In 
total 944 children with RTI symptoms were recruited and 557 (59.0 %) stool samples 
were obtained. Of those 557 children, 182 (32.7 %) had received at least one dose of 
the RotaTeq vaccine and formed the study material. 
A stool sample was collected from all children during the hospital stay or, if not 
successful, at home within two weeks with a provided sampling kit. The sample was 
shipped to laboratory and stored at -20°C until further analysis. The RV vaccination 
status (vaccine received, number of doses and dates of dosing) of each child was 
inquired from the respective child welfare clinics by a study nurse. 
4.1.2 Study II 
A prospective study was conducted at three vaccine research clinic sites in Finland 
(Espoo, Tampere and Turku) from August 2015 to February 2019. The study 
protocol (EudraCT 2014-004252-60) was approved by the Ethics Committee of the 
Hospital District of Southwest Finland and by the Finnish Medicines Agency. All 
children who received the RotaTeq vaccine according to the Finnish NIP at their 
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local child welfare clinic were eligible for the study. Informed consent was obtained 
from the parents by study nurse. 
A total of 301 children were enrolled (Fig. 4). At least two stool samples were 
collected from the participants; 292 samples 5-10 days after the first dose and a 
second sample was collected from 247 children 0-7 days before receiving the third 
dose of the RotaTeq vaccine. In 50 children, the second stool sample was positive 
for RV VP7 and a further third sample was obtained from 42 of those children six 
weeks after receiving the third vaccine dose. Similarly, a fourth stool sample was 
received from 9 out of 11 children who were detected with RV VP7 in the third stool 
sample. The fourth sample was taken a total 12 weeks after the third vaccine dose. 
Parents were provided with a stool sample kit for sampling at home and for the 
delivery of the sample by mail. A voluntary serum sample was requested from the 
parents of children who were detected to be RV positive in the third or fourth stool 
sample.  
 
 
Figure 4.  Flowchart of Study II. 
A diary card on possible symptoms following vaccination was filled by parents after 
each dose of the RotaTeq vaccine for seven days (vaccination at day one). The diary 
inquired temperature of the child (either axillary or rectal), maximal number (0, 1, 2-
4 and ≥5 times) of vomiting episodes per day and maximal number (0, 1-3, 4-5 and 
≥6 times) of diarrheal stools per day. Parents could also record other observations. 
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The severity of diarrheal symptoms was scored according to the 20-point Vesikari 
score system(106). Total of 284, 194 and 227 symptom diaries were received after 
the respective vaccine doses, from which 278, 182 and 224, respectively, were 
properly filled and eligible for further analysis. 
4.1.3 Studies III-IV 
Studies III and IV used the same study material collected in collaboration with the 
National Institute for Health and Welfare (THL). In 2013, RV was included as part 
of the microbe strain collection under the Finnish Communicable Diseases Act and 
Decree. Since then, all clinical laboratories in the country have been obliged to 
forward all RV positive samples to THL, from which the samples have been further 
referred to the Vaccine Research Center at Tampere University for genotyping. RV 
detection in clinical laboratories has mainly been based on ELISA but also to some 
extent on multiplex real-time PCR. 
Study III is based on two RV seasons from September 2013 to August 2015, 
during which 405 stool samples were received for genotype analysis. Study IV 
includes expanded material with 755 samples collected during the following three 
RV seasons up to August 2018, and the total number of samples in Study IV was 
1160. The samples were divided in half in THL, shipped to the Vaccine Research 
Center and stored at -20°C until further analysis. 
The following information from the RV cases was available: age with the accuracy 
of the year, gender, sampling date, original laboratory result from the clinical 
laboratory and location of the clinical laboratory, from which the sample was 
forwarded to THL. In some cases, additional information was included when the 
sample was referred for typing, such as RV vaccination status, travel history, or 
description of symptoms. 
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4.2 Laboratory methods 
4.2.1 Sample preparation 
Stool samples (I-IV) 
A 10% stool suspension was prepared in phosphate-buffered saline (PBS). The 
mixture was then vortexed, incubated at room temperature for 15 min and 
centrifuged at 14,700 x g for 5 min. The supernatant was collected for further use 
and stored at -20°C. In the case of diaper samples, the most representative part of 
the diaper was used instead of the stool and processed in a similar manner. 
 
Serum samples (II) 
Some 2-3ml of whole blood was taken by venous puncture into a separation tube. 
The tube was inverted at least six times and incubated at room temperature for at 
least 1 hour. The samples were then centrifuged at 1,000-1,300 x g for 10 min. After 
which, the separated serum was transferred into sterile tubes and stored at -20°C. 
4.2.2 RNA extraction (I-IV) 
Viral RNA was extracted from the 10 % stool suspensions using a QIAGEN 
QIAamp Viral RNA Mini Kit (Hilden, Germany) according to manufacturer’s 
instructions. Briefly, 140 μl of 10 % stool suspension was mixed with 560 μl of Buffer 
AVL-Carrier RNA solution, vortexed shortly and incubated at room temperature for 
10 min. Then 560 μl of 99.5 % ethanol was added to the mixture, of which, after a 
short vortex, 630 μl of the mixture at a time was transferred into a spin column and 
centrifuged at 6,000 x g for 1 min. The supernatant was discarded, and the column 
was washed by centrifuging 500 μl Buffer AW1 and AW2 at 6,000 x g for 1 min and 
at full speed for 3 min, in the respective order. Extracted viral RNA was then eluated 
to Buffer AVE after a 1 min incubation at RT and 1 min of centrifugation at 6,000 
x g. Viral RNA extracts were stored at -70°C. 
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4.2.3 RT-PCR (I-IV) 
4.2.3.1 VP7 detection and G-typing by RT-PCR 
First, 5μl of extracted viral RNA was combined with 2 μl of a primer mixture of Rota 
Beg9 fwd and Rota End9 rev (Table 4). The mixture was then denatured in thermal 
cycler at 94°C for 2 min and kept on a cold block. The RT-PCR reaction mix was 
prepared by combining 1.8 μl of nuclease free water, 1.2 μl of 25 mM MgCl2 
(Promega, Wisconsin, USA), 1 μl of 2.5 mM dNTP mix (Promega), 3 μl of 5 x Green 
Go Taq Flexi Buffer (Promega), 0.5 μl of AMV RT-enzyme (Promega) and 0.5 μl of 
RNasin ribonuclease inhibitor (Promega) per reaction. Then 8μl of RT-PCR mix was 
added to the denatured sample-primer mix. Primers were attached by incubation at 
42°C for 60 min. Samples were kept at 8°C, and a 1st PCR mix was prepared. The 
mixture consisted of 20.6 μl of sterile aqua, 10 μl of 5 x Green GoTaq Flexi Buffer, 
2 μl of 25 mM MgCl2, 2μl of 2.5 mM dNTP mix and 0.4μl of GoTaq DNA 
polymerase (Promega). Then 35 μl of 1st PCR mix was mixed with the samples and 
a PCR program was run as follows: 94°C for 3 min, 35 cycles of 94°C for 20 sec, 
56°C for 1 min and 72°C for 2 min, followed by a 5 min step at 72°C and a final 
hold at 8°C.  
For G-typing the samples, a 2nd PCR reaction with two different primer mixes (H 
and C pool mix) was conducted (Table 2). The 2nd PCR mix consisted of 24.8 μl of 
sterile aqua, 10 μl of 5 x Green GoTaq Flexi Buffer, 3 μl of 25 mM MgCl2, 4 μl of 
2.5 mM dNTP mix, 6 μl of H or C pool primer mix and 0.2 μl of GoTaq DNA 
polymerase with a total volume of 48 μl. Then 2 μl of 1st PCR products were added 
to 2nd PCR mix and the following PCR program was run: 94°C for 3 min, 25 cycles 
of 94°C for 15 sec, 53°C for 40 sec and 72°C for 70 sec, followed by a 5 min step at 
72°C and a final hold at 8°C. Then 10 μl of the final PCR products (1st, 2nd C and H 
pool) was pipetted into 2 % agarose gel with a molecular marker (GeneRuler 100 bp 
DNA Ladder, Thermo Fischer Scientific, Massachusetts, USA) and run for 105 min 
at 100 V. The gel was then UV-illuminated, and the amplicons defined by length 
(Table 4). 
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Table 4.  Oligonucleotide primer sequences and amplicon sizes for RV G-typing RT-PCR. 
Primer name Sequence (5’-3’) Amplicon size (bp) 
Rota Beg 9 fwd GGCTTTAAAAGAGAGAATTTCCGTCTGG 
1062 
Rota End 9 rev GGTCACATCATACAATTCTAATCTAAG 
H pool mix   
Rota H rev AACTTGCCACCATTTTTTCC  
Rota hG1 fwd CAAGTACTCAAATCAATGATGG 618 
Rota hG2 fwd CAATGATATTAACACATTTTCTGTG 521 
Rota hG3mod fwd ACGAACTCAACACGAGAGG 682 
Rota hG4 fwd CGTTTCTGGTGAGGAGTTG 452 
Rota hG8 fwd GTCACACCATTTGTAAATTCG 754 
Rota hG9mod fwd CTTGATGTGACTAYAAATAC 179 
Rota hG12 fwd CCGATGGACGTAACGTTGTA 387 
C pool mix   
Rota C fwd TAGCTCCTTTTAATGTATGG  
Rota cG1mod rev CCATCATTGATTTGAGTACTTG 298 
Rota cG2 rev GTTAGAAATGATTCTCCACT 244 
Rota cG3mod rev CTGTTGCAACTTCTTCAAACG 672 
Rota cG4 rev GGGTCGATGGAAAATTCT 403 
Rota cG8 rev CGAATTTACAAATGGTGTGAC 161 
Rota cG9mod rev TATAAAGTCCATCGCACTAG 110 
Rota cG12 rev TACAACGTTACGTCCATCGG 529 
bp = base pair   
4.2.3.2 VP4 detection by RT-PCR 
A RT-PCR mix was prepared by combining 1.6 μl of Nuclease free water, 1.5 μl of 
10 x PCR buffer II (Applied Biosystems, Foster City, CA), 1.2 μl of 25mM MgCl2 
(Applied Biosystems), 1.2 μl of 2.5 mM dNTP mix (Promega), 2 μl of AMV RT-
enzyme (Promega) and 0.5 μl of RNAsin (Promega). A primer mixture of Rota VP4 
fwd and rev (1 μl of each) was combined with 5 μl of sample RNA and the mixture 
was then incubated at 94°C for 2 min. (Table 5) 
Then, a 1st PCR mixture was prepared consisting of 24.25 μl of sterile aqua, 3.5 
μl of 5 x Green GoTaq Flexi Buffer, 4.2 μl of 25 mM MgCl2, 2.8 μl of 2.5 mM dNTP 
mix and 0.25 μl of GoTaq DNA polymerase. The prepared volume of 35 μl of the 
mixture was added to the incubated samples and the following PCR program was 
run: 94°C for 3 min, 30 cycles of 94°C for 20 sec, 50°C for 1 min and 72°C for 1 
min, followed by a 5 min step at 72°C and a final hold at 8°C. 
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P-typing was conducted by a 2nd PCR reaction. Some 2 μl of the 1st PCR product 
was combined with 2 μl of P pool primer mix (Table 5), 28.6 μl of sterile aqua, 10 μl 
of 5 x Green GoTaq Flexi Buffer, 3 μl of 25 mM MgCl2, 4 μl of 2.5 mM dNTP mix 
and 0.4 μl of GoTaq DNA polymerase. The primer-sample mixture was then moved 
to a thermomixer and the following PCR program was run: 95°C for 2 min, 25 cycles 
of 94°C for 35 sec, 45°C for 30 sec and 72°C for 70 sec, followed by a 5 min step at 
72°C and a final hold at 8°C. Then 10 μl of the final PCR product (1st and P pool) 
was pipetted into 1.5 % agarose gel with a molecular marker (GeneRuler 100 bp 
DNA Ladder) and run for 90 min at 100 V. The gel was then UV-illuminated, and 
the amplicons defined by length (Table 5). 
Table 5.  Oligonucleotide primer sequences and amplicon sizes for RV P-typing RT-PCR. 
Primer name Sequence (5’-3’) Amplicon size (bp) 
Rota VP4 fwd TATGCTCCAGTNAATTGG 
664 
Rota VP4 rev ATTGCATTTCTTTCCATAATG 
P pool mix   
Rota VP4 fwd2a GATGGTCCDTATCARCC  
Rota VP4 P[4] rev CTATTGTTAGAGGTTAGAGTC 289 
Rota VP4 P[6] rev2 AATTTGAAGTTGACGAGTA 381 
Rota VP4 P[8] rev TCTACTGGRTTRACNTGC 151 
bp = base pair   
4.2.3.3 VP6 detection by RT-PCR 
Bovine rotavirus VP6 (I) 
Some 5 μl of sample RNA was mixed with 5 μl of Molecular Biology Grade Water 
(Sigma Aldrich, Missouri, USA) and the sample was denatured at 95°C for 2 min. A 
total volume of 40 μl of RT-PCR mix per reaction was prepared consisting of 18 μl 
of Molecular Biology Grade Water, 10 μl of 5 x OneStep RT-PCR buffer, 2 μl of 
dNTP mix (10 mM each), 4 μl of Rota VP6 fwd Bovine primer, 4 μl of Rota VP6 
rev Bovine primer and 2 μl of OneStep RT-PCR enzyme mix. (Table 6) The 
denatured sample RNA and RT-PCR mix was combined on ice and the following 
PCR program was run: 50°C for 30 min, 95°C for 15 min, 40 cycles of 94°C for 45 
sec, 54°C for 45 sec and 72°C for 1 min, followed by a 10 min step at 72°C and a 
final hold at 8°C. 
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Then 10 μl of the final PCR products were then pipetted into 1.5 % agarose gel 
with a molecular marker (GeneRuler 100 bp DNA Ladder) and run for 90 min at 
100 V. The gel was then UV-illuminated, and the amplicons were defined by length 
(Table 6). 
Whole-genome VP6 (II-IV) 
The protocol was similar to the previously described bovine RT-PCR protocol with 
the following differences. The RT-PCR mix consisted of 20 μl of Molecular Biology 
Grade Water, 10 μl of 5 x OneStep RT-PCR buffer, 2 μl of dNTP mix (10 mM each), 
6 μl of Rota FG P6 fwd primer, 6 μl of Rota FG VP6 rev primer and 2 μl of OneStep 
RT-PCR enzyme mix. (Table 6) The PCR program also had some minor differences: 
45°C for 30 min, 95°C for 15 min, 40 cycles of 94°C for 45 sec, 45°C for 45 sec and 
68°C for 1 min, followed by a 10 min step at 72°C and a final hold at 8°C. 
Table 6.  Oligonucleotide primers and amplicon sizes for RV VP6 RT-PCR. 
Primer name Sequence (5’-3’) Amplicon size (bp) 
Rota VP6 fwd Bovine GAYGGNGCDACNACATGGT 
379 
Rota VP6 rev Bovine GTCCARTTCATNCCTGGYGG 
Rota FG VP6 fwd GGCTTTWAAACGAAGTCTTC 
1356 
Rota FG VP6 rev GGTCACATCCTCTCACT 
bp = base pair   
4.2.4 Sequencing and sequence analysis (I-IV) 
DNA size-selection by electrophoresis 
A 2 % agarose gel with 1 x TAE buffer was prepared and PCR products were loaded 
into wells. The gel was run for 90 min at 100 V. After electrophoresis, DNA bands 
were size-selected under UV illumination, cut and weighted. 
DNA was then extracted from the agarose gel using a QIAgen QIAquick Gel 
Extraction Kit (QIAgen, Hilden, Germany) as follows. Three volumes of Buffer QG 
were added to one volume of gel, and the mixture was then incubated for 10 min at 
in a 50°C water bath. When the size of the DNA fragment was under 500 bp or 
above 4kbp, after the gel had dissolved, one gel volume of isopropanol was added. 
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Then the sample was transferred to a QIAquick spin column and centrifuged at 
15,200 x g for 1 min. The flow-through was discarded, 0.5 ml of Buffer QG was 
added to the column and the column was centrifuged as previously. After discarding 
the flow-through for the second time, 745 μl of Buffer PE was added and the column 
was let to stand for 5 min before being centrifuged as previously. The flow-through 
was discarded and the column was centrifuged for 1 min at 16,100 x g. The column 
was then moved into a clean 1.5 ml Eppendorf tube and the DNA was eluted to 30 
μl of ddH2O. 
 
Sequencing PCR 
 
Another 2 % agarose gel with 1 x TAE buffer was prepared and loaded with a 
mixture of 2 μl of purified DNA, 10 μl of ddH2O and 2.5 μl of loading buffer. The 
gel was then run for 60-90 min at 100 V, and visualized under UV light. The volume 
(1-5.5 μl) of DNA of each sample was then determined on the basis of the visual 
intensity of each band, where 1 μl was used with a strong band and 5.5 μl with a 
barely visible band. A PCR mixture was prepared on ice, containing: 1-5.5 μl of 
DNA, 2 μl of BigDye TTR-mix, 3.2 pmol of primer, 1 μl of BDT 5 x Sequencing 
Buffer and ddH2O up to a total volume of 10 μl. The reaction was performed using 
96-well plate or 8 sample strips. Next, the following PCR program was run: 96°C for 
1 min, 25 cycles of 96°C for 10 sec, 50°C for 5 sec and 60°C for 4 min, and hold at 
8°C. The same primers were used as in the RT-PCR reactions (Table 4-6). 
 
Ethanol precipitation 
 
To remove extra nucleotides and primers, the samples were purified by ethanol 
precipitation. First, a mixture of 10 μl ddH2O, 2 μl of sodium acetate and 50 μl of 
99,5 % ethanol per sample was prepared, and 60 μl of the mix was added to each 
sample well. The plate or strip was then covered, vortexed, and incubated at room 
temperature for 15-30 min. After centrifugation at 2,000 x g at RT for 45 min, 
ethanol was removed, and 180 μl of 70 % ethanol was added and the samples were 
centrifuged at 2,000 x g for another 10 min. Ethanol was again removed by 
centrifuging the plate upside down at 700 x g for 1 min. The pellets were then 
resuspended into 15-25 μl of HiDi Formamide and incubated at room temperature 
for 5-15 min. The samples ready for sequencing were stored at +4°C until 
sequencing. 
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Sequencing 
 
Sequencing was performed using the BigDye Terminator v1.1 Cycle Sequencing 
Ready Reaction Kit (Applied Biosystems) on an ABI PRISM 310 Genetic Analyzer, 
and, since June 2018, using the BigDye Terminator v3.1 Cycle Sequencing Ready 
Reaction Kit on an ABI 3500XL Genetic Analyzer. 
 
Sequence analysis 
 
Sequences were analyzed with Sequencher 4.10.1 (Gene Codes Corp Inc., An Arbor, 
MI, USA) and compared with published reference strains from GenBank 
(http://www.ncbi.nlm.nih.gov/BLAST/, Nucleotide blast). In the unpublished data 
RotaTeq G1 VP7 (GenBank accession no. GU565057), RotaTeq P[8] VP4 
(GU565044) and RotaTeq VP6 (GU565056) sequences were used as references for 
comparison. 
4.2.5 ELISA 
Rotavirus detection in stools (I, II) 
RV antigen detecting ELISA in stools was conducted using a commercial RV ELISA 
kit, ProSpect (Oxoid Ltd, UK) according to the manufacturer’s instructions. Briefly, 
a stool suspension was prepared by adding 100 mg of stool to sample diluent. After 
mixing and incubating for 10 min at room temperature, the sample was centrifuged 
at 1,000 x g for 10 min at room temperature.  
One hundred microliters of sample was pipetted in two parallel wells coated with 
a rotavirus specific rabbit polyclonal antibody. Two negative and positive controls 
were included in each sample plate. After sample addition, two drops of conjugate 
were inserted into each well and the plate was covered with sealing tape, mixed, and 
incubated for 60 min at room temperature. After incubation, the wells were washed 
with Wash Buffer and double-distilled H2O using Denly Wellwash 4 (Denley 
Instruments Ltd, UK). Two drops of substrate were added to each of the washed 
wells, and the plate was mixed and incubated in the dark for 10 min at room 
temperature. The substrate reaction was stopped by adding two drops of stop 
solution. The optic density of the samples at 490 nm was then read by a microplate 
reader Victor2 1420 (Perkin Elmer, Waltham, MA). The cut-off value was 
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determined by adding 0.100 absorbance units to the absorbance value of the negative 
control. 
Serum VP6 IgA (II) 
Serum RV VP6 IgA levels of children with long-term shedding were determined by 
ELISA to study if the children were seroconverted by the RotaTeq vaccine. A 96-
well plate was coated with 1 μg/ml of rabbit anti-RV group A antibody (GenWay 
Biotech Inc., California, USA), and in a baculovirus-insect cell expression system 
produced VP6 antigens were added at a concentration of 1 μg/ml. The wells were 
blocked with 5 % milk and serially diluted serum samples (from 1:100 to 1:3,200) 
were added two-fold to the wells. VP6 IgA antibody binding was detected with 
1:4,000 diluted horseradish peroxidase-conjugated goat anti-human IgA (Thermo 
Scientific) and 0.4 mg/ml o-phenylenediamine dihydrochloride substrate (FAST-
OPD, Sigma-Aldrich). An optical density at 490 nm was measured by Victor2 1420 
(Perkin Elmer, Waltham, MA). A cut-off value was determined by adding the mean 
absorbance of the negative control to three times the standard deviation of the 
negative controls, and the value had to be ≥ 0.100. 
4.2.6 Cell culture in MA104 cells (I-II) 
In Study I, a 10% stool suspension containing 1ml of minimum essential medium 
(MEM) was vortexed and then supplemented at 3,000 x g for 15 min. The solution 
was then filtered through a 0.22 filter and diluted in MEM containing 10 % fetal calf 
serum with trypsin (0.5 μg/ml) (Gibco). The virus-MEM solution was then activated 
for 30 min in a humified 5 % CO2 incubator. MA104 cells seeded in a 25 cm2 tissue 
culture flask and six-well plate were washed with trypsin-MEM. The cells were 
infected with 2ml of virus dilution and incubated for 1h in a CO2 incubator. After 
24 hours, the virus dilution was replaced with a virus culture medium containing 
MEM with penicillin/streptomycin (1:100) and L-glutamine (1:100) as a supplement. 
The cell lines were monitored daily for a cytopathic effect. Cells that showed a 
cytopathic effect were stored at -20°C. Cells were scraped from the wells, harvested 
and centrifuged at 1,100 rpm for 5 min. Part of this passage 0 supernatant was then 
transferred into a new 25 cm2 flask and six-well plate which were treated with MEM 
and 0.5 μg/ml trypsin. After 48 hours, the passage 1 cells were scraped, harvested 
and centrifuged at 1,100 rpm for 5 min. This was repeated for a total of three 
passages, and the final supernatant was stored at -20°C until used in RT-PCR. 
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The protocol in Study II was otherwise similar but contained only passage 0, with 
the difference that the cells were observed for a cytopathic effect for seven days 
before scraping and harvesting. 
4.3 Statistical methods (II, III, IV) 
Statistical analyses were conducted using SPSS 23.0 (III) and 25.0 (II and IV) (IBM 
Corp., Armonk, NY). A p-value <0.05 was considered statistically significant.  
Depending on the sample size, Fisher’s exact test (III) or the chi-square test (II 
and IV) was used to determine the difference in genotype distributions of vaccinated 
and unvaccinated children (III and IV), and the relation of symptoms to the duration 
of shedding and to the genotypes shed (II). Exact values were calculated when the 
chi-square test assumptions were not met due to a too high proportion of low 
number contingency cells. The Mann-Whitney U test (II, IV) was used to calculate 
differences in the age and genotype distributions. 
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5 RESULTS 
5.1 Shedding of RotaTeq vaccine strain rotaviruses 
5.1.1 Prevalence of shedding (I,II) 
Study I examined RotaTeq vaccine virus shedding at random time points in children 
aged 2 to 8 months hospitalized for a RTI showing no gastroenteritis symptoms. In 
Study I, shedding of RotaTeq vaccine strain VP7 was detected by RT-PCR in the 
stools of 30 (16.5 %) out of 182 children who had received at least one dose of 
RotaTeq vaccine. Of these children, 28 had received the first dose of the RV vaccine 
and 14 (50.0 %) were found to shed the RotaTeq vaccine virus at the time of 
hospitalization. Some 38 children had received two doses, and of those 10 (26.3 %) 
were excreting vaccine strains in the stools. Most of the 182 children, 116 (63.7 %), 
had received all three doses of the vaccine, and only 6 (5.2 %) cases were positive 
for the RotaTeq vaccine strains. (Fig. 5) 
In Study II, shedding of RotaTeq vaccine viruses was detected in 272 (93.2 %) 
out of 292 children 5-10 days after the first dose of the vaccine. A second stool 
sample 0-7 days before the third dose was received from 247 children, of whom 50 
(20.2 %) were detected with vaccine strain in stools. Long-term shedding six weeks 
after receiving the third vaccine dose was found in 11 (26.2 %) out of 42 children 
who provided the third stool sample. Nine of the 11 children provided the last 
sample and two of those children continued shedding up to 12 weeks after the third 
dose at the age of eight months. (Table 7) 
5.1.2 Duration of vaccine virus excretion (I, II) 
Among the children hospitalized for RTI in Study I, the duration of shedding was 
calculated by subtracting the sampling date from the date of the latest vaccine dose 
given. In total, prolonged (over 14 days) shedding was detected in 16 (53.3 %) out 
of a total of 30 cases, with long-term shedding lasting over 30 days in nine (30.0 %) 
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cases. At its longest, RotaTeq vaccine strain was detected in the stools of one 
immunocompetent child 84 days after receiving the third dose of the vaccine. The 
proportion of prolonged shedders increased after each vaccine dose received, as 4 
out of 14 (28.6 %) children after the first, 7 out of 10 (70.0 %) after the second, and 
5 out of 6 (83.3 %) children after the third dose were shedding for longer than 14 
days following the inoculation. 
Study II was designed to study long-term shedding and the sampling points were 
timed to be relevant to the main goal. Fifty (20.2 %) of the 272 children were 
detected to shed RotaTeq vaccine strain 5-10 days after the first dose of the vaccine 
and then to continue shedding up to 0-7 days before receiving the third dose. After 
subtracting the sampling time frame, these children were shedding for a total of 
approximately 2.5 months. The third sampling point was six weeks after the third 
dose, and out of 42 children, 11 were detected with vaccine strain, meaning a total 
shedding time of 4.5 months. Extensively long shedding was found in two children 
who remained positive for RV vaccine virus six months after receiving the first dose, 
ergo up to the age of eight months. A voluntary serum sample was requested from 
these 11 children, of whom seven provided a sample. Out of the seven children, six 
showed to be seroconverted against serum VP6 IgA. All children were detected with 
RotaTeq G1 in their stools in all samples. (Table 7) 
 
Viability of long-term shed vaccine-derived rotaviruses by cell culture 
Five series of subsequent samples were selected for cell culture in MA104 cells. The 
RT-PCR results for both original stool samples and cell culture supernatants are 
shown in Table 8. In three cases (1-3) the first sample was ELISA positive. In the 
other two cases (4 and 5) ELISA was negative but RT-PCRs remained positive up 
to the fourth stool sample. The samples were cultivated for seven days without a 
visual cytopathic effect. In three cases (1-3), RT-PCRs for VP7, VP4 and VP6 of the 
cell cultured first samples were positive. In two of these cases (1 and 3), the vdG1P[8] 
strain was successfully cultivated. Some changes in the shed G-types was seen as in 
one case (2) the RT-PCR findings of the first and second samples (G1+G4+P[8] 
and G1P[8], respectively) differed from the cell culture findings (G1+G6+P[8] and 
G6P[8], respectively). In another case (5), the cell culture of the third sample showed 
G1 similar to the stool sample results; however, the previous cell cultures were 
(illogically) negative.  
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Table 7.  Summary of detected RotaTeq vaccine genotypes at each time point. 
Genotype combinations 
Time after the 1st dose, n (%) 
5-10 d (n=272) 3 m (n=50) 4.5  m (n=11) 6 m (n=2) 
G1 43 (15.8) 32 (64.0) 10 (90.9) 2 (100) 
G1P[5] 11 (4.0) 1 (2.0)   
G1P[8] 61 (22.4) 10 (20.0)   
G1+P[5]+P[8] 11 (4.0)    
G1+G3+P[8] 2 (0.7)    
G1+G3+G4 1 (0.4)    
G1+G3+G4+P[5]+P[8]  1 (2.0)   
G1+G4 12 (4.4)    
G1+G4+P[5] 18 (6.6)    
G1+G4+P[8] 31 (11.4)    
G1+G4+P[5]+P[8] 12 (4.4)    
G1+G4+G6 1 (0.4)    
G1+G4+G6+P[5] 1 (0.4)    
G1+G4+G6+P[8] 7 (2.6)    
G1+G6 1 (0.4)    
G1+G6+P[8] 7 (2.6) 1 (2.0)   
G1+G6P+[5]+P[8] 1 (0.4)    
G2 1 (0.4) 1 (2.0)   
G2P[5] 1 (0.4)    
G2+G4 1 (0.4)    
G2+G4+G6+P[8] 1 (0.4)    
G3 1 (0.4)    
G3P[8] 1 (0.4)    
G3+P[5]+P[8] 2 (0.7)    
G3+G4 1 (0.4)    
G3+G4+P[5] 3 (1.1)    
G3+G4+P[8] 1 (0.4) 1 (2.0)   
G3+G4+P[5]+P[8] 3 (1.1)    
G4 10 (3.7) 1 (2.0)   
G4P[5] 2 (0.7)    
G4P[8] 4 (1.5)    
G4+P[5]+P[8] 2 (0.7)    
G4+G6 1 (0.4)    
G4+G6+P[5] 1 (0.4)    
G4+G6+P[8] 7 (2.6)    
G6P[8] 7 (2.6)    
P[8] only  1 (2.0)   
VP6 only 3 (1.1) 1 (2.0) 1 (9.1)  
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Table 8.  RotaTeq vaccine G- and P-types detected in stool samples and cell cultures in five 
series of cases. VP6 positive samples are bolded. 
Case Sample type 
Sample 
1st 2nd 3rd 4th 
1 
SS G1+G4+P[8] G1P[8] - - 
CC G1P[8] neg - - 
      
2 SS G1+G4+P[8] G1P[8] - - CC G1+G6+P[8] G6P[8] - - 
      
3 SS G1P[8] G1P[8] G1 - CC G1P[8] neg neg - 
      
4 SS G1P[8] G1 G1 G1 CC neg neg neg neg 
      
5 SS G1 G1 G1 G1 CC neg neg G1 neg 
SS = stool sample, CC = cell culture    
5.1.3 Genotypes and combinations (I, II) 
In Study I, G1P[8] was the most common genotype detected in 8 (57.1 %) out of 14 
cases after the first dose of the vaccine. Whereas, after the second and third dose, 
G1 was most frequently detected. (Fig. 5) Of the 30 cases, bovine-origin VP6 was 
detected in 29 cases, and a human-origin VP6 in one case – in which the child was 
found with a combination of RotaTeq G1 VP7 and wild-type P[8] VP4 10 days after 
receiving the second dose of the vaccine. 
Stool RV antigen ELISA was conducted in 19 out of the 30 RT-PCR positive 
cases, while in the remaining cases the sample type (diaper) or amount was 
insufficient for analysis. Of the 19 samples, only four (16.7 %) were ELISA positive, 
all in children detected with vdG1P[8]. 
All detected genotype combinations in Study II are presented in Table 7. After 
the first dose (N=272), the most common detections were G1P[8], G1 alone and 
G1+G4+P[8] which were shed in stools in 61 (22.4 %), 43 (15.8 %) and 31 (11.4 %) 
cases, respectively. In comparison, the original vaccine strains G1P[5] (N=11), 
G6P[8] (N=7), G4P[5] (N=2) and G2P[5] (N=1) were much rarer findings. The fifth 
original strain, G3P[5], was detected only in combination with other G- or P-type. 
After the second dose, G1 alone had become the most common with 32 (64.0 %) 
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out of 50 detections, followed by G1P[8] (N=10). Other genotypes were single 
detections.  Likewise, G1 alone was also the only genotype detected 6 and 12 weeks 
after the third dose of the RotaTeq vaccine, with the exception of one case where 
only VP6 RT-PCR was positive (Table 7). 
 
Figure 5.  Number and genotypes of RotaTeq vaccine-derived strains detected at random time-
points after each dose of the vaccine. 
When examining G-types only, G1 was associated in 93.3 % of all the cases in the 
Study 1 (Fig. 5). In the Study II, G1 was predominant as well, as it was found in 220 
(81.8 %) out of 269 VP7 positive first stool samples, in 45 (93.8 %) out of 48 cases 
just before the third dose, and in each of the later stool samples (Fig. 6). Of the other 
RotaTeq vaccine contained G-types, G4 was the only common detection found in 
120 (44.6 %) of the VP7 positive stool samples after the first dose. Of the P-types, 
P[8] was by far more common than P[5], being found in 159 (81.1 %) of the 196 
VP4 positive cases after the first dose, whereas P[5] was detected in 68 (34.7 %). 
Bovine-origin VP6 was detected in 257 (88.0 %) out of the 292 first stool samples 
provided but only in 37 (15.0 %) of the 247 second stool samples (Fig. 6). As the 
only detection, VP6 was seen in three cases after the first dose of the vaccine, and in 
one case just before the third dose and six weeks after the third dose. Only two of 
the 11 VP7 positive third samples were also VP6 positive; however, both positive 
fourth samples given 12 weeks after the third dose, were also positive for VP6. 
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All RT-PCR positive first stool samples were studied by RV antigen ELISA. In 
45 cases, the test could not be performed due to the insufficient amount or type of 
the sample (diaper). Of the remaining 227 samples, 37 (16.3 %) were ELISA positive. 
The most common finding among the ELISA positive children was vdG1P[8] 
(N=23, 62.2 %). Other genotypes were G1+G4+P[8] (N=4, 10.8 %), G4+G6+P[8] 
(N=3, 8.1 %) and G6P[8] (N=2, 5.4 %), whereas G1 alone, G1+G4+P[5], 
G1+G4+P[5]+P[8], G1+G4+G6 and G1+G4+G6+P[8] were found as single 
detections. RT-PCR positive second, third, and fourth samples were also tested for 
ELISA, all being negative. 
 
Figure 6.  Distribution of different RotaTeq G-types (n=269), P-types (n=196) and VP6 (N=257) in 
first stool samples (n=292) collected 5-10 days after the first dose of the RotaTeq vaccine. 
5.1.4 Shedding of vaccine-derived double-reassortant G1P[8] (I, II, 
unpublished) 
VdG1P[8] was a common finding in both Studies I and II, especially after the first 
dose of the vaccine. In Study I, vdG1P[8] was detected in eight (57.1 %) children 
out of 14 after the first dose of the vaccine, and in 11 (36.7) children out of 30 in 
total. All of these children were hospitalized for RTI and had no AGE symptoms. 
Likewise, in Study II, vdG1P[8] was the most common detection right after the first 
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dose with 61 (22.4 %) out of 272 detections, and it was also detected in 10 (20.0 %) 
of the 49 second samples. 
 
Cell culture of vdG1P[8] 
In the unpublished data from Study I material, stool samples of three children 
detected with RotaTeq vdG1P[8] were cultured in MA104 cells. The children had 
recently received the first dose of RotaTeq vaccine and were ELISA positive. The 
samples were obtained six days (one case) and 14 days (two cases) after the 
vaccination. Two of the samples showed no sign of growth in cell culture, but in one 
case (sample obtained six days after vaccination), the virus was successfully 
propagated and remained stable in three passages of cell culture, indicating presence 
of a viable virus potentially acting as a pathogen. In comparison, in Study II, in two 
cases the vdG1P[8] strain was grown successfully in cell culture, which are previously 
described in section 5.1.2 and presented in Table 8. 
5.1.5 Genetics of long-term shedding (unpublished) 
Analysis of G1 VP7 sequences 
At least two subsequent G1P[8] or G1 VP7 sequences were available in 38 cases of 
the Study II material. In comparison to RotaTeq G1 VP7 sequence, no nucleotide 
level changes were found in the first stool samples, collected 5-10 days after the first 
dose of the vaccine. In 27 (71.1 %) of the 38 second stool samples, at least one 
nucleotide substitution was observed. In the majority (21 out of 27) of the cases, a 
transition of purines A to G was found. This transition caused an amino acid change 
of Aspartate to Asparagine at position 145, which is located in the epitope region 7-
2. In addition, in one sequence, there were two other amino acid changes, at position 
129 (Valine to Alanine) located in epitope region 7-1a, and at amino-acid position 37 
(Phenylalanine to Leucine), which is located outside epitope regions. Of other single-
point nucleotide mutations, there was a transition of purines G to A causing amino 
acid substitution from Aspartic acid to Asparagine at location 126, which is located 
outside epitope regions. The change was detected as singular in three cases, and in 
one case it was found in combination with the previously presented epitope region 
7-2 amino acid substitution at position 145.  
Third subsequent sequence was available only in 11 cases, of which in five (45.5 
%) cases, mutations were noted in comparison to the reference strain. In two cases, 
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the common amino acid mutation located at location 145 persisted from the second 
sample sequences, and in one case it was detected for the first time. Additional amino 
acid substitutions were also detected in those two cases that were found with the 
persisting amino acid mutation at location 145. These substitutions were at position 
96 (Glycine to Serine) in epitope 7-1a and at position 211 (Asparagine to Aspartic 
acid) in epitope 7-1b. All presented amino acid substitutions located in epitope 
regions, with the exception of position 129 in region 7-1a, have been shown to 
escape neutralization with monoclonal antibodies. This finding may provide further 
understanding to effectors of long-term shedding after vaccination. 
Based on this finding, the VP7 G1 sequences of the children reported in Study I 
were also studied. Of the 30 children, 28 were detected with G1 in stools, and in 14 
of those children, the duration of shedding was longer than 14 days. Sequences 
covering the particular site were available in 10 cases. The same transition from G 
to A causing the amino acid change was found in 5 out 10 (50.0 %) sequences. All 
of these five children had received a minimum of two doses of the vaccine and at 
least 28 days before sampling. The same children were detected with G1 VP7 with 
vaccine VP6, whereas VP4 was negative in every case. 
 
Analysis of P[8] VP8* and VP6 sequences 
 
A positive P[8] VP8* sequence was available from 21 of the first and nine of the 
second stool samples. In one of the first sample sequences, a nucleotide point-
mutation was detected. The mutation caused an amino acid change (Phenylalanine 
to Tyrosine) at position 203 that located outside the epitope regions. Another 
nucleotide level change was noted but it did not cause changes at the amino acid 
level. 
In the sequences of the second samples, only one nucleotide substitution was 
found: a transversion from G to T, causing an amino acid change from Valine to 
Leucine at position 163, outside the epitope regions. Although all VP8* amino acid 
changes were outside the epitope regions, all of the changes occurred in samples in 
which epitope region amino acid changes were detected in VP7. 
When comparing VP6 sequences to the reference RotaTeq VP6 strain, no 
changes were found regardless of the sampling point in Study II, indicating lower 
genetic pressure in VP6 sequences. In the Study I, one of the five children with an 
epitopically located amino acid change in VP7 was found with a transition of C to 
T, causing an amino acid change from Methionine to Isoleucine at locus 302, which 
is outside the epitope region. In two children, a transition of C to T was found at 
 75 
amino acid locus 324 in the epitope region. This mutation however caused no 
changes in the amino acid sequence and has been reported as indigenous(381). 
5.1.6 Symptoms associated with vaccine strain shedding (II) 
Symptoms related to RotaTeq vaccine shedding were evaluated using a symptom 
diary filled by parents for seven days. Some of the diaries were improperly filled or 
never returned, and out of 284, 194 and 227 diaries received after the respective dose 
of the RotaTeq vaccine, 278, 182 and 224, respectively, were included in the analysis.  
The occurrence of gastrointestinal symptoms decreased during the course of 
immunization as vomiting (at least one episode) was reported in 35.3 % (98 out of 
278), 34.6 % (63 out of 182) and 30.3 % (68 out of 224) children, after the respective 
vaccine doses (Table 9). Similarly, diarrhea (at least four stools per day) was recorded 
in 34.9 % (97 out of 278) children after receiving the first dose of the vaccine, in 30.2 
% (55 out of 182) after the second dose, and in 15.6 % (35 out of 224) after the third 
vaccine dose. The proportion of children having long lasting diarrhea decreased 
throughout the vaccination course. By contrast, the proportional occurrence of fever 
(≥38.0°C) increased after the later doses, which were received concomitantly with 
other vaccines. Only 1.1 % (3 out of 278) of the children had fever after the first 
dose, whereas 3.3 % (6 out of 182) and 10.7 % (24 out of 224) of the recipients 
reported a temperature greater than 38.0°C after the second and third dose, 
respectively. 
 Of the 24 children with fever after the third vaccine dose, only six also had 
diarrhea and vomiting, and in two of these cases, the clinical severity according to 
the Vesikari score was severe. Interestingly, only one of these six children was 
detected with RotaTeq vaccine virus in stools just before the third dose, whereas the 
others did not (in one case, the second stool sample was not received). 
The clinical severity of symptoms related to vaccination was evaluated by the 
Vesikari score. Similar to gastrointestinal symptoms, the clinical picture became 
milder after receiving more doses of the vaccine as the average of total score 
decreased from 5.3 after the first dose to 4.4 after the third dose of the vaccine. The 
median Vesikari score decreased from 5.0 to 4.0, respectively. 
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Table 9.  Reported symptoms after each dose of the RotaTeq vaccine for seven days graded 
according to the Vesikari Score. 
Symptom 
Vesikari 
Score 
point 
Diary 
1st  
(N=278) 
n (%)  
2nd  
(N=182) 
n (%)  
3rd  
(N=224) 
n (%)  
Duration of diarrhea (d)    
 0 0 54 (19.4) 42 (23.1) 67 (29.9) 
 1-4 1 78 (28.1) 57 (31.3) 84 (37.5) 
 5 2 19 (6.8) 14 (7.7) 16 (7.1) 
 ≥6 3 127 (45.7) 69 (37.9) 57 (25.4) 
Max no. diarrheal stool/24h    
 0 0 54 (19.4) 42 (23.1) 67 (29.9) 
 1-3 1 127 (45.7) 86 (47.3) 122 (54.5) 
 4-5 2 61 (21.9) 39 (21.4) 28 (12.5) 
 ≥6 3 36 (12.9) 15 (8.2) 7 (3.1) 
Duration of vomiting (d)    
 0 0 180 (64.7) 119 (65.4) 154 (68.8) 
 1 1 25 (9.0) 19 (10.4) 19 (8.5) 
 2 2 20 (7.2) 9 (4.9) 15 (6.7) 
 ≥3 3 53 (19.1) 35 (19.2) 36 (16.1) 
Max no. vomiting episodes/24h    
 0 0 180 (64.7) 119 (65.4) 156 (69.6) 
 1 1 37 (13.3) 29 (15.9) 32 (14.3) 
 2-4 2 44 (15.8) 29 (15.9) 26 (11.6) 
 ≥5 3 17 (6.1) 5 (2.7) 10 (4.5) 
Fever (°C)    
 <37.0 0 45 (16.2) 19 (10.4) 26 (11.6) 
 37.1-38.4 1 232 (83.4) 160 (87.9) 181 (80.8) 
 38.5-38.9 2 1 (0.4) 2 (1.1) 12 (5.4) 
 ≥39.0 3 - 1 (0.5) 5 (2.2) 
Symptoms in relation to duration of shedding 
Individual symptoms and the total clinical severity was compared in children with 
short- and long-term (RV positive stool sample before the third dose of the vaccine) 
shedding. No difference between individual symptoms and duration of shedding was 
detected after any dose of the RotaTeq vaccine (Supplementary Table 2 in Study II). 
However, long-term shedders were found with more severe symptoms after 
receiving the first dose of the RotaTeq vaccine, as of the 50 children with long-term 
shedding, 8 (16.0 %) had severe (Vesikari Score ≥11) and 12 (24.0 %) had moderate 
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(Vesikari Score 7-10) clinical severity whereas short-term shedders (N=172) the 
respective numbers were 10 (5.8 %) and 41 (23.8 %), respectively. The median (5.5 
vs 5.0, respectively) and mean (5.7 vs 4.9, respectively) Vesikari Scores were also 
higher among the long-term shedders compared to the short-term shedders 
(p=0.043, χ2 exact). No differences were found after the later doses (data not 
shown). 
Symptoms related to shedding of vaccine-derived double-reassortant G1P[8] 
The theorized higher virulence of vdG1P[8] genotype(357–359) was studied by 
comparing symptoms reported in cases where vdG1P[8] was found as the only 
genotype to cases with other genotypes, excluding combinations containing G1P[8] 
such as G1+G6+P[8]. In relation to the shed genotype, no difference in the total 
severity was found after the first dose of the RotaTeq vaccine. Of the 58 children 
detected with vdG1P[8], five (8.6 %) had a severe and 14 (21.9 %) a moderate clinical 
picture according to the Vesikari Score, whereas in children detected with other 
genotypes (N=198) the respective numbers were 15 (24.1 %) and 51 (25.8 %). While 
examining individual symptoms, no difference between the groups were found after 
any of the vaccine doses (Supplementary Table 1 in Study II). 
5.2 Rotavirus epidemiology in Finland 4 to 9 years after vaccine 
introduction (III, IV) 
Study III consisted of the first two years of the national RV follow-up from 
September 2013 to August 2015, and Study IV extended the surveillance for three 
more seasons up to August 2018. During this period, a total of 1,160 laboratory-
diagnosed RV positive samples were received, and of those, 1,024 (88.3 %) were RT-
PCR positive. Of the 1,024 RV cases, 837 (81.7 %) were detected in children, 55 (5.4 
%) in adults and 132 (12.9 %) in the elderly.  
RV seasonality 
In children, the number of RV cases detected per season remained stable during the 
first four seasons of follow-up, but during the last season (2017-18) the activity was 
by far higher (N=259) (Fig. 7). No distinct pattern such as biennial occurrence was 
detected. In addition, the duration of the RV seasons remained stable, typically 
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beginning in January to March and ending in May to June, and no shift or 
prolongation of the season was detected. 
 
 
Figure 7.  RV seasonality in children (N=837), adults (N=55) and the elderly (N=132) during five-
season follow-up from September 2013 to August 2018. 
In adults and the elderly, RV disease occurred more or less sporadically throughout 
the year for the first three seasons of follow-up. However, during the last two 
seasons, the occurrence of RV cases in both age groups followed a similar pattern to 
that of the children, with clearly higher activity during the spring months. 
5.2.1 Circulating rotavirus genotypes in children (III, IV) 
In total, G12P[8] was the most common genotype detected in children during the 
follow-up period from September 2013 to August 2018 (Fig. 8). The genotype was 
found in 195 (23.3 %) out of the 837 RV cases. However, it was mainly detected in 
the last season of surveillance (N=132). Of the other genotypes, G9P[8] (N=150), 
G1P[8] (N=128) and G2P[8] (N=105) were also typical findings in children. Other 
frequent detections were equine-like G3P[8] (N=68), G3P[8] (N=53), G9P[4] 
(N=50) and G4P[8] (N=43). 
Several previously unseen and partly zoonotic genotypes were found occasionally 
or as single detections (N=11). The most common ones were G8P[14] (N=3) and 
G29P[9] (N=2) followed by others such as G2P[8] and G4P[6]. Mixed infections 
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were identified in 11 children, most of them associated with G-type G3: 
G3+G12P[8] (N=5), G3+G9P[8] (N=4), G3+G8P[8] (N=2) and G4+G9P[8] 
(N=1). 
 
Figure 8.  RV genotype distribution in children (N=837) by age from 2013 to 2018. RotaTeq includes 
all combinations including vaccine strain.  
5.2.1.1 Rotavirus vaccine effects on rotavirus disease and circulating genotypes (IV) 
Age distribution 
The mean age for all 837 children was five years and the median 4.3 years, with a 
range from 8 days to 15 years. During the follow-up, the mean age of the children 
remained stable, from 4.9 years (2013-14) to 4.8 years (2017-18). However, a 
decrease in the median age was noted towards the end of surveillance, as the median 
age was 5 years in 2013-14 and 3.8 years in 2017-18. 
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Changes in the circulating genotypes 
In the first season of follow-up, 2013-14 (N=129), G1P[8] was the predominant 
genotype with 44 (34.1 %) detections accompanied by G2P[4] (N=26, 20.2 %) and 
G4P[8] (N=24, 18.6 %) (Fig. 9). However, the proportion of these previously 
common genotypes decreased during the follow-up, as they formed together only 18 
(6.9 %) out of the 259 cases detected in total during 2017-18. Correspondingly, the 
proportion of G12P[8] and G9P[8] increased, and a novel strain, G9P[4], appeared 
and became common. An equine-like G3P[8] was also detected for the first time 
during the 2014-15 season, and it soon became more common than the wild-type 
G3P[8]. A change in the predominant genotype was noted as the long-standing 
dominant genotype G1P[8] was first replaced by G9P[8] in the 2015-16 season, and 
G12P[8] became predominant from 2016-17 season. 
 
Figure 9.  Prevalence of RV genotypes in children during each season from 2013 to 2018. 
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If a child was too old to receive the RotaTeq vaccine in the NIP (aged over two 
months in September 2009) and the vaccination status was unknown, the child was 
considered unvaccinated. This assumption was done to study the possible indirect 
vaccine effects on the cohort of older children aged four years and above. The 
proportion of these older children with RV (N=282) of all the children diagnosed 
with RV (N=837) decreased throughout the study period from 50 % (65/129) in 
2013-14 to 20 % (52/258) in 2017-18. This decrease in the number of older children 
is in line with the decrease of the median age of children detected with RV, as 
described in the previous chapter. The changes in the circulating genotypes in this 
age cohort were similar to all children with the decrease of G1P[8] and G2P[4] and 
the increase of G9P[8] and G12P[8]. 
5.2.1.2 RotaTeq vaccine-derived strains (III, IV) 
In Study IV, RotaTeq vaccine-derived viruses were detected in six children. 
However, the vaccination status was known in only one case of a recently vaccinated 
two-month-old child, who was detected with RotaTeq G1P[5] in the stools. 
Nevertheless, it is legitimate to assume that also two other children, aged three and 
six months and detected with RotaTeq G1+G4+P[8] and RotaTeq G1 VP7 only, 
respectively, had also received a dose of the vaccine lately. In two other cases, a 
possible transmission of vdG1P[8] was seen in children aged one and three years. A 
three-year-old was also detected with a mixed infection of wild-type G3P[8] in 
combination with RotaTeq G1 VP7. 
5.2.1.3 Rotavirus in vaccinated and unvaccinated children (IV) 
Vaccination status was reported in only 276 of the 837 RV cases in children. Of these 
276 children, 172 were young enough to receive the vaccine in the NIP, and of these 
children, 96 (55.5 %) were known to have received at least one dose of the RotaTeq 
vaccine and 76 children were unvaccinated. In addition, 13 children had received RV 
vaccine before the beginning of mass-vaccinations; these children were not included 
in the following analyses. 
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Figure 10.  Age distribution of vaccinated (N=96) and unvaccinated (N=76) children with a RV 
infection. Figure reproduced and adapted with the permission of the publisher, 
Elsevier(382). 
Interestingly, both the mean and median age of vaccinated children (3 and 2.7 years, 
respectively) were higher than that of the unvaccinated children (2.7 and 2 years, 
respectively). This difference was statistically significant (p=0.05, Mann-Whitney U 
test) (Fig. 10). The genotype distribution was otherwise even but G12P[8] was a 
considerably more common cause of RV disease in vaccinated than unvaccinated 
children with 38 versus 13 detections, respectively (p=0.001, χ2 test). By contrast, 
G4P[8] was more common in unvaccinated (N=11) than in vaccinated (N=4) 
children (p=0.017, χ2 test) (Fig. 11). 
 
 
Figure 11.  Rotavirus genotype distribution of vaccinated (N=96) and unvaccinated (N=76) children. 
Figure reproduced and adapted with the permission of the publisher, Elsevier(382). 
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5.2.2 Rotaviruses detected in adults and the elderly (III, IV) 
In adults aged 16 to 69 years, total of 55 cases of RV were confirmed between 
September 2013 and August 2018. The mean and median ages were 38 and 41 years, 
respectively. Most of the cases were caused by G2P[4] (N=17, 30.9 %) followed by 
G9P[8] (N=7, 12.7 %) and G12P[8] (N=7, 12.7 %) (Fig. 12). Several zoonotic 
strains, such as G29P[9], G3P[6] and G6P[14], were also identified. Mixed infections 
(three cases caused by G3+G9P[8] and one case by G2+G12P[4]) were found in 
adults, but not in the elderly. 
The number of RV cases was more frequent in the elderly aged 70 years and 
above, where RV was detected in the stool samples of 132 cases. In this age group, 
the mean age was 84 years and the median age 85 years. The genotype distribution 
was similar to that for the adults; G2P[4] (N=50, 37.9 %) predominated and G12P[8] 
(N=30, 22.7 %) and equine-like G3P[8] (N=12, 9.1 %) were the second most 
common genotypes. In the elderly, G8P[14] was the only zoonotic strain detected. 
During the follow-up period, some changes in the circulating genotypes were 
noted in both age groups as G2P[4] dominated at the beginning of surveillance but 
was then replaced by G12P[8] during the last season of 2017-18. Actually, in addition 
to G12P[8], both G9P[4] and G9P[8] became common first in children and a season 
later in adults and the elderly. 
 
Figure 12.  RV genotypes by age in adults (N=55) and the elderly (N=132) during the five seasons of 
follow-up 2013-2018. 
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6 DISCUSSION 
6.1 Shedding of RotaTeq vaccine rotaviruses 
 
The section 5.1, which contains results of Studies I and II together with some 
unpublished data, increased the knowledge regarding the characteristics of the 
shedding of RotaTeq vaccine RVs. Study I already showed that excretion of vaccine 
viruses into stools after inoculation was more common than previously shown in the 
pre-licensure studies(363). In some cases, the duration of asymptomatic shedding 
was surprisingly long, raising questions about the prolonged infection of the gut in 
immunocompetent infants. However, the study material was not fit for evaluating 
the true extent and duration of shedding, as it consisted of children hospitalized for 
RTI at a random time point, in relation to the last received RV vaccine dose.  
The more systematic Study II showed that indeed almost all of the vaccine 
recipients excreted vaccine strains in the stools after receiving the first dose of the 
vaccine. This high rate is in line with findings of post-licensure studies by Hsieh et 
al.(367) and Ye et al.(368). Differing from the conducted study protocol, the 
intended original study design contained additional stool sampling immediately 
before and after the second vaccine dose accompanied by serum samples after each 
dose. Unfortunately, the study was forced to be re-designed to enhance recruitment, 
as the protocol was too burdensome for both the infants and parents. Logically, one 
might speculate that the rates would be even higher than those that were observed 
2.5 months and 1.5 months after the second and third doses, respectively. This is 
based on the high proportion of children shedding after the first dose of the vaccine, 
and also on the findings made by earlier studies in which the rates of shedding were 
high after the second and third dose of the vaccine(367,368). 
In Study I, half of the children were detected with prolonged shedding and a third 
continued to shed over a month after the last received dose of vaccine. However, in 
Study II, the number of shedders after the following doses decreased more rapidly 
than assumed. Only a fifth of children presented prolonged shedding between the 
first and the third dose, and a fifth of those continued shedding even after the third 
dose. A likely reason for the lower rates was the previously mentioned longer time 
from inoculation to sampling excluding shorter shedding. Still, in a few cases 
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shedding continued for four to 5.5 months in total. One of our original theories was 
that the long presence of the vaccine RVs in the gut of these children was possibly 
due to a lack of seroconversion or IgA. However, the great majority of the children 
in fact seroconverted against VP6 IgA suggesting that despite the extensively long 
asymptomatic shedding, these children had obtained protection from vaccination. 
Even though the number of samples was low, the seroconversion rate was similar to 
what has been previously reported(160,383). 
Genotyping of shed vaccine strains in children hospitalized for RTI without AGE 
symptoms was conducted to our knowledge for the first time in Study I. Other 
studies(366–368) have focused mostly on detecting vaccine viruses without 
classifying them, with the exception of a vaccine development study by Clark et 
al.(275) and a recent real-time RT-PCR methodology study by Higashimoto et 
al.(369). Compared to those, the predominance of G1 was surprising in both Studies 
I and II, and the strain was practically the only one associated with prolonged 
shedding. This suggests that despite containing several different RV strains, the 
RotaTeq vaccine might actually work in vivo in a similar manner as the single G1P[8] 
strain vaccine, Rotarix. This is supported by the fact that despite the difference in 
the number of RV strains between the vaccines, the efficacy is approximately the 
same against different genotypes(160,161,168,277). The backbone of the vaccine 
consists of the WC3 bovine strain, which as a vaccine candidate was shown to elicit 
insufficient protection in humans but was tolerated well(235,236). Reassortment 
with different human VP7 and VP4 proteins increased the immunogenicity of the 
vaccine to the proper level(384). In many cases, the human origin G1 VP7 and P[8] 
VP4 proteins were detected together, suggesting re-reassortment, which could be 
due to a structural preference, as these proteins in fact originate from the same 
G1P[8] RV strain and therefore they might combine more eagerly with each other 
than with the artificial bovine components. This theory might be argued as a similar 
re-reassortment of G3 and G4 with P[8] was minimal in the current material, while 
both of these VP7s originated from parent strains that contained P[8](271). 
On the basis of previous studies(357–359), vdG1P[8] was expected to be more 
virulent than the original vaccine strains, but the severity of the individual symptoms 
and the clinical picture by the Vesikari score of the children did not differ regardless 
of the genotype shed. In addition, several children in Study I were detected with 
vdG1P[8] and still were hospitalized due to RTI without AGE symptoms. Overall, 
the combination was common in both of the studies, suggesting the possibility that 
the newly formed vdG1P[8] would continue to infect other enterocytes and replicate 
 86 
at an even higher rate compared to the original vaccine strains. In fact, in a few cases 
the viability of the strain was successfully proved in cell culture. 
As discussed earlier in section 2.4.6, vdG1P[8] was originally noticed already in 
the studies of the quadrivalent version of the current RotaTeq vaccine. In fact, Ward 
et al.(275) even studied neutralizing antibody responses against vdG1P[8]. The strain 
showed similar rates of seroconversion as the sole G1, but the geometric mean titers 
were higher compared to other vaccine components, suggesting that vdG1P[8] could 
be immunologically important. After combining this information with the current 
findings of the strain being the most commonly shed combination in a real-life 
setting, despite not even being a part of the composition, the main mechanism of 
the function of the RotaTeq vaccine might be this recombination. If so, the two 
vaccines – RotaTeq, the five-strain-containing human-bovine reassortant vaccine, 
and Rotarix, the single human G1P[8] strain vaccine – may work similarly. This 
theory is supported by the absence of difference between the real-life effectiveness 
of the two vaccines in post-licensure studies(301). 
Another goal was to assess symptoms related to the duration of shedding, but no 
single symptom was found to relate to prolonged shedding. However, when 
assessing the clinical picture by using the Vesikari score, children who became 
prolonged shedders had a higher total score after the first dose of the vaccine. It may 
be speculated that for a still unknown reason, these individuals may somehow be 
more susceptible to RV in comparison to short-term shedders. The symptoms 
reported by the parents differed from those reported by the RotaTeq safety studies. 
In the present material, gastrointestinal symptoms were found far more often than 
previously reported, but this was possibly due to the over-reporting of newborns’ 
stools and spit-ups by the parents.(160) As it was not the original intention, the study 
did not include a placebo group that would at least partially eliminate such an over-
reporting bias. Interestingly, in comparison to the safety studies, fever was seen more 
seldom in the current material, even though concomitant vaccinations were also 
given in the safety studies. This positive effect has no good explanation; it is possible 
that the concomitant vaccines currently in use in Finland are less reactogenic than 
the ones used during the pre-licensure studies. Overall, the RotaTeq vaccine was well 
tolerated but in some individuals, severe symptoms related to the vaccination may 
predict the prolonged duration of shedding. 
The viability of the shed G1-containing strains was assessed by cultivating a 
selected subset of samples in MA104 cells. The selection was guided by the both RT-
PCR and ELISA results, and as assumed, a positive ELISA and a positive RT-PCR 
for all three capsid proteins were required for successful multiplication. It seems that 
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prolonged shedding was associated with the shedding of proteins rather than whole 
viral particles, as the samples obtained before and after receiving the third dose of 
the vaccine showed to be cell culture negative. Nonetheless, how only particles of 
viruses and not the whole viruses are preserved in the gut for months without active 
replication is a mystery. Gut microbiota might have a role, as in a study on the effect 
of the microbiome on the immunogenicity of Rotarix in Indian children, it was noted 
that the bacterial microbiome differed in relation to shedding status and that the 
shedders were found with more enteroviruses at the time of vaccination(385). 
Investigation of the sequences of the most commonly shed genotype, G1 
revealed a consistent change in the amino acid sequence of the majority of the 
second samples obtained from children with prolonged shedding. The mutation was 
located in the epitope region of VP7, and the locus is known to cause escape from 
neutralizing mAbs(334). Inspired by this finding, the randomly collected sample 
material of Study I was re-examined and the same single-point mutation was found 
in lower scale. Likewise, in all of those cases, shedding had continued for longer than 
14 days and the child had received at least two doses of the vaccine, similar to 
unpublished genetic data from the Study II material. Even though in the majority of 
cases there was only a one amino acid change, previous studies have shown that such 
a small change may a have large effect on neutralization overall. It is possible that 
this impairment could lead to a broader or more intense infection of the intestinal 
mucosa, which could then be seen in more severe clinical symptoms. However, the 
amino acid changes were not detected until after receiving the second dose of the 
vaccine, while the children with prolonged shedding were reported to have more 
severe symptoms after the first dose. Due to the sparse sampling between the first 
and the third dose, it is nevertheless possible that the change occurred already after 
the first dose. 
On the basis of these findings, it was surprising that during the five RV seasons 
reported in Studies III and IV, only a total of six children were found with the 
RotaTeq vaccine strain in stools. The number is much lower than what has been 
reported for example in England, where over 200 cases of the Rotarix G1P[8] strain 
were detected during three RV seasons with a ten-fold larger population(362). As 
the rates of shedding for both of the vaccines are roughly the same, one explanation 
might be differences in testing practices or the higher proportion of children in 
relation to the overall population(367). 
Nonetheless, in two cases, children aged one and three years, transmission of 
vdG1P[8] from a vaccinated contact was likely. Unfortunately, the vaccination status 
of the children was not available, but they would have been eligible to receive the 
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vaccine according to their age. These and the previously reported cases of 
symptomatic transmission of vdG1P[8] have been seen in children aged one year 
and above(357,359,386). The older age of these children may be a manifestation of 
immunological waning, as it could be assumed that these children would have 
received the RV vaccination and/or encountered RV beforehand, and therefore it 
would have elicited at least some level of protection. On the other hand, it is possible 
that, in contradiction to the current findings, vdG1P[8] indeed has a higher virulence, 
and, in combination with waning immunity, could lead to a symptomatic infection. 
From a clinical point of view, according to the data presented by this thesis, 
shedding of the RotaTeq vaccine strains is common but not harmful to a healthy 
individual, regardless of the duration. The long duration seems not to have a negative 
effect on protection, at least when studied by using seroconversion for serum VP6 
IgA. On the other hand, the development of difficult prolonged diarrhea has been 
reported in children with impaired immunity – such as undiagnosed severe combined 
immunodeficiency – who receive a live RV vaccine, development of difficult 
prolonged diarrhea have been reported(370,372). Another increasing population 
with potentially impaired immunity are the infants whose mothers are treated with 
tumor necrosis factor-alpha-antagonists during pregnancy. These drugs are IgG 
monoclonal antibodies that have been shown to actively transfer transplacentally, 
and measurable levels can be found even up to seven months after birth(387). The 
subject needs further investigation as there are no studies on whether these drugs 
have an affect on RV vaccination or not. In addition, viable vaccine viruses are shed 
for at least 10 days after inoculation, which in turn may form a threat to 
immunocompromised contacts of all ages. On the other hand, a more likely and 
beneficial scenario would be transmission of these vaccine strains to 
immunocompetent unvaccinated individuals eliciting protection without actual 
vaccination. 
6.2 Epidemiology of rotavirus in Finland 4 to 9 years after 
vaccine introduction 
During the five years of follow-up covering the fourth to the ninth year since the 
introduction of the RotaTeq vaccine in September 2009, the burden of RV in 
Finland has remained stable. A natural season-to-season fluctuation was detected, 
including higher RV activity in 2017-18 season. Despite the higher number of total 
RV cases during the particular season, the number of cases remained lower than in 
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the pre-NIP period, with the numbers indicating that the RotaTeq vaccine has 
maintained its high efficacy(201). Similar sustained low activity after introduction of 
the RV vaccine has been reported in other high vaccine coverage countries such as 
Belgium, the US and also the low-income country of Ghana(300,303,388). 
After the introduction of the RV vaccine, most of the previous studies have 
detected a shift of the disease to unvaccinated older children(300,389–391). On the 
contrary, the current findings suggest the opposite, as the age structure of the 
children was younger at the end of surveillance when compared to the first season. 
Similarly, following the robust approach of dividing children into the vaccine-eligible 
and -ineligible according to age, a consistent decline was seen in the number of RV 
cases in the older vaccine-ineligible children. A similar long-term tendency has been 
reported in Belgium also, which has a similar high-coverage setting with the Rotarix 
vaccine(300). This trend is probably due to the increasing number of vaccinated age 
cohorts, but also due to herd protection elicited by the vaccine. It is possible that a 
similar shift of the disease to older age groups, as reported by others, has also 
occurred in Finland during the first years after the vaccine introduction, but due to 
continuous mass vaccination at a high vaccination coverage, the cohort of 
unvaccinated older children has decreased constantly.  
RV strains have always fluctuated at some level, but changes in the predominant 
strains are more seldom. Current time frame contained the special turnover of 
strains, as the traditional G2P[4], G3P[8], G4P[8] and especially G1P[8] diminished 
and were replaced by the novel G9P[8], G9P[4] and G12P[8]. The waning of G1P[8], 
a strain that has been predominant in Finland almost uninterruptedly since the 1980s, 
was an important finding(200). The replacement of G1P[8] has been seen in many 
countries regardless of the vaccine used, but usually this change has been more rapid. 
The currently depicted genotype distribution in Finland resembles those reported in 
the US and Australian RotaTeq-using territories, and in turn it differs from the 
Rotarix-using countries, suggesting that RV mass vaccination might indeed have an 
effect on circulating strains.(316,324,326,362) 
Despite the changes in the circulating genotypes and the emergence of new 
strains such as G9P[4] and equine-like G3P[8], no drastic changes in the number of 
RV cases were detected. Even though the latest season of the follow-up seemed to 
include an outbreak caused by G12P[8], the vaccine efficacy against the strain was in 
fact approximately 85 % regardless of the number of received doses of RotaTeq 
(Tuija Leino, THL, personal communication, November 2018). Even though the 
information regarding vaccination status was available for only some of the children, 
G12P[8] was significantly more prevalent in the vaccinated compared to the 
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unvaccinated children. In the US, Ogden et al.(330) have reported the high 
prevalence of G12P[8] in vaccinated children, noting also that the strain differed 
significantly from the RotaTeq vaccine strains causing antigenic mismatch, 
potentially explaining the result being similar to ours. The increased diversity of 
detected RV genotypes may be partly due to the development of better detection 
methods such as RT-PCR and sequencing over RV antigen ELISA. However, other 
factors may have an influence as well, as the mobility of humans has increased in 
recent decades, enabling the more efficient spread of strains to new locations and to 
possibly more immunologically susceptible areas. Despite the increased diversity, the 
sustained low activity supports previous studies, suggesting that RotaTeq vaccine 
elicits broad heterotypic protection, and RotaTeq has been shown to be efficacious 
against these emerging strains(160,277,392,393).  
The study material consisted of all laboratory-confirmed RV cases covering all 
age groups, and therefore enabled to study RV disease in adults and the elderly. After 
the first two years of surveillance, as reported in Study I, it seemed that the RV 
disease in these age groups was significantly different from the disease seen in 
children. RV cases occurred evenly throughout the year without distinctive higher 
activity months and the genotypes were different. During the two first study seasons, 
G1P[8] continued to predominate and G9P[8] became common in children, whereas 
in adults G2P[4] was by far the most common genotype. These differences raised a 
theory that RV disease in children and adults could in fact be their own entities, and 
that the adults possibly function as a reservoir for the disease of the children. In fact, 
some of the previous studies have reported a lack of association between child 
contact and RV disease in adults who were hospitalized for RV(207,214).  
Extension of the surveillance time by another three seasons clarified the 
connection between children and adults. The disease in adults and the elderly began 
to follow the seasonal changes seen in children more clearly, with higher activity 
during the winter months. Previous studies have made the same 
finding(207,214,394). Contradicting the earlier theory, it seemed that the disease was 
in fact transmitted from children to older age groups, as the emergence of genotypes 
such as G9P[4], G9P[8] and G12P[8] was noticed a season before in children. This 
children-to-adult transmission was suggested already in the 1980s, and it is likewise 
supported by more recent studies reporting a decrease in the number of RV cases in 
the adult population after the vaccine introduction in children(204,210,394). 
However, such a decline was not observed probably because the surveillance was 
dated four to nine years after vaccine introduction and it contained no data before 
or immediately after the implementation of the vaccine. Overall, the number of RV 
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cases in adults (16 to 65 years of age) was small, whereas according to this thesis RV 
might be an underestimated pathogen in the elderly. Unfortunately, patient record 
were inaccessible to determine the possible co-morbidities that may predispose to 
RV infection(207–209). 
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7 CONCLUSION AND FUTURE PROSPECTS 
In 1980, Kapikian et al.(228) stated: “Before an effective rotavirus vaccine can be 
formulated, we must understand the mechanisms of host resistance to rotavirus 
infection”. Approximately 40 years later, we still do not know the exact mechanisms 
for RV immunity, nor the correlates of protection. However, we have instead 
witnessed the success-story of live-saving vaccines whose development was 
ultimately based on the Jennerian approach, like the smallpox vaccine. Despite the 
fact that RV vaccines have saved millions of lives and averted even higher number 
of hospitalizations, the basic underlying biology is still in many parts unknown. 
This thesis characterized the shedding of the live human-bovine reassortant RV 
vaccine RotaTeq that is currently used in Finland with a high vaccine coverage. 
Excretion of vaccine strains in the stools of recipients is common, and the duration 
may vary greatly from days to prolonged shedding continuing up to months, even in 
healthy asymptomatic children. The reason for the difference in the duration 
between individuals remains unknown and needs further investigation. A consistent 
amino acid mutation causing changes in the epitope region of the outer layer protein 
VP7 was found. This may cause escape of the virus from neutralizing antibodies and 
thereby explain the prolonged presence of the vaccine strain in the gut. In addition, 
more severe symptoms after the first dose may be an indication of the beginning of 
prolonged shedding. However, in the light of the current study, viable vaccine viruses 
are excreted into stools for only a short period after inoculation, whereas prolonged 
shedding consists of non-infectious particles of these viruses. From a clinical 
perspective, such information is important and close contacts between recently 
vaccinated infants and immunocompromised individuals should be avoided. On the 
other hand, the spread of vaccine viruses to unvaccinated toddlers would be 
beneficial, potentially eliciting protection in the unvaccinated recipient.  
Other possible and even more important findings were the major association of 
outer capsid protein G1 with shedding and the common formation of a so-called 
vaccine-derived double-reassortant G1P[8] strain. The latter has been previously 
connected to higher virulence, but support for such a linkage was not found. Overall, 
the data suggests that in a real-life setting, the RotaTeq vaccine containing five 
different reassortant RVs functions in a similar manner as the single G1P[8] strain 
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vaccine, Rotarix. This finding would well explain the almost similar effectiveness of 
these two vaccines, highlighting the importance of cross-protection despite the 
difference in the number of strains contained. 
The effects of mass vaccination on circulating RV strains has been discussed since 
the introduction of RV vaccines due to the fear of potential vaccine-related selection 
pressure leading to lower vaccine efficacy. Regardless of the lack of exact knowledge 
on the method of function of the RotaTeq vaccine, on national level in Finland, the 
vaccine has remained highly effective for nearly a decade after implementation. Mass 
vaccination at a high vaccine coverage has stabilized RV activity to a low level with 
minor natural fluctuation between the seasons. On the other hand, this five-season 
follow-up took place on the verge of a major shift of circulating genotypes in 
children, as the traditional strains; G1P[8], G2P[4] and G4P[8] were superseded by 
the emerging G12P[8], G9P[4] and G9P[8]. This phenomenon has been reported in 
other RotaTeq-using countries, such as the US and Australia, and it indeed may be a 
reflection of vaccine pressure. In addition to the turnover detected in the circulating 
genotypes,  broadening of the strain spectrum was identified in all age groups. These 
novel strains have mainly occurred as rare detections but genotypes such as equine-
like G3P[8] have spread globally and largely superseded the human originated 
G3P[8]. Nevertheless, these strains have not become common, supporting the 
heterotypic protection elicited by the current RV vaccines. 
RV samples were also received from adults and the elderly. These age groups 
were under keen interest during the first decade of the RV studies, but they have 
since been somewhat forgotten. The burden of disease in adults seems low but in 
the elderly, RV may in fact be a clinically important but underestimated cause of 
AGE. Unfortunately, despite RV disease in adults has been highly associated with 
other co-morbidities, the current material did not contain clinical data and studying 
co-morbidities was not possible. Yet, it is reasonable to assume that these cases were 
from hospitalized children and adults. 
Although RV disease in children seemed stable, important vaccination-related 
changes were detected. The number of children who were too old to receive the 
vaccine at the time of the introduction in September 2009 decreased consistently. 
Additionally, the age of diseased vaccinated children has exceeded the age of 
unvaccinated children. Both findings indicate the effects of herd immunity related 
to a near decade of high-coverage vaccinations. After all, the fact that RV continues 
to circulate, indicates that the current live oral RV vaccines are not able to eradicate 
the pathogen despite almost optimal conditions. Current vaccine development has 
taken the course towards non-live particle vaccines, potentially eliminating the few 
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imperfections that the current vaccines have – i.e. potential vaccine-related selection 
pressure, intussusception and lower real-life efficacy in high mortality settings. Only 
time will tell if the development of such vaccines will continue the success story of 
RV vaccines seen up to date. Nonetheless, one thing remains certain: Diarrhea is 
moist poo. 
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Abstract: We conducted a survey on the presence of RotaTeq vaccine 
viruses in infants hospitalized with respiratory infection, and detected shed-
ding in 17% of children (<2 years of age) who had ever received the vac-
cine. The latest detection was at the age of 8 months. We conclude that 
asymptomatic long-time shedding of RotaTeq viruses is not uncommon, 
and is particularly associated with genotype G1.
Key Words: RotaTeq, rotavirus, vaccination, shedding
(Pediatr Infect Dis J 2015;34:296–298)
RotaTeq® (Merck & Co., Whitehouse Station, NJ) is a live oral rotavirus (RV) vaccine consisting of 5 human-bovine reassor-
tant vaccine viruses. In Finland, RotaTeq vaccine was taken into the 
national immunization program in September 2009, and is admin-
istered on a 3 dose schedule at the ages of 2, 3 and 5 months.
Shedding of RotaTeq vaccine viruses was reported low in the 
prelicensure trials,1 but on a recent reanalysis of the  Rotavirus Efﬁcacy 
and Safety Trial (REST) study material using reverse transcription-
polymerase chain reaction (RT-PCR), shedding of RotaTeq vaccine 
viruses was detected in up to 65% of the vaccinees with gastroenteri-
tis symptoms.2 Thus, the full extent of shedding of RotaTeq vaccine 
viruses is not yet characterized. We examined the occasional presence 
of RotaTeq vaccine viruses in young children seen in hospital mainly 
for respiratory tract infection (RTI) and correlated these ﬁndings with 
history of RV vaccination. This approach yielded new information on 
the extent, duration, and type of RotaTeq vaccine virus shedding.
MATERIALS AND METHODS
Clinical Methods
A prospective study approved by the Ethics Committee of 
Pirkanmaa Hospital District on the etiology of RTI in children was 
conducted at Tampere University Hospital from September 1, 2009 
to August 31, 2011. All children under 15 years of age, who were 
admitted into pediatric ward with RTI were eligible for the study.
In this study a stool sample was collected during the hospitali-
zation by a study nurse or nurses working in the pediatric ward or, if 
not successful, the parents were provided with a sample kit to send 
a stool specimen within 2 weeks from home. We used this material 
to examine the presence of rotaviruses and speciﬁcally RotaTeq vac-
cine viruses and therefore excluded all children who had not received 
any dose of RotaTeq. Dates of administration of RV vaccine brand as 
well as the vaccine used was enquired from the parents and conﬁrmed 
from the records of the respective well baby clinic by a study nurse.
Laboratory Methods
Stool samples were stored in freezers at −70°C. Viral RNA 
was extracted using Qiagen QIAamp Viral RNA Mini Kit (Hilden, 
Germany) according to the manufacturer’s instructions. RV viral 
proteins VP7, VP4 and VP6 PCRs, enzyme-linked immunosorbent 
assay (ELISA) test and sequencing of PCR positive samples were 
performed as previously reported.3
Positive stool samples were propagated in fetal rhesus mon-
key kidney (MA104) cells as described previously3 with the modi-
ﬁcation of using minimum essential medium with 0.5 μg/mL of 
trypsin instead of minimum essential medium containing 100 U/mL 
penicillin, 100 U/mL L-glutamine and 100 μg/mL streptomycin.4
RESULTS
During the 2-year-study period a total of 944 children with 
RTI were recruited into the study and 557 (59.0%) children provided 
a stool sample. A total of these children, 182 (32.7%) had ever been 
vaccinated with RotaTeq at any time after September 1, 2009, thus 
forming our study population. The mean age of the study population 
was 256 days, ranging from 57 to 643 days; 73.1% were males.
Out of the 182 stool samples, 30 (16.5%) were RV positive 
by RT-PCR speciﬁc for VP7. RV positive samples were identiﬁed as 
RotaTeq vaccine type by sequence analysis. VP6 RT-PCR was posi-
tive in 29 and negative in 1 of the 30 VP7 positive cases. Bovine 
vaccine type VP6 was detected in 28 cases and human type VP6 in 
1 case, described later. VP4 RT-PCR was positive in 19 and nega-
tive in 11 cases.
RV antigen by ELISA was tested from 19 of the 30 VP7 posi-
tive cases. ELISA could not be performed from the remaining 11 
samples due to an insufﬁcient amount or type of the sample (diaper). 
Out of those 19 samples, only 4 (16.7%) were ELISA positive. The 
ELISA positive cases were all detected with RotaTeq G1P[8] double-
reassortant; 1 child was also detected with an additional P[5] VP4.
RotaTeq G1 sequence was detected in 28 cases (93.3%) 
out of 30 VP7 positive cases. The double-reassortant combination 
G1P[8] was detected in 11 children (36.7%). The original vaccine 
type G1 reassortant G1P[5] was detected in 4 children (13.3%), 
and 1 child had RotaTeq G1 with both P[5] and P[8]. Also 11 
children (36.7%) were detected with RotaTeq G1 alone (with no 
VP4 sequence detected). VP4 reassortant G6P[8] was detected in 2 
children. (Table 1)
One child was detected with human VP6 reassorted with 
RotaTeq G1 VP7 and human wild-type VP4 P[8]. The stool sample 
of this child was obtained 10 days after the second dose of RotaTeq 
vaccine. The sample was extracted for several times, and RT-PCR 
and sequencing were done twice for each protein from each extrac-
tion, but the RT-PCR and sequencing results remained identical. 
The sample could not be propagated in MA104 cells.
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A total of the 182 RV vaccinated children, 28 had received 
1 dose, 38 had received 2 doses and 116 had received all 3 doses 
of RotaTeq vaccine at the time they were hospitalized. Shedding of 
RotaTeq vaccine virus was detected in 14/28 (50.0%) stool samples 
collected after the ﬁrst and before the second dose. After the second 
and before the third dose vaccine virus shedding was detected in 10/38 
cases (26.3%), and after the third dose in 6 out of 116 cases (5.2%).
RotaTeq G1P[8] double-reassortant was commonly shed 
after each dose of the vaccine. After the ﬁrst dose 8 children shed 
RotaTeq vaccine-derived G1P[8], and 3 children shed after the sec-
ond and 1 child after the third dose. None of these children had 
diarrhea. The vaccine strains and combinations in relation to the 
latest vaccine dose are shown in Table 1.
The duration of shedding, as counted from the latest vac-
cination date, was over 14 days (prolonged) in 16 cases (53.3%) 
and over 30 days in 9 cases (30.0%). The proportion of long-time 
(over 14 days) shedders became larger after each dose of vaccine 
received; after the ﬁrst dose prolonged shedding was detected in 
4/14 (28.6%) children, respectively after the second 7/10 (70.0%) 
and after the third dose 5/6 (83.3%).
The longest duration of shedding was 84 days counted from 
the third immunization in a child detected with RotaTeq G1 VP7, 
while VP4 and VP6 RT-PCRs were negative. The other 5 cases 
after the third dose were detected 9, 22, 39, 52 or 53 days after the 
third dose, and the respective genotypes were RotaTeq G1 alone, 
G1P[5], G1 alone, G6P[8] and G1 alone.
DISCUSSION
In this study we used children hospitalized for respiratory 
infection without gastroenteritis symptoms as proxies for healthy 
children to follow the shedding of RotaTeq vaccine viruses after 
routine vaccination. In these children under the age of 2 years 
who had received RotaTeq vaccine we detected the presence of 
RotaTeq vaccine viruses in 16.5%. This is higher than detected in 
the prelicensure studies using the plaque assay method on sam-
ples collected within a week after each dose,1,5,6 but largely in 
line with more recent studies, which have shown shedding rates 
of around 20% using RT-PCR or enzyme immunoassay as detec-
tion methods.7–9
The previous studies have not detected prolonged shedding 
on such a scale, although Hsieh et al10 detected RotaTeq strains up 
to 28 days after inoculation. Very long shedding, like our ﬁnding up 
to the age of 8 months, has not been described previously in healthy 
infants, but Patel et al.11 detected shedding over 200 days in immuno-
compromised children. We detected 6 children with prolonged shed-
ding 9–84 days after the third dose of RotaTeq vaccine. However, it 
is not certain after which dose the shedding started in such cases. It is 
possible that our occasional sampling detected children who became 
long time shedders already after the ﬁrst dose, in which case the 
longest duration of shedding might have been 6 months.
Dominance of RotaTeq G1 genotype in shedding was a new 
ﬁnding, as G1 was detected in 93.3% of the cases. Still, also in 
prelicensure studies of RotaTeq G1 and P[8] were actually the most 
common genotypes shed after vaccination, and also the G1P[8] 
combination was detected already in the early studies.12,13 In the 
composition of RotaTeq vaccine, the titer of G1 is nearly the same 
as that of G3 and G4, and lower than G2; therefore the higher shed-
ding rate of RotaTeq G1 cannot be explained by a higher inocu-
lum.14 In fact we did not detect any other vaccine-derived human 
G-types but G1 among the shedders. The only unifying factor with 
prolonged shedding was RotaTeq G1 VP7, with the exception of 2 
cases with bovine–human G6P[8] combination. The properties that 
make G1 such a predominant genotype in prolonged infection, and 
consequently shedding, remain unknown and need further study.
The major limitation of our study was the design of the orig-
inal study, which was not planned to determine the rate or duration 
of shedding of RotaTeq vaccine, but only provided stool samples 
at random time points. However, even with this less than optimal 
study design we could determine that long term shedding of vac-
cine viruses is not uncommon. While we could not determine after 
which dose the long-term shedding started, it is reasonable to spec-
ulate that already the ﬁrst dose may select those individuals who 
eventually become long-term shedders.
Shedding of RV vaccine strains in asymptomatic children 
is usually not regarded as clinically signiﬁcant, with the possible 
exception of transmission to susceptible or immunocompromised 
contacts. The use of sensitive RT-PCR in detection of vaccine 
viruses has been criticized, and the plaque assay in cell culture 
defended, on the grounds that RT-PCR may not detect live infec-
tious viruses but only parts (RNA) of the virus.2 However, a pro-
longed presence of the vaccine viruses even as detected by RT-PCR 
only is an indication of prolonged infection in the intestinal cells 
and might be associated with clinical consequences, although these 
are unknown as yet.
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CURRENT ABSTRACT
Musher DM, Thorner AR. N Engl J Med. 2014; 371:1619–1628.
Community-acquired pneumonia (CAP) is a syndrome in which acute 
infection of the lungs develops in persons who have not been hospital-
ized recently and have not had regular exposure to the health care system. 
CAP in adults, which remains a major cause of complications and death, is 
reviewed by the authors.
In the pre-antibiotic era, Streptococcus pneumoniae caused 95% 
of cases of pneumonia. Although pneumococcus remains the most com-
monly identiﬁed cause of CAP, the frequency with which it is implicated 
has declined, and it is now detected in only about 10–15% of inpatient cases 
in the United States. In Europe and other parts of the world where pneumo-
coccal vaccines have been used less often and smoking rates remain high, 
pneumococcus remains responsible for a higher proportion of cases of CAP.
Other bacteria that cause CAP include Haemophilus inﬂuenzae, 
Staphylococcus aureus, Moraxella catarrhalis, Pseudomonas aeruginosa 
and other Gram-negative bacilli. Patients with chronic obstructive pulmo-
nary disease are at increased risk for CAP caused by H. inﬂuenzae, and M. 
catarrhalis. P. aeruginosa and other Gram-negative bacilli also cause CAP 
in persons who have chronic obstructive pulmonary disease or bronchiecta-
sis, especially in those taking glucocorticoids.
During inﬂuenza outbreaks, the circulating inﬂuenza virus becomes 
the principal cause of CAP that is serious enough to require hospitalization, 
with secondary bacterial infection as a major contributor. Despite the most 
conscientious efforts to determine the cause, no cause is found in about half 
the patients who are hospitalized for CAP in the United States, indicating an 
important area for future investigation.
Scoring systems may predict the severity of disease and help deter-
mine whether a patient with CAP requires hospitalization or admission to 
an intensive care unit. Validated instruments include the Pneumonia Sever-
ity Index, the CURB-65 score (a measure of confusion, blood urea nitrogen, 
respiratory rate, and blood pressure in a patient ≥ 65 years of age) and the 
guidelines of the Infectious Diseases Society of America and the American 
Thoracic Society (IDSA/ATS).
Guidelines for empiric antimicrobial therapy for CAP have con-
tributed to a greater uniformity of treatment, and their use in hospitalized 
patients has been associated with better outcomes. In 2012, the target period 
from initial contact with the medical care system until antibiotic administra-
tion was retired altogether and replaced by the recommendation that treat-
ment be initiated promptly and at the point of care where the diagnosis of 
pneumonia was ﬁrst made.
For patients with CAP who require hospitalization and in whom no 
cause of infection is immediately apparent, IDSA/ATS guidelines recom-
mend empiric therapy with either a beta-lactam plus a macrolide or qui-
nolone alone. These regimens have been studied extensively and generally 
produce a cure in about 90% of patients with CAP of mild or moderate 
severity.
A patient whose constellation of ﬁndings includes an acute onset of 
chills and fever, cough with sputum production, pleuritic chest pain, a high 
or suppressed white count with increased band forms, a dense segmental or 
lobar consolidation, or a serum procalcitonin level of more than 0.25 μg/L is 
likely to have typical bacterial pneumonia, such as pneumococcal pneumonia.
Patients with CAP who have none of the factors that favor bacterial 
infection, and who have known exposure to sick contacts, upper respiratory 
symptoms at the time of presentation, patchy pulmonary inﬁltrates, procal-
citonin level of 0.1 μg/L or less are unlikely to have bacterial pneumonia.
Comment: Macrolides inhibit important intracellular signaling pathways 
and suppress production of transcription factors, which decrease the pro-
duction of inﬂammatory cytokines and the expression of adhesion mole-
cules. Many, but not all, retrospective studies have shown that the addition 
of a macrolide to a beta-lactam antibiotic to treat pneumococcal pneumonia 
or all-cause CAP reduces morbidity and mortality, presumably by inhibiting 
the inﬂammatory response.
Statins block the synthesis of 3-hydroxy-methylglutaryl coenzyme 
A reductase, inhibiting the synthesis of farnesyl pyrophosphate and gera-
nylgeranyl pyrophosphate (which are needed to activate G proteins), thereby 
dampening inﬂammatory responses. Observational studies have shown bet-
ter outcomes in patients who were taking statins at the time of admission 
for pneumonia. However, no data from randomized trials to examine these 
effects of macrolides or statins in patients with CAP are available.
The 30-day rate of death in patients who are hospitalized for CAP 
is approximately 10–12%. After discharge from the hospital, about 18% of 
patients are readmitted within 30 days. Inﬂuenza pneumonia and bacterial 
pneumonia are each strongly associated with cardiac events.
Community-Acquired Pneumonia
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Abstract 
 
Background: Rotavirus (RV) vaccination using RotaTeq® vaccine exclusively was introduced 
into Finnish National Immunization Program (NIP) in 2009, and soon reached high (90 %) 
coverage. Since mid-2013, all stool samples from laboratory diagnosed cases of RV 
gastroenteritis in the entire country have been typed.  
Methods: 364 RV positive stool samples collected from clinical laboratories over a 2-year 
period were G- and P-typed using RT-PCR, and the results were confirmed by sequencing. In 
addition, the genome segment encoding for VP6 was sequenced to distinguish between wild-
type and vaccine origin (bovine) RVs.  
Results: RV winter epidemic seasons 2013–2014 and 2014–2015 lasted until July each. The 
age distribution of RV cases showed two unusual clusters: one in children 6–16 years of age, 
too old to have been vaccinated in NIP, and the other in elderly over 70 years of age. In children 
diverse genotypes were observed without any obvious predominance. The most common ones 
were G1P[8] (30.0 %), G2P[4] (22.4 %), G9P[8] (15.8 %), G3P[8] (12.2 %) and G4P[8] (11,2 
%). The genotype distribution was not different among vaccinated and unvaccinated children. 
Most cases in the elderly were associated with G2P[4].  
Conclusions: Even at high vaccine coverage and high effectiveness of RV vaccine, RV activity 
continues to persist, particularly in unvaccinated older children. RV genotypes show greater 
diversity than before RV vaccinations. We conclude that RV disease can be controlled but not 
eliminated by vaccinations. Herd-protection in long-term follow-up may be less than at the start 
of RV vaccinations.  
 
 
Introduction 
Following extensive safety and efficacy trials [1,2], two live oral RV vaccines, Rotarix™ and 
RotaTeq®, were licensed in 2006. Finland adopted RotaTeq® vaccine exclusively for the 
National Immunization Programme (NIP) in September 2009, and the coverage of RV 
vaccination has since been over 90 % (Vaccination register, National Institute for Health and 
Welfare). The NIP has had high impact on rotavirus gastroenteritis (RVGE), resulting in 90 % 
reduction of hospitalizations and 90 % of outpatient clinic visits due to RVGE in 2012-2014 
compared to pre-licensure years [3]. In May 2013, RV was included in the Finnish 
Communicable Diseases Act and Decree as part of the microbe strain collection, and all 
detected RVs in Finland have been referred for typing.  
Real-life effectiveness of RV vaccines for RVGE hospitalization in high coverage countries, 
such as Finland (RotaTeq®) and Belgium (Rotarix™), has been over 90 % [3,4]. In the US, 
Payne et al. [5] reported 84 % effectiveness of RotaTeq in a 4-year follow-up study with 
vaccine coverage of 75-80 %. In the US, the peak activity RVGE has become biannual after 
the introduction of RV vaccines but this has not been observed in Finland or in Austria at 
higher RV vaccination coverage rates [3,6,7] 
While RV vaccinations have shown an indirect impact on RVGE hospitalizations in 
unvaccinated children and adults in the US and Europe soon after their introduction, in longer 
follow-up it has been observed that RV activity will persist, and the indirect protection may 
be less than reported soon after the start of vaccinations[8,9]. We and others have previously 
reported a shift of RV disease to older unvaccinated children [3,10-12]. In the US, persisting 
RV disease has also been described in the elderly and in immunocompromised individuals of 
all ages [13].  
RV vaccinations have had some selection pressure on circulating RV strains as new and also 
unusual genotypes have emerged. In Latin America, particularly in Brazil, G2P[4] became a 
predominant genotype for many years after the introduction of Rotarix™ vaccine in NIPs 
[14,15]. After the introduction of RotaTeq®, a previously unusual genotype G3P[8] and a 
new genotype G12P[8] have become common in the US and Finland, respectively [5,11]. 
However, both RV vaccines have remained fully effective against severe RVGE associated 
with the new genotypes [3,15,16].  
Circulating RV strains are constantly monitored and studied, however these studies are 
usually single- or multi-centered. In this nationwide study we characterize the residual RV 
activity in Finland, based on routine diagnoses of RVGE in clinical laboratories in years 5 and 
6 after the implementation of RV vaccine into NIP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and methods 
In May 2013, 4 years after the introduction of RV vaccination into the Finnish NIP, RV was 
included in the Finnish Communicable Diseases Act and Decree as part of the microbe strain 
collection. Since then the surveillance of RV in Finland has included genotyping of all RV 
positive findings from clinical laboratories around the country. Clinical laboratories may use 
RV antigen detection with enzyme-linked immunosorbent assay (ELISA) or, more rarely, 
reverse transcription-polymerase chain reaction (RT-PCR) for primary diagnosis, and positive 
samples are shipped to National Institute for Health and Welfare (THL). For the period of 
2013-2015, these samples were further referred to the Vaccine Research Center, University of 
Tampere, for genotyping.  
Viral RNA was extracted from stool samples using the Qiagen QIAamp Viral RNA Mini Kit 
(Hilden, Germany) according to the manufacturer’s instructions. The RNA extracts were 
stored in a freezer at -70°C until tested by RT-PCR. RV VP7 and VP4 sequences were 
detected using a previously described primers and methods [17]. VP6 sequences were 
detected with a whole-genome PCR method adapted from Matthijnssens et al. [18]. Five l of 
RNA was prepared and denatured at 97°C for 2 minutes, otherwise the method was as 
previously described.  
Positive RT-PCR detections were further analyzed by sequencing with the same primers as in 
RT-PCR. Positive amplicons (VP7, VP4, and VP6) were purified using the Qiagen QIAquick 
Gel Extraction Kit (Hilden, Germany) and sequenced using the BigDye Terminator v1.1 
Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA) on an ABI 
PRISMTM 310 Genetic Analyzer. Sequences were analyzed with SequencherTM 4.10 and 
compared with published reference strains from GeneBank 
(http://www.ncbi.nlm.nih.gov/BLAST/, Nucleotide blast).  
Statistical analysis was conducted using SPSS 23.0 (IBM SPSS Statistics, IBM Corp.), and p-
values between prevalence of genotypes were calculated using Fisher’s exact test and Mann-
Whitney U test, p-value of < 0.05 was considered as statistically significant. 
Because of personal data protection, only limited information from the RV cases was 
available. This consisted of age with the accuracy of year, gender, sampling date, original 
result from the clinical laboratory and location of the clinical laboratory which sent the 
sample to THL. In some cases additional information such as RV vaccination status, travel 
history, or description of symptoms could be obtained retrospectively. 
We arbitrarily divided the cases into four age groups: children aged up to 6 years who were 
eligible to receive RV vaccine in the NIP, older children aged between 6 and 16 years who 
were ineligible for the vaccine in NIP, adults aged between 16 and 70 years, and elderly aged 
70 years or above. 
 
 
 
 
 
 
 
 
 
 
 
Results 
We received 405 stool samples during the two RV seasons from the beginning of September 
2013 to the end of August 2015, covering years 5 and 6 after the start of RV vaccinations in 
NIP. Of the samples, 172 (42.5 %) were collected during the first RV season (year 5) and 233 
(57.5 %) during the second season, 2014-2015 (year 6).  
RT-PCR was performed on all 405 samples, and 364 (89.9 %) were found positive for RV 
VP7. The remaining 41 samples had previously been found to be RV positive by the local 
clinical laboratories using RV antigen detection. RNA extraction and VP7 RT-PCR were 
done twice on these apparently false positive samples, but the results remained negative. Also 
the VP4 and VP6 RT-PCRs of these samples were negative. All 364 VP7 positive samples 
were positive for RV VP4, and all except for one sample were positive for VP6. Of these 363 
samples, human type VP6 was detected in 358 (98.2 %) cases, one had a feline-like origin 
VP6 (G3P[9]), three had VP6 of bovine origin (G8P[14], G6P[14], and a RotaTeq® vaccine 
strain), and one sample could not be sequenced for VP6.  
Of the 364 RV VP7 positive cases, 303 (83.2 %) were from children to adolescents aged less 
than 16 years, 44 (12.1 %) from the elderly (aged 70 years or above), and only 17 (4.7 %) 
cases were from adults aged 16-70 years. Of the 303 children, 160 (52.8 %) were aged 
between 0 to 6 years of age and were considered as eligible to have received RV vaccination 
in the NIP. The remaining 143 (47.2 %) children were from 6 to 16 years of age, and 
therefore too old to have received the vaccine in the NIP.  
Of all 364 RV positive samples, 160 (44.0 %) were collected during the first RV season and 
204 (56.0 %) during the second RV season. The monthly distribution of RV cases during the 
two seasons is shown in Figure 1. In both years, RV activity continued late until July. The 
seasonality in adults and elderly was not different from that in children. 
 
Genotypes 
In total, G2P[4] was the most common genotype as it was detected in 112 (30.8 %) of the 364 
VP7 positive cases. The second most common genotype was G1P[8] with 98 (26.9 %) 
detections. Other common genotypes were G9P[8] with 48 (13.2 %) and G3P[8] with 41 
(11.3 %) cases. G12P[8] was detected in 19 (5.2 %) samples. Other genotypes were less 
frequent and are presented in Table 1. [Table 1 near here] 
In children (n=303), in both 0-6 years and 6-16 years, G1P[8] was the most predominant 
genotype with 91 (30.0 %) detections during both seasons combined. However, in the 0-6 
year olds G9P[8] was more frequently detected than G1P[8] during the second season 2014-
2015. In adults (n=17) and the elderly (n=44), G2P[4] was detected most frequently with 11 
(64.7 %) and 33 (75.0 %) cases, respectively. There were only minor changes in the 
genotypes between these two seasons. The proportion of G9P[8] increased from 8.3 % to 22.7 
% in the 0-6 year olds and from 10.5 % to 18.6 % in 6-16 year olds from the first to the 
second season. During the same period G4P[8] decreased from 23.6 % to 6.8 % in the 0-6 
year olds. (Table 1) 
Genotypes in vaccinated and unvaccinated children 
Of the 303 children, 29 (9.6 %) were known to have received at least one dose of rotavirus 
vaccine, 80 (26.4 %) had not received vaccine, and the vaccination status of the rest, 194 
(64.0 %) children, was unknown. We estimated that from those 80 unvaccinated children, 31 
were eligible to have received the vaccine according to their age, and therefore 49 children 
were unvaccinated and ineligible to have received the vaccine. G1P[8], G9P[8] and G12P[8] 
were seen more often in vaccinated children (24.1 %, 20.7 % and 13.8 % in comparison to 
16.1 %, 12.9 % and 6.5 %, respectively, in unvaccinated children) whereas G2P[4], G3P[8] 
and G4P[8] were more frequently detected in unvaccinated children (10.3 %, 3.4 % and 20.7 
% in comparison to 19.4 %, 12.9 % and 29.0 %, respectively). However, the differences in 
genotypes between unvaccinated and vaccinated children were not statistically significant 
(p=0.425, Mann-Whitney U test). G4P[8] was the only genotype more frequently detected in 
the unvaccinated eligible than in unvaccinated ineligible older children (29.0 % vs. 10.4 %, 
respectively); the difference was statistically significant, p=0.039 (Fisher’s exact test). (Figure 
2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
We conducted a nationwide study on RV detections in patients of all age during two RV 
seasons, 2013-2014 and 2014-2015, in years 5 and 6 after the introduction of RotaTeq® 
vaccine into the NIP in Finland.   
This study showed that RV continues to circulate and cause clinical disease despite high 
vaccination coverage (90-95 %) and high effectiveness (94.4 %) against RV hospitalizations 
in Finland [19]. It may be speculated that the RV activity is maintained from an unvaccinated 
children population not eligible for RV vaccination in NIP started in 2009. We noted a cluster 
of RV activity in children aged 6 to 16 years, too old to have received RV vaccine in NIP. 
Also in Belgium, a country with long-term use of Rotarix™ at high coverage, RV activity has 
remained at the same level from years 4 to 6 after implementation of RV vaccine, and has 
been hypothesized to be maintained from a source outside of the vaccinated population [12]. 
We also noted a second age cluster of RVGE in people 70-90 of age. RVs in adults might 
form a reservoir which contributes to continuing RV activity in children. This speculation is 
also supported by a study of Prelog et al. [7] from Austria who noted that as the RV activity in 
newborns has not decreased even after several years of universal mass vaccination, there must 
be an unknown reservoir of RV which has frequent contacts with the newborns. RV activity 
in the elderly is of interest since it may follow its own epidemiology as reported from Japan 
where the RV activity in adults was observed all-year-round [20]. RV disease in adults as a 
separate entity is also supported by the finding that the RV vaccines have no herd-effect on 
the disease in the adults outside epidemic season [21]. Clearly, continued surveillance of RV 
disease in adults is required to obtain a full view of the remaining RV activity in the 
population. RV genotype distribution in adults has previously been found to be broader than 
in children with G2P[4] usually the most predominant genotype [8,22]. Our results were 
similar: G2P[4] was the most common genotype in both seasons.  
Various zoonotic strains were detected in adults and children. The G8P[14] and G9P[6] 
genotypes were detected for the first time in Finland; G8P[14] has been previously detected 
also in the US [23] and Mali [24], and G9P[6] in the Netherlands [25] and India [26]. Also 
genotype G8P[8], which is globally more common, was detected for the first time in Finland. 
In Finland before RV vaccine was added to the NIP, G1P[8] was the predominant genotype 
causing more than 60 % of the RV cases [17]. In the US G1P[8] accounted for 78.5 % of all 
RV infections between the years 1996 and 2005 [27]. After introduction of RV vaccination 
G2P[4] and G3P[8] have become predominant RV genotypes in Rotarix™ (G2P[4]) and 
RotaTeq® (G3P[8]) using countries such as Belgium and some territories of Australia, 
respectively [28,29]. Interestingly, in Finland the effect of RotaTeq® vaccine on circulating 
RV strains was not so clear as G1P[8] continued to predominate in the first years of 
NIP[3,11,17], while also G3P[8], G4P[8], and G12P[8] emerged [30]. The present findings in 
years 5 and 6 after NIP confirm the continued presence of G3P[8], G4P[8], and G12P[8], and 
G9P[8] becoming common in year 6. Altogether, the genotype diversity we observed in this 
study has not been reported before to such an extent in a country with high vaccine coverage 
and vaccine effectiveness of RV vaccine. 
Interestingly, there was no major difference in RV genotype distribution of vaccinated and 
unvaccinated children. This suggests that the genotype specificity of RotaTeq® vaccine is not 
critical for protection against severe RV disease, and breakthrough cases may be caused by a 
multitude of RV genotypes. This is consistent with the hypothesis that most of the protection 
against severe RVGE is mediated by non-neutralizing antibodies against RV VP6 [31,32]. 
We have recently shown that shedding of RotaTeq® vaccine viruses into stools is common 
[33]. In this study, only one child in the susceptible age group (under one year of age) was 
detected with RotaTeq® vaccine-derived double-reassortant G1P[8] (vdG1P[8]) RV in stool 
specimen. VdG1P[8] is linked with more severe symptoms which may lead to 
hospitalization[30] whereas the single reassortant vaccine strains do not have similar 
virulence and are usually shed without symptoms [30,33]. The low detection rate of vaccine 
strains in our study may be because most specimens from children with RVGE were mostly 
from hospitalized or otherwise severe cases, and cases with mild gastrointestinal symptoms 
would not be referred to laboratory studies. Severity of the cases is discussed below.The high 
number of false-positive clinical laboratory RV findings is remarkable. However, as most of 
the clinical laboratories in Finland use commercial ELISA RV antibody detection kits, which 
have the specificity of 80-90 %, our detection rate of false-positive findings (around 10 %) is 
not out of line [34]. Bowen et al. [6] described a similar proportion (around 15 %) of false-
positive RV samples while analyzing ELISA positive samples with RT-PCR and qRT-PCR.  
The true number of RV cases in children is probably higher as clinically milder cases are 
usually taken care without laboratory diagnostics. In the adults and elderly RV is rare and is 
not tested routinely. Therefore, it can be speculated that most of the cases have had severe 
RVGE which has led to healthcare contact and diagnostic testing. Our study was nationwide 
and took advantage of the recent legislation that every clinical laboratory (public or private) is 
required to send all positive RV samples for further typing. The major limitation of our study 
was the limited clinical information. We did not receive medical history, vaccine status, 
clinical picture, or travel history in most cases. This was due to two reasons. Firstly, the 
referral form by the clinicians was free narrative and therefore was often left unfilled. 
Secondly, the privacy of health information is strictly defined in the Finnish legislation and 
due to the epidemiological nature of our study our access to medical histories was limited. 
Despite the limitation of incomplete clinical information available to us, a strength of the 
study is that we likely collected all RV cases which were diagnosed in Finland during these 
two RV seasons, including cases in adults and the elderly, and therefore the material is 
exceptionally comprehensive. In 2014 Lawrence et al. [35] reported on the safety and 
immunogenicity of RotaTeq® vaccine in the elderly with promising results. The vaccine 
increased RV IgA levels even after one dose, and was well tolerated. In the light of our study, 
the burden of disease caused by RV in the elderly is small and perhaps not sufficient to 
warrant a standalone RV vaccination. However, as part of combined norovirus-RV vaccine 
currently under development also the RV component might be of significance and add the 
value of such a vaccine in the elderly [36].  
In conclusion, residual RV activity is persisting 6 years after RV vaccine in NIP despite the 
high vaccine coverage and effectiveness. Our results show that the RV activity is shifting 
towards older unvaccinated children, while also being maintained in the elderly population. 
Furthermore, probably under vaccine-induced immune pressure, the diversity of RV 
genotypes in the remaining RV cases has increased. We conclude that RV disease can be 
controlled but not eliminated by vaccination with live oral RV vaccines.  
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 Figure 1. Seasonality of RV cases (n=364) in children, adults and elderly from September 
2013 to August 2015. 
 
 
 Figure 2. Proportion of RV genotypes detected in vaccinated, unvaccinated RV vaccine 
eligible and unvaccinated RV vaccine ineligible children in years 5 and 6 after 
implementation of RV vaccination with RotaTeq® vaccine. 
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